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`Would  you tell me, please, which way I ought to go from here?' 
`That depends a good deal on where you want to get to,' said the Cat. 
`I don't much care where--' said Alice. 
`Then it doesn't matter which way you go,' said the Cat. 
`--so long as I get SOMEWHERE,' Alice added as an explanation. 
`Oh, you're sure to do that,' said the Cat, `if  you only walk long enough.' 
From “Alice in Wonderland” by Lewis Carroll
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Signal transduction
In a multicellular organism a proper balance needs to be established between prolifera-
tion, differentiation and cell death in order to maintain tissue homeostasis. To achieve
this, a signaling network has evolved by which cells can communicate. To allow commu-
nication between cells, in addition to cell-cell contact, mechanisms have evolved that
include secretion of  growth factors and cytokines which can bind to their cognate recep-
tor on the outside of  target cells. Ligand-receptor interaction triggers a cascade of  intra-
cellular events, which can ultimately lead to a plethora of  responses, including survival or
apoptosis (programmed cell death), proliferation, differentiation and modulation of  activ-
ities of  differentiated cells. This cascade of  events, which is triggered upon ligand-recep-
tor interaction, is termed signal transduction. 
Signal transduction is characterized by the coordinate action of  kinases and phos-
phatases, as well as the release of  second messengers. This can result in posttranslational
modification, as well as relocalization of  proteins, thus altering their activity. The impor-
tance for regulation of  proliferation, differentiation and apoptosis is illustrated in that
dysregulation of  this balance is associated with cancer, chronic inflammatory diseases and
degenerative diseases as a result of  inappropriate cell death. To understand the mecha-
nisms underlying these diseases, ultimately allowing clinical interference, it is important to
study signal transduction and how its dysregulation is associated with disease. In this the-
sis, research investigating mechanisms underlying proliferation and survival by cytokines
in inflammatory cells is described. We focused on cytokines of  the IL-3, IL-5 and GM-
CSF family, which play a crucial role in proliferation, survival and differentiation of  cells
of  the myeloid lineage1.
The IL-3, IL-5 and GM-CSF family: structure and function
Cytokines of  the interleukin (IL)-3, IL-5 and Granulocyte Macrophage Colony
Stimulating Factor (GM-CSF) are secreted amongst others by activated T cells and mast
cells and promote survival, proliferation and differentiation of  cells of  the hematopoiet-
ic lineages. The receptors for IL-3 and GM-CSF are expressed on a broad range of
hematopoietic cells, whereas the expression of  the IL-5 receptor is more restricted, being
present on eosinophils and basophils in man, as well as on B cells in mice2,3. 
Receptors for IL-3, IL-5 and GM-CSF consist of  a cytokine-specific alpha chain, IL-
3a, IL-5 a and GM-CSFa, glycoproteins of  60-80 kD, and a common beta chain (bc), a
120 kD glycoprotein, which is shared by these receptors. The bc does not bind cytokine
itself, but forms a high-affinity receptor with the alpha subunit upon ligand binding4.
Receptors for IL-3, IL-5 and GM-CSF belong to the cytokine receptor superfamily, which
consists of  a variety of  receptors that are structurally and functionally related2. The extra-
cellular domain of  the a chains and bc contains structural motifs that are conserved
throughout this superfamily. These motifs consist of  4 cysteines and a WSXWS repeat,
both of  which are involved in ligand binding (Fig. 1). The intracellular domain of  a sub-
units is short (~50 amino acids) and contains a proline-rich motif. In contrast, the intra-
Introduction
13
introduction.qxd  4-5-01  9:37  Page 13
cellular domain of  bc is relatively large (436 aa in man and 432 aa in mouse), containing
structurally conserved membrane-proximal regions, known as "box 1" and "box 2", and
six tyrosine residues in the membrane-distal region. Whereas in man all a subunits bind
to bc, in mice an additional b subunit is present, bIL-3, that binds exclusively to IL-3Ra
5. bIL-3 is highly homologous to bc and has probably arisen by gene duplication6.
Analysis in knockout mice, however, has revealed no additional function of  bIL-3 com-
pared to bc7. Six tyrosine residues in bc are conserved from mouse to man, although the
murine bc has an additional tyrosine, of which the relevance for signal transduction
remains to be established. Ligand binding results in receptor dimerization, triggering sub-
sequent signaling events, transduced through the bc. Although some signal transducing
activity has been attributed to the alpha subunit, in particular the proline-rich region, there
are conflicting data as to whether this contributes to cell proliferation or survival8-12.
Given their cytokine-specificity, the alpha subunits might be involved in mediating dif-
ferentiation of  target cells, although this is still largely unconfirmed. 
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Figure 1. Activation of  signaling pathways by the IL-3, IL-5 and GM-CSF recep-
tor family. Binding of  IL-3, IL-5 and GM-CSF to their cytokine-specific alpha chain triggers het-
erodimerization with the bc, resulting in activation of  JAK2. JAK2 then phosphorylates tyrosine residues
in the bc, which recruits binding of  cytoplasmic signaling proteins. These proteins either directly pro-
mote transcription (STAT5) or in turn recruit other signaling proteins to the bc, resulting in the activa-
tion of multiple signaling pathways.
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Intracellular signals elicited by IL-3, IL-5 and GM-CSF
Initial studies on signal transduction of  IL-3, IL-5 and GM-CSF revealed that they elicit
similar patterns of  tyrosine phosphorylation of  cytosolic proteins13,14. As is true for
many cytokine receptors, neither the a chains nor bc possess intrinsic tyrosine kinase
activity, but instead a tyrosine kinase, JAK2, is associated with the box 1 region of  bc15,16.
Receptor-ligand-induced dimerization of  bc subunits promotes cross-phosphorylation
and activation of  JAK2, which then phosphorylates tyrosine residues in the cytoplasmic
tail of  bc (see Fig. 1). Activity of  JAK2 is both necessary and sufficient for the initiation
of  signaling, since mice deficient in JAK2 fail to respond to either IL-3 or GM-CSF17.
Moreover, constitutive activation of  JAK2, by constructing a chimeric receptor (bc
/JAK2), consisting of  bc extracellular and transmembrane regions fused with JAK2,
abrogates the need for cytokines for proliferation or survival18. Deletion analysis of  bc
revealed that signaling through the membrane proximal region induces a transient prolif-
erative response, potentially mediated by induction of  the serine threonine kinase pim1
and transcription factor c-myc19, whereas the membrane distal region is required for cell
viability20,21.
The membrane distal region of  bc also contains tyrosine residues that are phospho-
rylated upon the action of  IL-3, IL-5 and GM-CSF14. These phospho-tyrosines are capa-
ble of  recruiting cytoplasmic signaling molecules through their Src-homology 2 (SH2)
domain. Subsequently, relocalization of  these signaling molecules promotes their activa-
tion, triggering subsequent signaling events. Furthermore, the distal region of  bc is also
important for activation of  kinases of  the Src family, such as Lyn, Hck and Fyn, which
may occur independently of  bc tyrosine phosphorylation. Interestingly, this family of
kinases has also been proposed to contribute to tyrosine phosphorylation of  bc22-24. 
Activation of STAT5 through bc.
One signaling protein that can bind directly to phospho-tyrosines on the bc is the tran-
scription factor STAT5 (Signal Transducer and Activator of  Transcription). Binding of
STAT5 to the bc results in its subsequent phosphorylation and dimerization that then
translocate to the nucleus and promote transcription of  target genes which include pim1,
CIS1, Bcl-xL and cyclin D1 (reviewed in 25; Fig. 1). There is some redundancy in bc-medi-
ated activation of  STAT5, since STAT5 can bind to multiple phosphorylated tyrosine
residues, including Tyr577, Tyr612, Tyr695, and Tyr750 on the human bc26. Moreover,
Tyr806 and Tyr866 have also been described to promote its activation, but direct binding
of  STAT5 to these residues has not been demonstrated27.
Activation of the small GTPase p21ras and its intracellular targets.
Other signaling routes initiated through the distal region of  the tyrosine-phosphorylated
bc involve the activation of  the small GTPase p21ras28. Downstream effectors of  p21ras
activation include the dual specificity kinase MEK and its target ERK (MAPK), resulting
in induction of  the transcription factors c-fos and c-jun28,29. Besides activating MEK-
ERK, p21ras can also induce PI3K activity by direct binding to its p110 catalytic subunit30
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(see below). Finally, signaling through bc can also activate two other members of  the
MAPK family, p38 and JNK, although their role in transducing a proliferative response
and the precise mechanism of  their activation still remains to be resolved31-33. 
The activation of  p21ras through the bc is complex and requires intermediate pro-
teins. Two proteins that function as adaptor proteins and can bind directly to phospho-
rylated tyrosine residues on bc are Shc and the protein tyrosine phosphatase SHP2 (also
known as PTP-1D, PTP-1C, SH-PTP2 or Syp). Shc binds to phosphorylated Tyr577 of
the bc, whereas SHP2 binds Tyr612. Both proteins become tyrosine-phosphorylated
upon binding to bc34-36. Subsequently, the phosphorylated tyrosine residues on Shc and
SHP2 serve as docking sites for the SH2 domain of  another adaptor protein, Grb237. In
addition to its SH2 domain Grb2 possesses two SH3 domains that  bind to the proline-
rich region of  the GTP-exchange factor Sos. Recruitment of  Sos to the plasma mem-
brane subsequently activates p21ras (Fig. 1). 
Regulation of phosphatidylinositol 3-kinase activation
Another mechanism by which signals from the distal part of  the bc may promote cell sur-
vival is through activation of  the lipid kinase phosphatidyl inositol 3-kinase (PI3K)21,38.
The PI3K family consists of  several isoforms (reviewed in 39), of which the classical form
consists of  two subunits, a p85 regulatory subunit, containing two SH2 domains, and a
catalytic subunit, p110. Recruitment of  p85 to the bc results in membrane targeting,
allowing phosphorylation of  the phosphatidylinositol (PI) lipids, phosphatidylinositol-4-
phosphate (PI-4P) and phosphatidylinositol-4,5-bisphosphate PI4,5-P2 on the D3 posi-
tion (reviewed in 40). Following this phosphorylation, activation of  PI(3,4,5)-trisphos-
phate dependent kinase (PDK-1) is promoted upon binding to PI(3,4,5)P341.
Downstream targets of  PDK-1 include the serine-threonine kinase Protein Kinase B
(PKB, also known as Akt)42, and p70S6K42-44 (see Fig. 1).
In addition to direct activation by p21ras30, there are several alternative mechanisms
by which PI3K can be activated through bc, which again involve intermediate adaptor
proteins. The mechanism of  cytokine-mediated PI3K activation has been elusive until the
recent discovery of  involvement of  the adaptor protein p97/ Gab245. Gab2 can be
recruited to the bc through association with either tyrosine-phosphorylated SHP2 or
Grb2. Following recruitment to bc Gab2 is itself  tyrosine-phosphorylated and these
tyrosines serve as docking sites for the p85 subunit of  PI3K46 (Fig 1). Interestingly, ser-
ine phosphorylation of  the bc has also been reported to be critical for PI3K activation47.
Recently, IL-3 stimulation was demonstrated to result in the phosphorylation of  Ser585
in the human bc, and site-directed mutagenesis of  this residue specifically impaired the
PI3K signaling with a concomitant reduction in cell survival48. Ser585 is conserved from
mouse to man, and is located in a consensus phosphorylation site for PKA, serving as a
docking site for 14-3-3 proteins. 14-3-3 proteins are regulatory molecules that can bind
various signaling molecules and might thus serve as adaptor proteins (reviewed in 49).
Binding of  14-3-3 to this site has been suggested to recruit the p85 subunit of  PI3K,
Chapter 1
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either directly or via an intermediate, promoting PI3K activation47. This suggests that
there are multiple signaling pathways that could contribute to the proliferative and anti-
apoptotic signals through bc.
Turning off the signal
Phosphatases
Following IL-3, IL-5 or GM-CSF binding, a transient increase in tyrosine phosphoryla-
tion of  bc and intracellular proteins is observed. Addition of  phosphatase inhibitors both
elevates and extends the duration of  this tyrosine phosphorylation, resulting in enhanced
proliferation and survival13,14. This suggests that the action of  phosphatases is necessary
to regulate a transient signal, and that dysregulation of  these phosphatases might be
linked to aberrant proliferation or survival. Several phosphatases have been implicated in
IL-3, IL-5 or GM-CSF-induced signaling. These include SHP1 (also referred to as PTP-
1C, HCP or SH-PTP1), SHP2, SHIP (SH2-containing inositol 5-phosphatase)36,50,51 and
PTEN (Phosphatase and Tensin homolog). SHP1 binds to bc, presumably to Tyr-612, to
which it might compete for binding with SHP236. Overexpression of  SHP1 decreased IL-
3-induced proliferation and was effective in dephosphorylating the bc in vitro50, suggest-
ing that SHP1 can directly abrogate recruitment of  signaling molecules to bc. Little is
known regarding the functional significance of  SHP2 phosphatase activity in bc-mediat-
ed signaling, although it has been proposed to dephosphorylate Gab245 and demonstrat-
ed to dephosphorylate STAT5 in vitro52. Another phosphatase involved in inhibiting bc-
generated signals is SHIP, an inositol 5' phosphatase that hydrolyzes the PI3K product
PI(3,4,5)P3 to PI(3,4)P253,54, making it a direct modulator of  downstream signaling of
PI3K. Indeed, SHIP is important for inhibiting activation of  PKB, since SHIP(-/-) mice
exhibited a prolonged PI3K-dependent PI(3,4,5)P3 accumulation and PKB activation in
response to IL-3 and GM-CSF55. Moreover, as SHIP binds to tyrosine-phosphorylated
SHP256 and Shc57,58, SHIP might interfere with the propagation of  bc signals by com-
peting with Grb2 and Gab2 for binding. SHIP-deficient mice exhibit a chronic hyperpla-
sia of myeloid cells which are more resistant to apoptosis55, suggesting a role for this
phosphatase in oncogenesis. The lipid phosphatase PTEN can directly counteract PI3K
action by dephosphorylating 3-phosphorylated phosphoinositides on the D3 position59.
Besides the recent observation that phosphorylation of  PTEN at the C-terminus increas-
es its stability to proteasome-mediated degradation60,61, little is known regarding the reg-
ulation of  its phosphatase activity. The importance of  PTEN in downregulating signals
is illustrated in PTEN (+/-) mice.  These mice were investigated instead of  PTEN (-/-) mice
deletion of  both PTEN alleles caused early embryonic lethality. PTEN (+/-) mice developed
a lethal autoimmune disorder accompanied by decreased apoptosis and increased prolif-
eration upon activation in T lymphocytes from these mice62. Furthermore, loss of  PTEN
activity resulting in an elevation of  PKB activity has been observed in tumor cells.
Reintroduction of  PTEN in these cells reduced PKB activity63 and abrogated their
tumorigenicity64,65. 
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SOCS proteins
Another mechanism through which cytokine-induced signaling can be abrogated is
through downregulating its own signal. The signals that are generated upon cytokine
binding to its receptor can promote transcriptional upregulation of  proteins that inhibit
the further transduction of  signals, thus providing a cytokine signaling-induced feedback
loop. One family of  proteins involved in "turning off" cytokine-induced signals is the
SOCS/CIS/SSI (Suppressor Of Cytokine Signaling/ Cytokine Induced SH2 containing
protein/ STAT-induced STAT Inhibitor) family (reviewed in 66). All members of  the
SOCS/CIS/SSI family contain a conserved domain at their C-terminus, called the SOCS-
box, which interacts with components of  the ubiquitin system. Thus, SOCS proteins may
act as adaptor molecules that target activated cell signaling proteins to the protein degra-
dation pathway67. STAT5 transcriptionally upregulates CIS1, which can bind to the tyro-
sine-phosphorylated bc and thereby reduce the IL-3-induced growth rate upon overex-
pression68. Higher levels of CIS1 inhibit STAT5 activity possibly through "shielding" the
bc tyrosines or alternatively, ubiquitin-mediated degradation of  the bc by the protea-
some69. This mechanism of  CIS1-induced abrogation of  cytokine-induced signaling has
been suggested for the erythropoietin receptor70. With respect to this it is interesting that
treatment of  cells with proteasome inhibitors prolonged IL-3-induced activation of
JAK/STAT pathway, as well as ERK phosphorylation71. Two other SOCS-family mem-
bers, JAB (Jak Binding protein, also known as SOCS-1 or SSI-1) and SOCS-3 (or Ssi-3,
CIS3 OR JAB2) directly bind to JAK2 tyrosine kinase domain, and inhibit its kinase activ-
ity72,73. 
A further cytokine-induced inhibitor of  proliferation is p56(dok-2), which inhibits
phosporylation of  Shc through an as yet unidentified mechanism74. Altogether, cytokine
receptors possess a variety of means to "turn off" cytokine-induced signaling, illustrated
in Fig. 2. As discussed above, deletion or mutation of  some of  these proteins, has recent-
ly been demonstrated to play a role in oncogenesis. 
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Mechanisms of growth factor and cytokine-induced 
proliferation
To get a complete picture as to how cytokines and the signaling pathways that they acti-
vate regulate proliferation, one needs to understand the complex process of  cell division.
Growth factors and cytokines regulate cell proliferation through a network of  signaling
cascades, regulating assembly and activation of  components of  the cell cycle machinery,
which are described below.
Progression through the cell cycle 
The events occurring in the eukaryotic cell cycle include duplication and condensation of
the chromosomes, their migration into a spindle network and segregation into two daugh-
ter cells (reviewed in 75,76). With respect to these events, the cell cycle can be divided into
four phases: an S (synthesis) phase, in which the chromosomes are duplicated, and M
phase (mitosis) separated by two intervals, G1 (gap 1) the interval between M and S and
Introduction
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Figure 2. Turning off  IL-3, IL-5 and GM-CSF-induced signals. Signals elicited through
the bc can be abrogated through the action of  phosphatases, SHP1, SHP2, SHIP and PTEN.
Alternatively, signal transduction through the bc also promotes transcription of  inhibitors, such as CIS
or p56(dok-2) that interfere with bc-generated signals.
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G2, the interval between S and M (Fig. 3). In addition to these phases there is also G0,
representing the quiescent state of  cells that are not cycling, which include terminally dif-
ferentiated cells. Before initiating the cell cycle, controlling systems ensure that the cell
only divides when it has attained the proper size and only when it receives positive sig-
nals from its environment. In addition, there are regulatory mechanisms to ensure correct
chromosome replication and proper alignment before undergoing mitosis. These con-
trolling systems include the so-called "checkpoints", present in G1 (R, for Restriction
point), or G2 and M (also called spindle formation checkpoint). In this section, focus is
on R as passage through this checkpoint is an important means by which growth factors
and cytokines are able to override the intracellular controls that block cell cycle progres-
sion. 
The sequential events of G1-S-G2-M are coordinated by so-called "cyclins" and their
associated catalytic subunit cyclin-dependent kinases (CDKs). The regulated expression
of  cyclins and their association with distinct CDKs varies through each phase of  the cell
cycle (Fig. 3), resulting in an altered CDK substrate specificity77. The distinct substrates
that are phosphorylated during the different phases of  the cell cycle promote the specif-
ic events associated with each phase. The cyclin/CDK complexes that are present in G1
and promote the progression through G1 and the G1-S transition are the D-type cyclins,
associated with CDK4 and CDK6, and the E-type cyclins, associating with CDK2. The
induction of  S-phase by cyclin D(1,2,3)/CDK(4,6) and cyclin E/CDK2 is largely
dependent on their ability to phosphorylate members of  the Rb (retinoblastoma) family,
consisting of  Rb, p107 and p13078 (reviewed in 79). Rb proteins associate with E2F tran-
scription factors and hereby inhibit their activity. Phosphorylation of  Rb proteins by G1
cyclin/CDK complexes results in the release of  E2F, allowing transcription of  its targets,
including cyclin E and cyclin A80,81, the predominant cyclin in S phase. This allows fur-
ther progression through G1 and initiation of  S phase (see Fig. 3).
The cyclin-dependent Kinase Inhibitors (CKIs)
In addition to the Rb family, there is another class of  proteins that negatively regulates
G1 progression, the Cyclin-dependent Kinase Inhibitors (CKIs). These associate to, and
thus inhibit, the activity of  cyclin/CDK complexes. CKIs can be divided into two class-
es, one being the p16/INK4 family, inhibitors of D-type cyclin/CDK4,6, and members
of  the p21CIP1, p21KIP1, p57KIP2 family (for review, see 82). The p16/INK4 family will not
be discussed further here. The p21CIP1, p27KIP1, p57KIP2 family can inhibit cyclin D, as
well as cyclin E- associated kinase activities. When present at lower concentrations how-
ever, p21CIP and p21KIP1 are also involved in the assembly of  CDK/ cyclin complexes,
without actually inhibiting their activity83. p21CIP1 promotes DNA-damage induced cell
cycle arrest, when its levels are transcriptionally elevated in a p53-dependent manner
(reviewed in 84). In response to growth factors, levels of  p27KIP1 dramatically decrease85-
87, which appears to be a critical mechanism by which growth factors are capable of
inducing cell cycle progression. Moreover, antisense inhibition of  p27KIP1 expression pre-
Chapter 1
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vents cell cycle arrest in response to growth factor depletion85. This suggests that upreg-
ulation of  p27KIP1 might be a key mechanism by which cell cycle arrest is induced in
response to growth factor deprivation. Interestingly, decreased levels of  p27KIP1 have also
been described to be associated with a poor prognosis in cancer88,89. An important means
by which expression of  p27KIP1 is regulated is via posttranslational mechanisms; phos-
phorylation on Thr-187 results in subsequent targeting for degradation by the ubiquitin
system85,90,91. This phosphorylation is mediated by cyclin E/CDK291,92, providing a neg-
ative feedback control through cell cycle progression (Fig. 3).
Molecular mechanisms regulating the onset of proliferation
Given that cytokines and growth factors can promote proliferation, considerable effort
has been invested in elucidating how and which signal transduction pathways are involved
in this process. Signaling pathways promoting proliferation generally act in concert and
one should keep in mind that there is considerable crosstalk between those pathways.
However, it is possible to determine what the relative contribution of  each pathway is to
inducing proliferation. For this purpose, either pharmacological inhibitors or overexpres-
sion of  active or dominant-negative forms of  components of  a signaling pathway are uti-
lized.
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Figure 3. Regulation of the cell cycle. CDK/cyclin complexes promote progression through the
different phases of  the cell cycle, G1-S-G2-M. The initial onset of  the cell cycle requires phosphorylation of  Rb,
thus allowing transcription factor E2F to promote transcription of  components of  the cell cycle machinery.
Activity CDK/cyclin complexes can be inhibited by CKIs. The regulation of  their expression includes tran-
scriptional upregulation (p21) or posttranslational modification (p27). Adapted from 1.
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Growth factor and cytokine-induced signaling rapidly induces transcription of  so-
called immediate-early genes, such as c-fos, c-jun and c-myc, all of  which have been asso-
ciated with the induction of  a proliferative response29,93. One of  the earliest events in
growth factor-induced proliferation is the synthesis of  cyclin D. Higher levels of  cyclin
D are able to override the inhibitory effects of  CKIs, resulting in the activation of  asso-
ciated CDK4,6, cyclin E/CDK2, and the onset of  proliferation (reviewed in 79).
Upregulation of  cyclin D is cannot be attributed to one specific signaling pathway, since
elevation of  cyclin D1 has been associated with STAT594, p21ras95, MEK 95,96, as well as
PI3K activity97. PI3K-promoted entry into S-phase may be mediated through its down-
stream target p70S6K, which has been demonstrated to be essential for G1 progression
and elevation of  cyclin D198,99. The importance for PI3K in proliferation is demonstrat-
ed by the observation that proliferation is impaired in B cells that were derived from mice
deficient for the p85 subunit of  PI3K100. PKB has also been implicated in promoting
cyclin D expression by enhancing its translation101, possibly through promoting the phos-
phorylation and subsequent inhibition of  a repressor of mRNA translation, 4E-BP1102. 
Elevation of  cyclin D levels might also be linked to the transcription factor c-myc, as
growth factor stimulation increases levels of  c-myc through transcriptional and posttran-
scriptional mechanisms involving p21ras103,104. Moreover, c-myc has been demonstrated
to rapidly induce cyclin E/ CDK2 kinase activity through promoting sequestration of
p27KIP1 via elevation of  cyclin D levels105,106.
Mechanisms of growth factor and cytokine-induced rescue
from apoptosis
Cellular proliferation induced by growth factors or cytokines can only occur in the pres-
ence of  distinct survival signals. Cells receiving proliferative signals, in the absence of  sur-
vival signals do not proliferate, but rather die, by a process termed apoptosis. One exam-
ple illustrating this is that ectopic expression of  c-myc alone, which can act as an induc-
er of  proliferation, drives cells into apoptosis in the absence of  p21ras  and PI3K activi-
ty107-109. In this way apoptosis may be an important mechanism for the elimination of
cells harboring mutations in cell cycle regulatory proteins, which may otherwise create an
imbalance in normal cell proliferation. Thus, oncogenesis is promoted by aberrant pro-
liferative signals together with deregulated apoptosis, allowing uncontrolled cell division
(reviewed in 110,111). Programmed cell death is also required during the normal develop-
ment of  a multicellular organism, in the turnover and renewal of  cells in the adult body
and in the elimination of  cells that do not or inappropriately respond to signals from their
intracellular environment.
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Characteristics of apoptotic cell death
Apoptosis is a process characterized by morphologically distinct features including bleb-
bing and shrinking of  the nucleus and the cytoplasm, loss of mitochondrial transmem-
brane potential, cleavage of  intracellular proteins and degradation of  chromosomal
DNA. DNA is cleaved into fragments of  distinct size, called "DNA laddering", a hall-
mark often used to characterize apoptotic cells112. Furthermore, the lipid content on the
outside of  apoptotic cells changes, resulting in an increase in phosphatidylserine, which
can be recognized by macrophages, which phagocytose dying cells. These events are dis-
tinct from necrosis, cell death caused by injury, resulting in swelling and bursting of  the
cell and random degradation of  chromosomal DNA. 
The specific cleavage of  proteins and induction of DNA laddering in cells undergo-
ing apoptosis is carried out by cysteine proteases or "caspases" that cleave specific sites,
carboxy-terminal to an aspartate residue (reviewed in 113. Caspase activity also results in
the activation of  CAD (caspase-activated deoxyribonuclease), which is responsible for
chromosomal DNA degradation during apoptosis114,115. Caspases exist as inactive pro-
enzymes in the cell and possess an N-terminal prodomain, containing protein-interaction
motifs, together with large and small subunits. The prodomain generally targets the cas-
pase for activation, which occurs through proteolytic cleavage, resulting in the release of
the prodomain and rearrangement of  the large and small subunits to form an active cas-
pase. Initial caspase activity in apoptosis is induced through the recruitment of  caspase
pro-enzymes to activator molecules, promoting pro-caspase oligomerization and auto-
activation. These activated "initiator caspases" then cleave and activate downstream cas-
pases, resulting in cleavage of  apoptotic substrates (reviewed in 116,117).
Molecular events regulating apoptosis or cell survival
An important family of  proteins involved in the control of  apoptosis is the Bcl-2 family
(reviewed in 118). The first member, Bcl-2, was identified due to its deregulation in B cell
lymphomas bearing the t(14;18) translocation, resulting in constitutive Bcl-2 expres-
sion119,120. Many more Bcl-2 members have been identified and characterized since, based
on homology in conserved regions, called Bcl-2 homology (BH 1-4) domains. Bcl-2 pro-
teins are conserved though evolution, and in the nematode worm Caenorhabditis elegans,
Bcl-2 homolog CED-9 is able to suppress apoptosis by preventing activation of  the cas-
pase, CED-3 (reviewed in 121). Analogous CED-9 members in mammals include Bcl-2,
Bcl-xL, A1 and Mcl-1122. Further dissection of  the apoptotic pathway in C. elegans led to
the identification of  a CED-9 antagonist, EGL-1123. EGL-1 binds to and inactivates
CED-9, and activates CED-3 through a mechanism involving CED-4, the homolog of
mammalian Apaf-1, apoptosis activating factor-1 (Fig. 4). 
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Interestingly, EGL-1 also belongs to the Bcl-2 family, but of  the conserved BH domains
in the Bcl-2 family, it only contains the BH3 domain. EGL-1 homologs in mammals have
also been identified, including Bad, Bid, Bik, Bim and Hrk (harakiri), which have been
termed BH3-only proteins. In addition, mammals also contain other pro-apoptotic Bcl-2
proteins that can induce apoptosis independent of  binding to Bcl-2, such as Bax122.
Interestingly, antiapoptotic Bcl-2 family members were found to inhibit apoptosis by pre-
venting the release from cytochrome c from mitochondria124. The mechanism by which
cytochrome c could promote activation of  caspases has been a mystery until the identifi-
cation of  a cofactor, Apaf-1, which can form a complex with caspase-9 in the presence
cytochrome c and dATP, resulting in its activation125,126 (Fig. 5). 
Homology to bacterial toxins with pore-forming activities and experiments in vitro
suggested that Bax, but also anti-apoptotic Bcl-2 members form pores in the outer mem-
branes of mitochondria, with Bax promoting release of  cytochrome c127. Conversely,
anti-apoptotic Bcl-2 family proteins prevent mitochondrial changes associated with
cytochrome c release124,128, also through inhibition of  Bax channel-forming activity129.
Maintaining an appropriate balance between pro- and anti-apoptotic Bcl-2 family
members is a crucial mechanism by which cellular homeostasis is achieved. Growth fac-
tors and cytokines have been demonstrated to be able to promote survival through tran-
scriptional upregulation of  anti-apoptotic Bcl-2 family members or inactivation of  pro-
apoptotic Bcl-2 proteins130-132. Interestingly, caspases have also been shown to cleave 
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Figure 4. Evolutionary conservation of  the apoptotic program. In C. elegans, as well as
in mammals, induction of  apoptosis requires the activation of  caspases. One mechanism of  activating
caspases can be mediated by Apaf-1/ CED-4 and can be inhibited by the action of  Bcl-2/ CED-9.
Activity of  BH3-only proteins/ EGL-1 can result in induction of  apoptosis through the inhibition of
Bcl-2/ CED-9.
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Bcl-2, thus inhibiting its anti-apoptotic activity and this way provide a positive feedback
loop in executing the apoptotic program133,134. With respect to Bcl-2 regulation in lym-
phocytes an important observation was made in Bim (-/-) knockout mice. Lymphocytes
derived from these mice failed to undergo apoptosis in response to cytokine withdraw-
al135. This suggests that Bim is indispensable for hematopoietic homeostasis and that
there is a unique role for Bim in promoting cytokine withdrawal-induced apoptosis. With
respect to this, it is interesting that Bcl-2 deficient mice develop lymphopenia, providing
genetic evidence of  the importance of maintaining the balance between pro- and anti-
apoptotic Bcl-2 family members136. 
Other evolutionarily conserved players in mediating survival are IAPs (Inhibitors of
Apoptosis Proteins), that suppress apoptosis by directly binding to and inhibiting the
activity of  caspases137, (reviewed in 138). Although their regulation by growth factors has
been suggested in endothelial cells139, regulation in lymphocytes remains to be demon-
strated. 
In addition to growth factor deprivation-induced activity of  pro-apoptotic members
of  the Bcl-2 family, there is another mechanism of  initiating apoptosis, which occurs
through the activation of  so-called "death receptors", such as Fas (also known as CD95
or Apo-1) and results in a rapid induction of  the apoptotic program. Fas-induced apop-
tosis has been described as an important mechanism of  eradicating activated T cells
(reviewed in 140,141). Ligation of  Fas with Fas ligand, FasL, recruits caspase-8 (also known
as FLICE) into a multimeric complex via adaptor protein FADD, which triggers its acti-
vation (reviewed in 140; see Fig. 5). Caspase-8 promotes induction of  apoptosis though
direct cleavage of  apoptotic substrates, but can also activate other caspases by cleaving
BH3-only protein Bid. Cleaved Bid is then recruited to the mitochondria and inhibits
anti-apoptotic Bcl-2 family members, resulting in the activation of  further caspases
(reviewed in 140,141, also Fig. 4). Cytokines have been reported to interfere with death
receptor-induced apoptosis via induction of  c-FLIP (FLICE-inhibitory protein), which
competes with caspase-8 in binding to FADD142. 
Finally, a third mechanism by which apoptosis can be initiated is through DNA dam-
age. DNA damage results in activation of  transcription factor p53, which can trigger
apoptosis through transcriptional upregulation of Bax143, as well as BH3-only protein
Noxa144 (see Fig. 5). 
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Signal transduction pathways regulating cell survival
As discussed, signaling through growth factors and cytokines can trigger proliferation,
which requires simultaneous regulation of  components of  the cell cycle machinery, as
well as inhibiting apoptosis. A predominant mechanism of  promoting survival is through
enhancing the anti-apoptotic and inhibiting the pro-apoptotic activity of  the Bcl-2 fami-
ly members. 
A direct requirement for STAT5-induced Bcl-xL in anti-apoptotic signaling145
through the EpoR was confirmed in STAT5 deficient mice which had low numbers of
erythroid progenitors, showing higher levels of  apoptosis146. Another anti-apoptotic tar-
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Figure 5. Regulation of  apoptosis in higher eukaryotes. Induction of  the apoptotic program can be
induced through regulation of members of  the Bcl-2 family, consisting of  anti-apoptotic members, such as Bcl-2
(white) or pro-apoptotic members (black). Enhancement of  the activity of  the pro-apoptotic Bcl-2 family members
results in the release of  cytochrome c, which, together with Apaf-1, promotes caspase activation. An alternative way
of  activating caspases is triggered through Fas/ Fas ligand signaling, resulting in the direct activation of  caspase-8.
The action of  caspase-8 also involves activation of  other caspases via cleavage of  Bid. 
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get of  STAT5 is the serine-threonine kinase pim1147, which may regulate the expression
or activity of  pro- and anti-apoptotic members of  the bcl-2 family, although this still
remains to be demonstrated148. 
Utilizing ectopic expression of  an oncogenic p21ras mutant, it was demonstrated that
p21ras could also contribute to rescue from apoptosis through upregulation of  Bcl-2 and
Bcl-xL149. This might be mediated by its effector ERK, which can phosphorylate Bcl-2
and increase its anti-apoptotic potential150,151, possibly by making it more resistant for
degradation152. Furthermore, p21ras activity has also been linked to the transcription fac-
tor Aiolos, described to induce Bcl-2 in T cells153, and NFIL3 (E4BP4), which can rescue
cells from apoptosis154, although its transcriptional targets remain to be identified. 
One protein that has recently received considerable attention as a suppressor of  apop-
tosis is the PI3K effector PKB. Thus far, several mechanisms have been demonstrated by
which this serine-threonine kinase mediates cell survival. First, PKB activity can affect the
balance of  the Bcl-2 family by transcriptionally upregulating anti-apoptotic Bcl-2 family
member Mcl-1155, which is an essential component of  the survival response conferred by
GM-CSF156. Furthermore, phosphorylation of  BH3-only protein Bad by PKB inhibits its
activity42,157, however, whether this is a critical target for PKB-mediated rescue from
apoptosis is still debatable158. Inhibitory phosphorylation of  caspase-9 by PKB might
also be a way of  inhibiting apoptosis in some but not all systems159,160. Recently, PKB
activity has also been linked to inhibition of  death receptor-induced apoptosis through
the increase of  c-FLIP expression161. The importance of  PKB in attenuating death recep-
tor-induced apoptosis is supported by the observation that in PTEN (+/-) mice Fas-
induced apoptosis was impaired62. 
Given that STAT5, p21ras and also PI3K regulate transcription of  genes involved in
proliferation, as well as rescue from apoptosis, it is no surprise that these signaling mole-
cules or their downstream targets may mediate cellular transformation. Although there is
little evidence for a direct oncogenic potential of  STAT5, it has been described to con-
tribute to oncogenesis162,163. p21ras was initially identified as a molecule that was mutat-
ed in certain tumors, including hematological abnormalities, resulting in its constitutive
activation, and is one of  the most common contributors to induction of malignancies
(reviewed in 164). Increased PI3K activity has also been proposed in lymphoproliferative
disorders165, and inactivation of  its inhibitory phosphatase PTEN has been extensively
reported in cancer166,167.
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Scope of this thesis
Signal transduction in response to growth factors or cytokines enables cells to appropri-
ately respond to their environment and thus establish a balance between cell proliferation,
differentiation and apoptosis in order to maintain homeostasis. Dysregulation of  this bal-
ance is often correlated with changes in activity of  components of  the signaling work,
which can result in malignancies or inflammation. This study focuses on the mechanisms
by which IL-3, IL-5 and GM-CSF mediate proliferation and survival of  hematopoietic
cells. Utilizing pharmacological inhibitors of  signal transduction pathways, we analyzed
which signaling pathways are indispensable for cytokine-mediated proliferation and sur-
vival. We identified PI3K as the crucial target of  IL-3, IL-5 and GM-CSF in mediating
proliferation and survival and PKB as the PI3K target involved in mediating the PI3K-
induced survival signal.  Therefore, we analyzed activation of  the PI3K-PKB pathway in
response to IL-3, IL-5 and GM-CSF and how this pathway can promote survival and pro-
liferation.
In chapter 2, we analyzed which tyrosine residues of  the bc are important for the acti-
vation of  PKB. Next, we set out to identify novel targets by which PI3K might promote
proliferation and survival. This has resulted in the identification of  Forkhead transcrip-
tion factor FKHR-L1, a novel inhibitory target of  PI3K-PKB signaling through the bc,
whose activity promotes apoptosis, as well as cell cycle arrest (Chapter 3). Upon analyz-
ing how transcriptional activity of  FKHR-L1 could result in these events, two FKHR-L1
targets were found (Chapter 3 and 4). Next, we analyzed by which intracellular mecha-
nisms FKHR-L1 could promote apoptosis (Chapter 5). In addition, we provide evidence
that cytokine withdrawal-mediated induction of  apoptosis is mediated by FKHR-L1.
Finally, to identify additional FKHR-L1 targets, we compared gene array filters derived
from cells in which FKHR-L1 activity was present or absent (Chapter 6).
Altogether, our findings provide a novel mechanism by which PI3K-PKB can induce
rescue from apoptosis, as well as promote induction of  proliferation.
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Abstract
Interleukin (IL)-3, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-
CSF) regulate proliferation, differentiation and apoptosis of  target cells. Receptors for
these cytokines consist of  a cytokine-specific a subunit and a common shared bc subunit.
Tyrosine phosphorylation of  the bc is thought to play a critical role in mediating signal
transduction events. We have examined the effect of mutation of  bc tyrosines on the acti-
vation of multiple signal transduction pathways. Activation of  Protein Kinase B (PKB)
required JAK2-binding and was inhibited by dominant-negative phosphatidylinositol 3-
kinase (PI3K). Overexpression of  JAK2 was sufficient to activate both Protein Kinase B
(PKB) and Extracellular Regulated Kinase-1 (ERK1). Tyrosine 577 and 612 were found
to be critical for the activation of  PKB and ERK1, but not activation of  STAT tran-
scription factors. Activation of  both PKB and ERK has been implicated in the regulation
of  proliferation and apoptosis. We generated GM-CSFR stable cell lines expressing recep-
tor mutants to evaluate their effect on these processes. Activation of  both PKB and ERK
was perturbed, while STAT activation remained unaffected. Tyrosines 577 and 612 were
necessary for optimal proliferation; however, mutation of  these tyrosine residues did not
affect GM-CSF mediated rescue from apoptosis. These data demonstrate that while
phosphorylation of  bc tyrosine residues 577 and 612 are important for optimal cell pro-
liferation, rescue from apoptosis can be mediated by alternative signaling routes.
Introduction
The cytokine receptor family that consists of  the receptors for interleukin (IL)- 3, IL-5
and granulocyte-macrophage colony-stimulating factor (GM-CSF) have a cytokine-spe-
cific alpha chain (IL-3Ra, IL-5Ra and GM-CSFRa) and a common beta chain, bc, which
are both required for high affinity ligand binding. The biological effects of  these
cytokines on hematopoeietic cell lineages and their precursors include induction of  pro-
liferation, differentiation, inflammation, cell adhesion, regulation of  effector functions
and rescue from apoptosis; reviewed in 1-3. Furthermore, recent data has implicated this
family of  cytokines in the pathogenesis of  various leukemias. A naturally occurring trun-
cated isoform of  bc has been identified in a significant proportion of  patients with acute
leukemia4, while it has also been demonstrated that inhibition of GM-CSF prevents dis-
semination and induces remission of myelomonocytic leukemia5. Surprisingly, expression
of  the GM-CSF receptor has also been found in human prostate cancer implying that
prostatic tissues may also be responsive to GM-CSF6.
Signal transduction events elicited by each of  these cytokines are thought to be simi-
lar, since they all utilize the common bc2. Although no specific signaling events have been
attributed to the a-chains, intracellular truncation results in aberrant signal transduc-
tion7,8. The bc does not possess intrinsic tyrosine kinase activity, but associates with a
cytoplasmic tyrosine kinase, JAK2 (Janus Kinase 2), via the membrane proximal region9.
Following cytokine stimulation, the receptor multimerizes, allowing transphosphorylation
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of  the bc, resulting in the recruitment of  signaling molecules to the bc and activation of  down-
stream signaling events3,9,10. The precise mechanisms and specific tyrosine residues involved
remain to be fully elucidated. The bc contains docking sites for SH2-domain containing proteins
such as the cytoplasmic transcription factors STATs (signal transducers and activators of  tran-
scription; reviewed in 11). However, there is a high redundancy for STAT binding sites on the
cytoplasmic bc; mutation of  a single tyrosine residue does not affect STAT activation12,13. 
Another critical signaling pathway activated by IL-3/IL-5/GM-CSF is initiated by the lipid
kinase PI3K, which phosphorylates phosphoinositides on the 3' position14-18. Generated phos-
phatidylinositol-3,4,5-trisphosphate is known to be critical for the activation of  several protein
kinases including Protein Kinase B/c-Akt (PKB), and the recently identified PtdIns(3,4,5)P3-
Dependent protein Kinase (PDK1)19,20. Pathways associated with PI3K have been linked to
both proliferation through p70S6K21, as well as the rescue from apoptosis through PKB22-24,
although the precise mechanism by which PI3K is activated through the bc still needs to be elu-
cidated. Since various candidates regulating bc activation of  PI3K have been reported, it is like-
ly that there are multiple pathways from the bc that can trigger activation of  PI3K14,25-27.
In this study, we have investigated which tyrosine residues in the common bc are important
for activation of  PI3K-mediated signaling events in comparison with activation of  the ERK
MAP kinases and the STAT transcription factors. We have also assessed the role of  bc tyrosine
residues in proliferation, as well as in rescue from apoptosis induced by hGM-CSF. We have
demonstrated for the first time that activation of  PKB by IL-3/IL-5/GM-CSF requires the
phosphorylation of  specific bc tyrosine residues. Furthermore, PKB appears to play a role in
cytokine-mediated proliferation. These data provide novel insights into mechanisms of  activa-
tion and function of  bc-mediated signal transduction.  
Materials and Methods
Cells, reagents, antibodies
Rat-1 fibroblasts were cultured in Dulbecco's Modified Eagle's medium (Gibco) supplemented
with 8% heat-inactivated FCS; Ba/F3 cells were cultured in RPMI 1640 supplemented with 8%
Hyclone serum (Gibco) and recombinant mouse IL-3 (mIL-3) produced in COS cells61. Human
IL-5 (hIL-5) was a kind gift of Dr. D. Fattah (Glaxo Wellcome group research, Stevenage, UK).
Recombinant human GM-CSF was obtained from Genzyme (Boston, MA, U.S.A.). The con-
structs for p21ras N17, Dp85, HA-PKB, HA-ERK1 and JAK2 have been described previous-
ly28,62. Human IL-5Ra and human bc, as well as bc DboxI, bc DboxI/II, bc Y577G, bc Y612F
and bc Y577G/Y612F mutants were cloned into expression vector pSG513 either with or with-
out the hygromycin gene as described previously13. pCDNA3 GM-CSFRa63 and kinase-dead
JAK264 were kind gifts from Dr A. Kraft. 
Rabbit polyclonal antiserum against the human bc has been described previously13. bc mAb
and polyclonal ERK1 (C16) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Phospho-Ser-473 PKB and phospho-ERK antibodies were from New England Biolabs
(Beverly, MA, U.S.A). 
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Generation of stable transfectants
For the generation of  polyclonal transfectants pcDNA3-GMCSFRa containing the
neomycin resistance gene was electroporated into Ba/F3 cells (0.28 V; capacitance 960
mFD) together with either empty vector, bc wt, bc Y577G, bc Y612F or bc Y577G/612F
cloned into pSG513 containing the hygromycin resistance gene. Cells were cultured in the
presence of mIL-3 and selected in 500 mg/ml hygromycin and/or 500 mg/ml G418
(Boehringer Mannheim, Germany). 
Western Blotting and Immunoprecipitation
For determining the presence of  human bc in the Ba/F3 GM-CSFR stable cell lines
1.5x107 cells were lysed in 20 mM Tris.HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 1
mM EDTA, 1mM PMSF, 0.1 mM aprotinin and 1 mM sodium orthovanadate. Lysates
were cleared by centrifugation at 4°C and incubated with the appropriate antibody on a
rotating wheel at 4°C for 1 hr. After that, Protein A beads were added and incubated for
another hour. Protein A beads were washed 3x with lysis buffer and boiled in Laemli sam-
ple buffer for 5 min at 95°C. Subsequently, samples were run on SDS-polyacrylamide gels
and proteins transferred to PolyVinyl DiFluoride (PVDF) membranes. Blots were incu-
bated with appropriate antibodies and developed utilizing Enhanced Chemiluminescence
(ECL, Amersham). 
In vitro kinase assays
Cells were transfected transiently using calcium phosphate precipitation and the medium
refreshed 8 hours later. 36 hours after transfection, the cells were transferred to 0.5% FCS
overnight. After a further 12 hours, the cells were stimulated with the appropriate stimu-
lus, washed twice with cold PBS and lysed in a buffer containing 1% Triton X-100, 50mM
Tris-HCl pH 7.5, 5 mM EDTA for ERK assays or 1% Triton X-100, 50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 5 mM EDTA for PKB assays, both supplemented with 10 mg/ml
aprotinin, 1 mM leupeptin, 1 mM PMSF, 1 mM Na3VO4, 40 mM b-glycerophosphate and
50 mM NaF. Kinase assays were performed as described previously28. 
CAT assays
Rat-1 cells (6-well plates) were transiently transfected with 3 mg IL-5Ra and 3 mg bc
(either wildtype or the tyrosine mutant 577, 612 or 577/612), together with 4 mg
4xIREtkCAT reporter construct65. 36 hours after transfection, cells were incubated
overnight with IL-5 (10-10 M). Cells were washed with PBS and harvested in PBS/EDTA
(25 mM) and lysed in 100 ml CAT buffer (250 mM Tris-HCl pH 7.4, 25 mM EDTA).
Membranes were spun down and 50 ml of  the supernatant was incubated with 150 ml
incubation buffer (50 ml CAT buffer, 7.5 ml 50% glycerol, 81.5 ml 250 mM Tris-HCl pH
7.4, 10 ml 6.7 mg/ml butyrylCoA, 1 ml 14C Chloramphenicol 0.025 mCi) for 2 hours at 37°C.
Unincorporated 14C Chloramphenicol was separated from butyrylCoA using Xylene-
Pristane (1:2) and 14C-ButyrylCoA was counted. 
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The fold induction was calculated as the amount of  counts in the stimulated versus unstimulat-
ed cells65. Data represent the mean of  three independent experiments ± SEM.
Gel retardation assays
Nuclear extracts were prepared from 107 stimulated and unstimulated cells as described previ-
ously66. Synthetic oligonucleotides of  the FcgRI GAS36 were labeled by filling in the cohesive
ends with [a-32P]dCTP using the Klenow fragment of DNA polymerase I. Gel retardation
assays were carried out according to published procedures with slight modifications67. Briefly, 5
mg nuclear extract were incubated in a final volume of  20 ml, containing 10 mM HEPES pH 7.8,
50 mM KCl, 1 mM EDTA, 5 mM MgCL2, 10% glycerol, 5 mM dithiothreitol, 2 mg poly (dI-dC)
and 20 mg bovine serum albumin with 0.1-1.0 ng of  32P-labeled oligonucleotides for 20 min at
room temperature. Subsequently, samples were run for 2 hours on a 5% non-denaturing poly-
acrylamide gel at room temperature, vacuum-dried and exposed to Fuji RX film at -70°C for 1-
2 days.
Apoptosis and proliferation assays
For apoptosis assays Ba/F3 cells were counted, washed twice with PBS and seeded in 24 well
dishes (0.4x 106 cells per well). After two hours cytokines were added and after a further 48 hours
cells were harvested, washed twice in PBS and fixed for 2 hours in 300 ml PBS and 700 ml
ethanol. Cells were spun down gently and permeabilized in 200 ml 0.1 % Triton X-100, 0.045 M
Na2HPO4 and 0.0025 M sodium citrate at 37°C for 20 minutes. Next, 750 ml apoptosis buffer
(0.1 % Tx100, 10 mM PIPES, 2 mM MgCl2 40 mg/ml Rnase, 20 mg/ml propidium iodide) was
added and incubated for 30 minutes in the dark. The percentage of  apoptotic cells was analyzed
by FACS as the percentage of  cells with a DNA content of <2N. For cell proliferation assays
Ba/F3 cells were seeded in 24 well dishes (0.1x 106 cells per well) together with hGM-CSF and
the number of  viable cells was counted every 24 hours by Trypan Blue exclusion.
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Results
Activation of PKB and ERK1 requires the bc tyrosine residues 577 and
612.
The mechanisms of  PI3K activation by bc are ill-defined3. We and others have previous-
ly identified PKB as a downstream effector of  PI3K activity stimulated by growth fac-
tors28,29 and that PKB is activated by IL-5 and IL-3 in both cell lines and human granu-
locytes, although the mechanisms have not been defined18,30. To analyze the mechanism
by which bc can activate PKB we transiently transfected Rat1 cells with IL-5Ra and bc
together with epitope-tagged PKB (HA-PKB) and analyzed PKB kinase activity in vitro.
These cells have no endogenous bc and demonstrate a relatively strong activation of
PI3K pathways by growth factors, thus being a suitable model system28. As shown in Fig.
1A, PKB is activated following IL-5 stimulation. This activation is mediated through
PI3K, as cotransfection of  dominant negative PI3K (Dp85)31 blocks IL-5 dependent
PKB activation. To determine whether IL-5 dependent PKB activation required tyrosine
phosphorylation of  the bc we cotransfected bc that had a deletion of  box I and box II,
which prevents the binding of  JAK2 and thus prevents receptor phosphorylation9,32. We
found that box I/II of  bc are critical for the activation of  PKB, since deletion almost
completely abrogated PKB activation (Fig. 1A, left panel). To rule out the possibility that
this abrogation is due to a generally non-functional receptor we also transfected kinase-
dead JAK2, which has been described to function as a dominant-negative kinase for
endogenous JAK2 in interferon-g signaling33. Overexpression of  this mutant of  JAK2
indeed decreased activation of  PKB (Fig. 1A, right panel), indicating the importance of
bc phosphorylation for PKB activation. To determine if  tyrosine residues 577 or 612
were responsible for mediating activation of  PKB, we transfected cells with bc contain-
ing either single or double point mutations of  these residues. While activation of  PKB
was mediated predominantly by bc tyrosine residue-577, tyrosine-612 also appears to play
a role, since activation is only completely blocked by mutation of  both tyrosines (Fig. 1B).
Reprobing the same blot revealed equal expression of  PKB in all lanes. We also verified
whether expression of  the various bc constructs was equal (Fig. 1B, left panel). Similar
results were obtained by transfecting 293 cells (data not shown). 
Previous work has demonstrated a potential role for Shc binding to tyrosine-577 as a
mechanism of  initiating MAP kinase activation12,34,35. To determine if  the same tyrosine
residues were indeed necessary for activation of  the MAP kinase, ERK1, we performed
similar cotransfection experiments. ERK1 activation also required an intact box I/II
region and was dependent on p21ras (data not shown). Mutation of  tyrosine-577 abro-
gated ERK1 activation (Fig. 1C), suggesting this tyrosine is also critical for activation of
ERK1. 
To demonstrate that the bc with mutations in these tyrosine residues is still function-
al in the activation of  other signaling pathways we analyzed activation of  STAT tran-
scription factors. For this purpose we transiently transfected cells with IL-5Ra and the bc
Chapter 2
42
Chapter 2.qxd  2-5-01  18:07  Page 42
mutants together with a tkCAT reporter plasmid containing 4XIRE binding sites and analyzed
the induction of  CAT activity by IL-5. We have previously demonstrated that this is a specific
STAT-binding reporter construct36. While neither bc tyrosine mutant affected STAT activation,
the bc DboxI/boxII mutant completely abrogated IL-5 mediated STAT activation (Fig. 1D).
Thus, while STAT activation appears to allow redundancy in bc phosphotyrosine residues,
p21ras-ERK and PI3K-PKB signaling require tyrosine phosphorylation of  specific bc residues.
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Figure 1. Activation of Multiple Signaling Pathways in response to IL-5.
(A) Rat1 cells were transiently transfected with IL5a (2 mg) and bc (2 mg, lanes 1, 2, 5-10) together with HA-PKB
(2 mg) dominant-negative p85 (4 mg;  Dp85, lanes 5 and 6), or dn JAK2 (2 mg; lanes 9 and 10) . 48 hours after
transfection serum-starved cells were left unstimulated or stimulated with hIL-5 (10-10 M) for 7 minutes, HA-
PKB was immunoprecipitated and an in vitro kinase assay was performed using Histone 2B (H2B) as a substrate.
H2B and autophosphorylated PKB are indicated. (B) Rat1 cells were transfected with bc wildtype or bc tyrosine
mutants (10 mg) and the bc was immunoprecipitated, blotted and reprobed with a bc antibody (left panel). For
in vitro kinase assays cells were transfected as indicated and stimulated as described above. Equal expression of
HA-PKB was determined by 12CA5 Western blotting (lower right panel). (C) Rat1 cells were transfected with
HA-ERK1 (2 mg) and bc tyrosine mutants as indicated and stimulated as described above. HA-ERK was
immunoprecipitated and an in vitro kinase assay was performed using myelin basic protein (MBP) as a substrate.
(D) Rat1 cells were transiently transfected with IL-5Ra and either of  the bc mutants together with a tkCAT
reporter plasmid (4 mg) containing 4XIRE STAT binding sites (lane 1, wt bc; lane 2, bc DboxI/II; lane 3, DY577;
lane 4, DY612; lane 5, DY577/612). 36 hours after transfection cells were left unstimulated or hIL-5 was added
to the cells overnight and CAT activity was determined the next day as described in Materials and Methods. The
fold induction is indicated as the amount of  CAT activity of  the hIL-5 stimulated cells compared to the unstim-
ulated cells.
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Overexpression of JAK2 activates both PKB and ERK1.
As we found that JAK2 binding and phosphorylation of  the bc is required for both PKB
and ERK activation (Fig. 1), we next addressed whether JAK2 overexpression itself  was
sufficient to activate these signaling pathways, as has previously been demonstrated for
STATs37. JAK2 was overexpressed in Rat1 cells and ERK1 or PKB assays were per-
formed. Interestingly, increased JAK2 expression was sufficient to activate both ERK1
(Fig. 2A, compare lane 1 and lane 3) or PKB (Fig. 2B, compare lane 1 and 3), indicating
that overexpression of  JAK2 is sufficient to activate downstream signaling pathways.
Overexpression of  JAK2, however, did not result in a 'superinduction' of ERK1 and
PKB activity in the presence of  IL-5 (Fig. 2A and 2B, compare lanes 2 and 4). This sug-
gests that either the level of  bc phosphorylation is playing a limiting role or perhaps more
likely, that this activation is independent of  bc.
Expression of bc in BaF3 cell lines and activation of signaling pathways.
Activation of  both PI3K and MAP Kinase have been proposed to be critical for both
proliferative and anti-apoptotic effects of  IL-3/IL-5/GM-CSF30,38-40. To analyze the
potential function of  bc tyrosine residues 577 and 612 we utilized Ba/F3 cells, a mouse
pre-B cell line that is dependent on murine IL-3 for its growth. As the IL-5Ra subunit
was found to interact with the endogenous mouse bc (data not shown) we generated poly-
clonal stable cell lines with the GM-CSFRa subunit which did not interact with endoge-
nous mouse bc (see Fig. 3A). We transfected either GM-CSFRa alone or together with
wildtype human bc (hbc), or hbc in which either tyrosine-577 (D577), 612 (D612) or both
(D577/612) had been mutated. Expression of  the hbc in the Ba/F3 cell lines was verified
by immunoprecipitation with an antibody that specifically recognizes the hbc. Fig. 3A
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Figure 2. Overexpression of  JAK2 activates both ERK1 and PKB.
(A) Rat1 cells were transiently transfected with IL-5Ra (2 mg), bc (2 mg) together with JAK2 (4 mg) and
HA-ERK1 (2 mg) and kinase assays were performed as described above. (B) Same as (A), but transfect-
ed with HA-PKB (2 mg).
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demonstrates that the expression in bc wt, D577, D612 and D577/612 is comparable. To analyze
whether GM-CSF Receptor signaling in these cell lines can be reconstituted, we first analyzed
STAT activation following hGM-CSF stimulation, using an electromobility shift assay. 
Comparable STAT DNA-binding activity was seen following hGM-CSF stimulation in all stable
cell lines except for the Ba/F3 cells expressing only GM-CSFRa, indicating that signaling of
these hGM-CSF-R stable cell lines specifically utilizes the human bc (Fig. 3B). Moreover, STAT
activity was not diminished in the BaF3 cells containing the hbc with tyrosine mutations.
However, when PKB activation was analyzed using activation-specific antibodies against phos-
pho Ser473, which is phosphorylated together with Thr308 following elevation of
PtdIns(3,4,5,)P3, a product of  PI3K41,42. We found, in agreement with the data for the Rat1 cells,
that activation is mediated predominantly through tyrosines 577 and 612, as the double tyrosine
mutant was unable to phosphorylate PKB Ser-473 (Fig. 3C). Addition of  the PI3K inhibitor
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Figure 3. Signaling of  hGM-CSFR in Ba/F3 cells.
(A) Ba/F3 cells were stably transfected with hGM-CSFRa together with either empty vector or bc wt, D577,
D612 or D577/612. Expression of  the human bc was verified by precipitating the human bc from 15x106 cells
as described in Materials and Methods. (B) Nuclear extracts were prepared from serum-starved untreated or
mIL-3 or hGM-CSF (10-10 M) stimulated cells and gel retardation assays using a FcgRI GAS probe were carried
out as described in the Materials and Methods. The identity of  STAT1 and STAT3 complexes was confirmed by
supershift analysis (data not shown). (C) Ba/F3 cells (0.25x106) were serum-starved for 4 hours and then left
untreated stimulated with hGM-CSF (10-10 M) or stimulated with mIL-3 with or without pretreatment with 10
mM LY294002 for 20 minutes as indicated. PKB activation was analyzed by phospho-PKB immunoblotting. (D)
ERK activation was measured by phospho-ERK immunoblotting as described above.
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LY294002 completely abrogated PKB activation following mIL-3 in all GM-CSFR stable
cell lines, indicating that phosphorylation of  PKB on Ser473 is indeed downstream of
PI3K. Activation of  ERK1 and ERK2 was also almost completely eliminated by muta-
tion of  these residues (Fig. 3D). Additional tyrosine residues may be involved in the acti-
vation of ERK1/2, since the D577/612 mutant still demonstrated slight ERK activation,
although activity was much reduced compared to the wild-type bc. Measuring activity of
endogenous ERK2 using a substrate-based assay yielded the same results (data not
shown).
Optimal proliferative response to hGM-CSF requires bc tyrosines
577/612.
GM-CSF induces cell proliferation and rescue from apoptosis in a dose-dependent man-
ner. To determine whether mutation of  tyrosine-577 and 612 affected proliferation of
cells when grown on hGM-CSF, cells were grown for three days with two different con-
centrations of  hGM-CSF and the cell numbers determined every 24 hours. Cells express-
ing only the GM-CSFRa chain failed to proliferate when challenged with GM-CSF,
demonstrating the necessity for interaction with the human bc (Fig. 4). No significant
effect was observed by mutating either tyrosine 577 or 612 independently. However, a 2-
3-fold decrease in proliferation was seen in Ba/F3 cells containing the bc D577/612. A
slight, but reproducible, effect was also seen on the proliferation of  the bc D577 cell line
when the cells were grown on a lower concentration (10-12 M) hGM-CSF (Fig. 4B). To
demonstrate that the effect on proliferation in the Ba/F3 bc D577/612 stable cell line is
not a clonal artefact we also compared proliferation of  this cell line with Ba/F3 bc wt
when grown on mIL-3. No difference in proliferation with mIL-3 was found between
those cell lines (Fig. 4C), ruling out a clonal difference between those cell lines. Thus it
appears that while the ability to proliferate is not completely abrogated by mutation of
tyrosine 577 and 612, it is substantially reduced. This suggests that activation of  PKB
and/or MAP kinase may play a critical role in regulating bc-mediated proliferative
responses. Furthermore, since STATs are still activated in this bc mutant (Fig. 3B), it sug-
gests that they are not themselves sufficient to mediate cytokine induced proliferative
responses without the cooperation of  other signaling pathways.
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GM-CSF mediated cell survival does not require bc tyrosines 577/612.
In addition to inducing proliferation, agonists such as GM-CSF also prevent apoptosis in
responsive cells. To investigate whether the decrease in proliferation that was seen in the
D577/612 stable cell line was due to increased apoptosis, we determined the percentage of  apop-
totic cells after 48 hours incubation with or without cytokine. Cells expressing only the GM-
CSFRa chain exhibited no GM-CSF mediated rescue from apoptosis, although they could clear-
ly be rescued by incubation with mIL-3 (Fig. 5). We did not observe a significant decrease in the
rescue from apoptosis in the single or double D577/612 cell lines following incubation with
hGM-CSF (10-10 M), suggesting that these tyrosine residues are not necessary for mediating
apoptotic rescue (Fig. 5). The same results were obtained at lower cytokine concentrations (10-
12 M hGM-CSF; data not shown). Thus it appears that activation of  PKB and, to some extent,
ERK are not critical for GM-CSF mediated cell survival. It is possible that the residual ERK
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Figure 4. Proliferation of  the Ba/F3 hGM-CSFR cell lines. 
Ba/F3 cells containing the GM-CSFRa, GM-CSFRa and bc wt, D577, D612 or D577/612 were cultured with
hGM-CSF 10-10 (A) or 10-12 M (B) and the number of  cells was counted every 24 hours. (C) Ba/F3 cells con-
taining the GM-CSFRa and bc wt or D577/612 were cultured with mIL-3 and the number of  cells was count-
ed every 24 hours.
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activity may still contribute to the rescue from apoptosis, however, we did not find a dif-
ference in the rescue from apoptosis upon addition of  the MEK inhibitor PD98059 (see
chapter 3). 
Discussion
Cytokines of  the IL-3/IL-5/GM-CSF family are important regulators of  hematopoiesis
through modulation of  proliferation, differentiation and survival of  various hematopoi-
etic cell lineages and their precursors2,3. Although the receptors for these cytokines do not
possess any intrinsic kinase activity, tyrosine phosphorylation of  cellular substrates by bc-
associated JAK kinases is rapidly observed in stimulated cells. One of  these substrates is
the bc itself, generating phosphotyrosine docking sites for SH2-containing downstream
signaling molecules. In recent reports, as well as in this study, it has been shown that sin-
gle mutation of  any bc tyrosine residue has no effect on STAT activation by IL-3/IL-
5/GM-CSF, suggesting a high degree of  redundancy12,13; Fig. 1D and 3B. 
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Figure 5. Analysis of  apoptosis in the Ba/F3 GM-CSFR stable cell lines. 
Ba/F3 cells containing the GM-CSFRa, GM-CSFRa and bc wt, D577, D612 or D577/612 were
cultured with hGM-CSF 10-12 M for 48 hours and the percentage of  apoptotic cells was deter-
mined as described in Materials and Methods.
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In this paper we report that in various cell lines tyrosine 577 and 612 are important for the
activation of  both PKB and ERK. One pathway that induces activation of  ERK is most likely
mediated through the adapter protein Shc, which binds to phosphorylated Y-577 on the bc and
is itself  tyrosine phosphorylated after IL-3/IL-5/GM-CSF stimulation allowing Grb2-Sos bind-
ing and activation of  p21ras34,35,43. However, an alternative means of ERK activation may be ini-
tiated through SHP2, which has been reported to interact through its SH2 domain with Y577
and to be phosphorylated by either Y-577, Y-612, or Y-69544-47. Activation of ERK by SHP2 can
occur through interaction of  phosphorylated SHP2 with Grb2-SOS and subsequent p21ras acti-
vation, observations that suggest redundancy in ERK activation45. An alternate means of  ERK
activation may also be provided by Shc binding directly to JAK2, which has been demonstrated
for the EPO receptor48. This may explain the small residual ERK activity seen in the Ba/F3 bc
D577/612 stable cell line (Fig. 3D).
Activation of  PI3K through bc is complex and likely to be mediated through multiple sig-
naling pathways. While the mechanisms of  activation of  its downstream effector PKB have not
been previously investigated, PI3K activity has been found to be associated with anti-phospho-
tyrosine immunoprecipitates, but not with anti-bc immunoprecipitates15. Studies have reported
binding of  the regulatory subunit of  PI3K to a novel, yet to be identified protein (p80), that may
link PI3K to the receptor26, as well as by associating with Lyn, a Src-like kinase that binds to the
bc14. Furthermore, SHP2 was also found to coimmunoprecipitate with the p85 subunit of  PI3K,
potentially linking activation of  both PI3K and p21ras pathways25. The potential involvement of
Lyn in the activation of  PI3K is of  particular interest, since this kinase has been linked to inhi-
bition of  apoptosis in human granulocytes and decreased Lyn activity has been associated with
a abrogation of  PI3K activity49-51. Together, this strongly suggests that there are multiple redun-
dant pathways that promote activation of  PI3K. This is in agreement with our finding that both
tyrosine-577 and 612 (Fig. 1C) activate its downstream target, PKB. We and others have previ-
ously demonstrated that PKB can be activated by cytokines of  the IL-3/IL-5/GM-CSF fami-
ly18,30. However, this is the first study to demonstrate the relevance of  bc tyrosine residues in
PI3K mediated signal transduction and activation of  downstream targets such as PKB. Although
we have shown that bc-mediated PKB activation requires the p85a subunit of  PI3K (Fig. 1A),
further studies are needed to determine precisely how PI3K is itself  activated after cytokine
stimulation.
Interestingly, we found that simply overexpression of  JAK2 was sufficient to induce activa-
tion of  both PKB and ERK1 (Fig. 2). Overexpression of  JAK2 in Ba/F3 cells has previously
been found to delay apoptosis52. In addition, abnormal activation of  JAK2 has been implicated
in acute lymphoblastic leukemia53. Thus overexpression or constitutive activation of  JAK2 may
lead to an inappropriate activation of  p21ras-ERK and PI3K-PKB, resulting in enhanced pro-
liferation or cytokine-independent survival. A direct role for bc itself  in leukemogenesis has
recently been implied by the recent observation that a truncated bc was found in patients with
acute leukemia4. This further suggests that inappropriate regulation of  bc phosphorylation and
subsequent downstream signaling events causes defective proliferative responses in some cells. 
We have studied the effect of mutation of  bc tyrosines 577 and 612 on proliferation and rescue
from apoptosis. Whereas we did not find an effect on cell survival with either of  the mutants
(Fig. 5), we did observe a decrease in proliferation in the GM-CSFR D577/612 cell line (Fig. 4).
Interestingly, recent reports have shown that inhibition of  STAT activation in Ba/F3 cells, for
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example by overexpression of  dominant-negative STAT5, significantly repressed IL-3
dependent growth54. In contrast, we have demonstrated that repression of  proliferation
does not have to be linked with STAT activation, since the D577/612 cell line effectively
activates STATs but has reduced proliferative capacity (Fig. 4). Our approach to deter-
mine the effects of  the double tyrosine mutant bc has allowed the analysis of  effects that
may be overlooked with the single mutants. This may explain findings of  others suggest-
ing that tyrosine 577 was not necessary for cell viability12,47. Since we demonstrated that
tyrosines 577 and 612 on the bc were important for activation of  both PKB and ERK,
we were unable to distinguish their specific role using these tyrosine mutants. Recently, it
has been shown that introduction of  a dominant-negative MAP kinase kinase (MAPKK)
in Ba/F3 cells results in an increase in the level of  IL-3 required to stimulate cell prolif-
eration, suggesting a role for MAP kinase activation39. A role for MAPK in proliferation
may be negligible, since overexpression of  dominant negative ras N17 was not found to
affect proliferation in Ba/F3 cells55. Furthermore, addition of MEK inhibitor PD98059
was not found to affect proliferation in Ba/F3 GM-CSFR stable cells (data not shown).
A role for PI3K in proliferation can be further supported by the observation of  a pro-
found decrease in proliferation when Ba/F3 GM-CSFR cells were incubated with the
immunosuppressant rapamycin, an inhibitor of  p70S6K, which is a downstream target of
PI3K (data not shown). It has been described previously that blocking mIL-3 induced
p70S6K in BaF3 cells with rapamycin partially inhibited mIL-3 dependent 3H-thymidine
incorporation, suggesting a role for PI3K signaling in cellular proliferation21.  However,
further work utilizing specific pharmacological inhibitors and interfering mutants of  var-
ious signaling pathways will be necessary to identify the precise nature of  this prolifera-
tive mechanism.
The fact that we did not observe a decrease in the rescue from apoptosis by hGM-
CSF in the D577/612 stable Ba/F3 cell line, which fails to activate PKB may seem in
apparent contrast with recently published data30,56. Although our data indeed imply the
potential for apoptotic rescue independently of  PKB, we have recently found that over-
expression of  an novel effective dominant-negative PKB construct57 in BaF3 cells abro-
gated IL-3-mediated rescue from apoptosis (data not shown). Previous studies have relied
on the overexpression of  constitutively active PKB mutants, demonstrating a cytokine-
independent rescue from apoptosis30. It is difficult to determine the specificity of  these
overexpression studies since constitutively active PKB is oncogenic and may induce
autocrine or anti-apoptotic effects in these cells and these data should thus be interpret-
ed with caution. 
There are several explanations for the apparent discrepancy between survival by
hGM-CSF in the D577/612 stable Ba/F3 cell line and the observation that overexpres-
sion of  dominant-negative PKB abrogated IL-3-mediated rescue from apoptosis. First, it
might be that there is some residual PKB activity in the D577/612 stable Ba/F3 cell line
that is not detected by phospho-specific antibodies. Interestingly, after completing these
studies, an alternate mechanism of  activating PI3K-PKB through bc was provided
through phosphorylation of  serine-585 on bc58. Mutation of  this residue impaired IL-3-
Chapter 2
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mediated survival. An alternate explanation might be that the apoptosis experiments were car-
ried out in the presence of  serum, which could contribute to survival mediated by GM-CSF
independently of  PKB. Indeed, the recent identification of  serum and glucocorticoid inducible
kinases (SGKs) in the anti-apoptotic response by IL-359,60 after completion of  this studies sup-
ports this. A role for PKB in mediating the anti-apoptotic response is further examined in
Chapter 3 and 5.  
The studies presented here provide insight not only into the mechanisms of  bc-mediated sig-
nal transduction but also the potential role of  these signaling pathways in maintaining prolifera-
tive capacity and viability of  cytokine-dependent cells. Activation of  PI3K and PKB by IL-3/IL-
5/GM-CSF has been previously demonstrated in cell lines and leukocytes18,30,56. This is the first
study to demonstrate a role for c tyrosine residues in the activation of  PKB and suggests speci-
ficity between activation of  PI3K-PKB, p21ras-ERK and JAK-STAT signaling pathways. 
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CHAPTER 3
Forkhead transcription factor FKHR-L1 modulates
cytokine-dependent transcriptional regulation of  p27KIP1
Pascale F. Dijkers, Rene H. Medema, Cornelieke Pals, Lolita Banerji, N. Shaun B.
Thomas, Eric W.-F. Lam, Boudewijn M. T. Burgering, Jan A.M. Raaijmakers, Jan-Willem
J. Lammers, Leo Koenderman and Paul J. Coffer
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Abstract
Interleukin-3 (IL-3), IL-5 and granulocyte-macrophage colony-stimulating factor (GM-
CSF) regulate the survival, proliferation and differentiation of  hematopoietic lineages.
Phosphatidylinositol 3-kinase (PI3K) has been implicated in the regulation of  these
processes. Here we investigate the molecular mechanism by which PI3K regulates
cytokine-mediated proliferation and survival in the murine pre-B cell line Ba/F3. IL-3 was
found to repress the expression of  the cyclin-dependent kinase inhibitor p27KIP1 through
activation of  PI3K, and this occurs at the level of  transcription. This transcriptional reg-
ulation occurs through modulation of  the forkhead transcription factor FKHR-L1, and
IL-3 inhibited FKHR-L1 activity in a PI3K-dependent manner. We have generated Ba/F3
cell lines expressing a tamoxifen-inducible active FKHR-L1 mutant (FKHR-
L1(A3):ER*). Tamoxifen-mediated activation of  FKHR-L1(A3):ER* resulted in a strik-
ing increase in p27KIP1 promoter activity and mRNA and protein levels, as well as induc-
tion of  the apoptotic program. The level of  p27KIP1 appears to be critical in the regula-
tion of  cell survival since mere ectopic expression of  p27KIP1 was sufficient to induce
Ba/F3 apoptosis. Moreover, cell survival was increased in cytokine-starved bone marrow-
derived stem cells from p27KIP1 null-mutant mice compared to that in cells from wild-
type mice. Taken together, these observations indicate that inhibition of  p27KIP1 tran-
scription through PI3K-induced FKHR-L1 phosphorylation provides a novel mechanism
of  regulating cytokine-mediated survival and proliferation. 
Introduction
Cytokines of  the interleukin-3 (IL-3)/IL-5/ granulocyte-macrophage colony-stimulating
factor (GM-CSF) family are important regulators of  proliferation, differentiation and
effector functions of  various hematopoietic cell lineages and their precursors1,2. IL-3 and
GM-CSF regulate the proliferation and survival of multiple hematopoietic lineages,
whereas IL-5 has a more restricted role in the differentiation of  eosinophils and
basophils, as well as of murine B cells2,3. Phosphatidylinositol 3-kinase (PI3K), and its
downstream target protein kinase B (PKB) have been linked to regulation of  prolifera-
tion and survival in a variety of  hematopoietic systems4-6. PI3K activity is negatively reg-
ulated by the PTEN (phosphatase and tensin homolog) phosphatase, which specifically
dephosphorylates the D3 position of  phosphatidylinositol, thus inhibiting the action of
PI3K7-10. Several mechanisms have been proposed to explain the requirement for PI3K
activity in cytokine-mediated cell survival. For example, IL-3 regulates PKB-induced
phosphorylation of  the pro-apoptotic Bcl-2 family member BAD, inhibiting its pro-apop-
totic activity6. However, it has recently been shown that this phosphorylation does not
correlate well with cell survival11. Another target of  PKB possibly accounting for its anti-
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apoptotic effect is the apoptotic protease caspase-9, which is inactivated upon phospho-
rylation by PKB12. However, this phosphorylation site is not evolutionarily conserved13,
leaving its relevance in vivo to be demonstrated. More recently, PKB was demonstrated
to be involved in negatively regulating the activity of  the forkhead family of  transcription
factors which can mediate apoptosis as well as proliferation14-16. 
To identify a potential mechanism by which PI3K could exert its proliferative and
anti-apoptotic effects, we focused on cyclin-dependent kinase (CDK) inhibitor p27KIP1.
Upregulation of  p27KIP1 is linked to cell cycle arrest in G0/G1 through its interaction with
CDK-cyclin complexes17. Regulation of  p27KIP1 levels has been described as occurring
predominantly posttranslationally, by cyclin E-CDK2-mediated phosphorylation, which
subsequently targets p27KIP1 for degradation by the proteasome17-20. p27KIP1 in turn also
inhibits cyclin E-CDK2 complexes, suggesting that the balance of  p27KIP1 and cyclin E-
CDK2 is important for G1 progression. Mitogens upregulate cyclin D levels, subse-
quently sequestering away p27KIP1 from cyclin E/CDK2 complexes and hereby activat-
ing these complexes21. Interestingly, p27KIP1 has also been implicated in the regulation of
immunoglobulin M (IgM)-induced B cell apoptosis, which can be rescued by CD40 lig-
and engagement22,23. The exact mechanism by which cytokines are able to regulate
p27KIP1 levels and what the importance of  this is for mediating its proliferative and anti-
apoptotic effects in hematopoietic cells are largely unknown. 
Here we show that an important means by which cytokine-mediated proliferation and
survival are regulated is through downregulation of  p27KIP1. Transcriptional induction of
p27KIP1 is regulated by the forkhead-related transcription factor FKHR-L1. Activation of
FKHR-L1 is sufficient to elevate p27KIP1 mRNA and protein levels, as well as to induce
apoptosis. Importantly, apoptosis of  bone marrow derived hematopoietic stem cells from
p27KIP1 null-mutant mice is decreased upon cytokine withdrawal compared to that of
cells from wild-type mice, demonstrating the importance of  regulating p27KIP1 levels in
vivo for cell survival. Our data provide a novel mechanism by which cytokines can both
regulate cell cycle progression and inhibit apoptosis by the PI3K-PKB-mediated down-
regulation of  p27KIP1. We propose that the regulation of  p27KIP1 transcription by fork-
head-related transcription factors may be a general mechanism by which hematopoietic
cells can respond appropriately to their environmental conditions, resulting in survival,
proliferation, or differentiation.
Materials and Methods
Cell culture
Ba/F3 cells were cultured in RPMI 1640 supplemented with 8% Hyclone serum (Gibco)
and recombinant mouse IL-3 produced in COS cells24. Peripheral blood eosinophils from
healthy volunteers obtained from the Blood Bank (Utrecht, The Netherlands) were iso-
lated as described previously25. Fetal liver-derived myeloid cultures were prepared from
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day-17 mouse embryos by culture of  suspension cells in RPMI 1640 supplemented with
IL-3, IL-6, and stem cells factor (SCF) as previously described26. Bone marrow cells were
flushed out of mouse femurs and resuspended in Iscove's modified Eagle Medium con-
taining 20% Myclone Super Plus fetal calf  serum and red blood cells were lysed by dilut-
ing them 1:1 with acetic acid- phosphate-buffered saline (PBS). Sca1 positive cells were
isolated using Sca1 antibody microbeads (Miltenyi, Gladbach, Germany). Cells were cul-
tured for 5 days in medium supplemented with murine IL-3, IL-6, SCF (R&D, Abingdon,
United Kingdom) before analyzing apoptosis upon cytokine withdrawal. Twenty-four h
after cytokine withdrawal, cells were washed with ice-cold PBS, resuspended in binding
buffer (10 mM HEPES [pH 7.4], 140 mM NaCl, 2.5 mM CaCl2). Cells were then incu-
bated with fluorescein isothiocyanate (FITC)-conjugated Annexin-V for 10 min at room
temperature, washed and resuspended in binding buffer containing 1 mg of  propidium
iodide (PI)/ml and fluorescence was analyzed by fluorescence-activated cell sorter
(FACS).
Reagents and antibodies
LY294002, PD098059, and SB203580 were from Alexis (San Diego, CA, U.S.A.).
Rapamycin was a kind gift from Dr. N. Lomax from the Drug Synthesis and Chemistry
Branch of  the National Cancer Institute (Bethesda, MD, U.S.A.). pRC-p27KIP1 (mouse)
was a kind gift from R. Bernards (Netherlands Cancer Institute, Amsterdam), and spec-
trin-linked green fluorescent protein (GFP) was a kind gift from Dr. A. Beavis and T.
Sheck (Princeton, USA) and has been described previously27. myrPKB:ER* was a kind
gift of Dr. A. Klippel (Chiron Corporation, Emeryville, CA, U.S.A.). pSG5-
mycPTENcaax was obtained by PCR amplification of  PTEN from human neutrophil
cDNA and shuttling through pGEM-T_caax28 before subsequent cloning into pSG5.
FKHR-L1 constructs were a kind gift from M.E. Greenberg (Boston, MA, U.S.A.)14,
pCDNA3-FKHR-L1(A3):ER* was generated by cloning FKHR-L1(A3) without the stop
codon into a pCDNA3 vector containing the hormone-binding domain of  the estrogen
receptor (pCDNA3-ER). Constructs for haemagglutinin (HA-PKB, gagPKB, cyclin D1,
cyclin D1 promoter, kinase-dead CDK4 and the low-affinity nerve growth factor recep-
tor (LNGFR) have been described previously29-31. The pGL2-p27KIP1 luciferase promot-
er construct32 was a kind gift from Dr. I.P. Touw (Erasmus University, Rotterdam, The
Netherlands). Histone H1 and actinomycin D were purchased from Sigma, and protein
A agarose was purchased from Boehringer GmbH (Mannheim, Germany). p27KIP1 and
RACK1 mAb were purchased from Transduction Laboratories (Lexington, Kentucky,
U.S.A.), PKB, cyclin E, CDK2, ERK1 and ERK2 antibodies were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, U.S.A.). Phospho-Ser473 PKB was from New
England Biolabs (Beverly, MA, U.S.A), while FKHR-L1 and phospho-Thr32 FKHR-L1
were from Upstate Biotechnology Inc. (Lake Placid, NY, U.S.A.). 
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Western blotting
For the detection of  p27KIP1, cells were lysed in Lowry sample buffer and the protein
concentration was determined as described previously33. Equal amounts of  each protein
sample were analyzed by 15% SDS-PAGE and Western blotting with p27KIP1 antibody.
Blots were subsequently probed with RACK1 antibody (or ERK1 and ERK2 in the case
of  eosinophils) to confirm equal protein loading. For the analysis of  CDK2 levels, equal
amounts of  protein of  cells lysed in ELB buffer33 together with inhibitors (see the
description of  kinase assays below) and were analyzed in parallel with the cyclin E-asso-
ciated kinase activity. For detection with phosphospecific antibodies, cells were lysed in
ELB buffer together with inhibitors, and equal amounts of  protein were run on gel, blot-
ted, and probed with phosphospecific antibodies. 
Northern blotting
Ba/F3 cells were cultured with IL-3 and then starved for various times, or were starved
for IL-3 overnight and subsequently stimulated with IL-3. In some experiments cells were
cultured with IL-3 and 4-hydroxy tamoxifen (4-OHT) was added. Total RNA was isolat-
ed as described previously34. Twenty micrograms of  total RNA was used for Northern
blotting and hybridized with a p27KIP1 probe consisting of  full-length p27KIP1 cDNA.
Equal RNA loading was verified by stripping and reprobing the blots with a 1.4 kb cDNA
fragment of  the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.
Apoptosis and proliferation assays
For apoptosis assays cells were counted, washed twice with PBS, resuspended in RPMI
1640 containing 8% Hyclone, and seeded in 24-well dishes (0.4 x 106 cells per well). After
two h inhibitors were added as indicated, and after a further 30 min cytokines were added.
After 48 h cells were harvested, washed twice in PBS and fixed for at least 2 h in 300 ml
of  PBS-700 ml of  ethanol. Cells were spun down gently and permeabilized in 200 ml of
0.1% Triton X-100-0.045 M Na2HPO4- 0.0025 M sodium citrate at 37°C for 20 min.
Next, 750 ml of  apoptosis buffer (0.1% Triton X-100, 10 mM PIPES [piperazine-
N,N'bis{2-ethanesulfonic acid}], 2 mM MgCl2, 40 mg of  Rnase/ml, 20 mg of  propidium
iodide/ml) was added, and cells were incubated for 30 min in the dark. The percentage
of  apoptotic cells was analyzed by FACS as the percentage of  cells (10,000 cells counted)
with a DNA content of <2N. Thresholds were set to gate out cellular debris. For Ba/F3
cells transfected with GFP-spectrin, 5,000 GFP-positive cells were analyzed. Cell cycle
profiles were determined using a FACScalibur (Becton Dickson, Mountainview, CA,
U.S.A.) and analyzed using Cell Quest and MofFit software. For cell proliferation assays
Ba/F3 cells were seeded in 24-well dishes (0.1 x 106 cells per well) together with IL-3 with
or without inhibitors and the viable cells were counted every 24 h by trypan blue exclu-
sion.
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Transient electroporations and generation of stable cell lines
For transient transfections, Ba/F3 cells were electroporated (0.28 kV; capacitance 960 mF)
and 2 h after electroporation dead cells were removed by separation through a Ficoll gra-
dient (2,500 rpm for 20 min). Cells were harvested 24 h after electroporation and ana-
lyzed by FACS as described above. For the generation of  polyclonal transfectants con-
structs were electroporated into Ba/F3 cells together with pSG5 conferring neomycin
resistance and maintained in 500 mg/ml G418 (Boehringer GmbH) in the presence of  IL-
3. Monoclonal cell lines were generated by limited dilution, and results shown are repre-
sentative of  at least two separate clones. For the analysis of  p27KIP1 levels in cells tran-
siently overexpressing p27KIP1, cells were electroporated together with LNGFR as a
marker31. Dead cells were removed, and LNGFR expressing cells were separated using
monoclonal LNGFR antibody 20.431 and goat anti-mouse microbeads (Miltenyi Biotech).
Equal protein concentrations were analyzed by p27KIP1 western blotting.
Cyclin E-CDK2 kinase assays
Cyclin E-associated kinase activity was determined as described previously33, using his-
tone H1 as a substrate. CDK2 levels were determined in parallel by Western blotting.
Luciferase assays
Ba/F3 cells were electroporated with the pGL2-p27KIP1 luciferase promoter construct32,
a pGL2 thymidine kinase luciferase construct or a pGL2 control luciferase construct, the
internal transfection control (pRL-TK; Promega), and expression plasmids. 24 h after
transfection cells were harvested and luciferase activity was measured. Values were cor-
rected for transfection efficiency and growth and represent the means of  at least three
independent experiments (± standard errors of  the means).
Results
Signaling pathways regulating cytokine-mediated proliferation and 
survival.
Lymphoid and myeloid lineages require cytokines and growth factors to both induce cell
division and act as survival factors. The mouse pre-B cell line Ba/F3 requires IL-3 to pro-
liferate as well as to overcome a default apoptotic program. To define signaling pathways
critically involved in mediating the proliferative response to IL-3, we analyzed the effect
of  various pharmacological inhibitors on Ba/F3 cells cultured with IL-3. Cells were cul-
tured for 72 h and the number of  trypan blue-excluding cells was determined every 24 h.
Proliferation was not affected when the cells were cultured with IL-3 in the presence of
mitogen-activated protein kinase (MAPK) kinase inhibitor PD09805935 or with p38
MAPK inhibitor SB20358036, indicating that the proliferative response is not affected by
inhibition of MAP kinases (Fig. 1A). Activation of  ERK and p38 kinases was potently
inhibited under these conditions (data not shown). IL-3-dependent proliferation was pro-
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foundly inhibited when the cells were cultured in the presence of  either PI3K inhibitor
LY29400237 or rapamycin, an inhibitor of  the activation of  p70S6K, a target of  PI3K sig-
naling.
To determine whether the inhibition of  proliferation may be due to a decrease in cell
survival, we analyzed the effect of  pharmacological inhibitors on apoptosis. For this pur-
pose we used FACS analysis of  PI-labeled cells and marked cells containing less than 2N
DNA content as apoptotic. These results were also confirmed by DNA laddering (data
not shown). As expected, addition of  PD098059 or SB203580 did not affect cell survival,
implying no significant role for MAPKs in the regulation of  apoptosis (Fig. 1B).
However, IL-3-induced rescue from apoptosis was abrogated when cells were incubated
with LY294002. Although rapamycin could efficiently block proliferation, it had no effect
on IL-3 mediated rescue from apoptosis, demonstrating that inhibition of  cell cycle pro-
gression is in itself  insufficient to initiate the apoptotic program. Identical results were
also found in 32D cells, a murine IL-3-dependent cell line, cultured with IL-3 (data not
shown). 
To exclude aspecific effects introduced by using pharmacological inhibitors of  PI3K
we developed a novel inhibitory tool, using the 3-phosphatidylinositol lipid phosphatase
PTEN. Although the mechanisms of  PTEN regulation are unclear, regulation by mem-
brane localization has been suggested by the recent analysis of  its crystal structure38. We
generated a PTEN construct containing a C-terminal CAAX-box derived from Ki-Ras28,
resulting in constitutive membrane-association (PTENcaax). In contrast to what was
found for wild-type PTEN, phosphorylation of  PKB was largely abrogated upon expres-
sion of  this construct, demonstrating that PTENcaax is capable of  potently inhibiting
PI3K activity (Fig 1C; left, lane 3). To analyze whether PTEN could affect cytokine-medi-
ated rescue from apoptosis, we electroporated cells with PTEN expression vectors. We
observed a minor increase in apoptosis in Ba/F3 cells overexpressing wild-type PTEN
(data not shown). Ba/F3 cells ectopically expressing PTENcaax exhibited a much higher
percentage of  apoptosis than control Ba/F3 cells expressing GFP-spectrin alone (Fig. 1C;
right). This observation clearly demonstrates the importance of  PI3K generated phos-
phatidylinositol lipids for cell survival.
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Figure 1. Regulation of  IL-3-mediated proliferation and survival. 
Ba/F3 cells were cultured in the presence of  IL-3 without inhibitors or with PD098059 (50 mM),
LY294002 (10 mM), SB203580 (10 mM), or rapamycin (20 ng/ml), and cells were counted every 24 h as
indicated. (B) Ba/F3 cells were cultured in the absence of  IL-3 (bar 1) or presence of  IL-3 either alone
(bar 2) or with LY294002 (10 mM; bar 3) PD098059 (50 mM; bar 4), SB203580 (10 mM; bar 5) or
rapamycin (20 ng/ml; bar 6) and the percentages of  apoptotic cells were determined after 48 h. (C, Left).
COS cells were transfected with either 8 mg empty vector, or the myc-PTEN or the myc-PTENcaax vec-
tor together with 2 mg of  the HA-PKB vector. HA-PKB was immunoprecipitated with an HA antibody
(12CA5) and analyzed for activity by immunoblotting with phospho-Ser473 PKB antibody (top).
Expression of HA-PKB and mycPTEN was verified by immunoblotting with either 12CA5 (middle) or
myc antibody (9E10;bottom). (Right) Ba/F3 cells were electroporated with 2 mg of  the spectrin-GFP
vector together with either 18 mg of  empty vector (pSG5) or 18 mg of  the myc-tagged PTENcaax vec-
tor. Dead cells were removed 2 h after electroporation by separation through a Ficoll gradient. Twenty-
four h after electroporation cells were fixed and stained with PI and the DNA content of  5,000 GFP-
positive cells was analyzed by FACS. The data depicted are representative of  several independent exper-
iments. 
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P27KIP1 protein levels correlate with induction of apoptosis. 
The CDK inhibitor (CKI) p27KIP1 is the only CKI whose expression declines upon mito-
genic stimulation, as demonstrated for IL-2 and platelet-derived growth factor (PDGF)39-
41. Upregulation of  p27KIP1 levels has been correlated not only with a decrease in prolif-
eration, but also with induction of  apoptosis, suggesting that PI3K activity might be asso-
ciated with a decrease in p27KIP1 levels. 
To determine whether IL-3 can regulate p27KIP1 levels, Ba/F3 cells were cultured with
or without IL-3 and after 24 h the level of  p27KIP1 expression was determined by Western
blotting. Equal protein loading was confirmed by probing the blot with a RACK1 anti-
body. Cells cultured without cytokines or with IL-3 in the presence of  LY294002 exhib-
ited a significant increase in p27KIP1 expression, whereas inhibition of MAPK kinase, p38
MAPK, or p70S6K had no significant effect (Fig. 2A), correlating with a lack of  effect of
these inhibitors on apoptosis. Expression of  another CKI, p21CIP1, was unaffected (data
not shown), suggesting that upregulation of  p27KIP1 upon induction of  apoptosis may be
specific for this CKI. 
Next, we wished to determine the kinetics by which p27KIP1 levels changed upon IL-
3 withdrawal and the role of  transcription therein. Cells were treated with or without the
transcription inhibitor actinomycin D, and IL-3 was withdrawn. Levels of  p27KIP1
increased after IL-3 withdrawal, which precedes induction of  the apoptotic program in
these cells (data not shown). However, this increase was completely blocked in cells treat-
ed with actinomycin D (Fig. 2B), indicating that transcriptional regulation is important for
elevating p27KIP1 levels following IL-3 withdrawal. Addition of  IL-3 to cells that were
cytokine-starved overnight resulted in a decrease in p27KIP1 levels (Fig. 2C). To determine
if  cytokine-mediated regulation of  p27KIP1 levels is a more general phenomenon, we ana-
lyzed primary mouse fetal liver cells cultured in the presence or absence of  survival fac-
tors26. Indeed, in cells cultured without cytokines a striking increase in p27KIP1 levels also
correlated with an induction of  apoptosis (Fig. 2D).
These data raise the possibility that repression of  p27KIP1 levels through cytokine-
mediated PI3K activation is required for cell survival. To separate a role for p27KIP1 in
survival from its role in proliferation, we utilized freshly isolated peripheral blood human
eosinophils. Since these terminally differentiated quiescent cells no longer divide, any reg-
ulation of  p27KIP1 will be independent of  cellular proliferation. Again, either removal of
the cytokine or inhibition of  PI3K resulted in both a decrease in cell survival and an
induction of  p27KIP1 (Fig. 2E). We could not detect any expression of  the CKI p21CIP1
in these cells (data not shown), suggesting a specific function of  p27KIP1 distinct from the
regulation of  cellular proliferation. 
Finally, to determine if  the increased levels of  p27KIP1 were indeed functional, we ana-
lyzed whether this increase resulted in a decrease in cyclin E-associated kinase activity. In
cells cultured without IL-3, little cyclin E-associated CDK2 activity was observed (Fig. 2F,
top). 
63
FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27KIP1
chapter3_2803.qxd  2-5-01  18:10  Page 63
Similarly, addition of  LY294002 substantially blocked cyclin E-associated CDK2 activity,
correlating with an increase in p27KIP1 levels. Together these data demonstrate that PI3K
represses the expression of  functional p27KIP1 and that this strongly correlates with cel-
lular survival. 
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Figure 2. Upregulation of  p27KIP1 protein levels correlates with apoptosis. 
Ba/F3 cells were cultured overnight in the absence or presence of  IL-3 without inhibitors or with
LY294002 (LY; 10 mM), PD098059 (PD; 50 mM), SB203580 (SB; 10 mM) or rapamycin (rp; 20 ng/ml).
Equal amounts of  protein were loaded and the levels of  p27KIP1 (top) and RACK1 (bottom) were deter-
mined by immunoblotting as described in Materials and Methods. (B) Ba/F3 cells were cultured
overnight with IL-3 and cytokine-starved for the the indicated times in the presence or absence of  acti-
nomycin D (5 mg/ml) and p27KIP1 levels were analyzed as in for panel (A). (C) Ba/F3 cells were
cytokine-starved overnight and were stimulated with IL-3 for the indicated times and levels of  p27KIP1
were analyzed as for panel (A). (D) Mouse fetal liver cultures were treated with or without cytokines for
24 h, the percentages of  apoptotic cells were measured and equal amounts of  protein were analyzed for
p27KIP1 expression. (E) Human peripheral blood eosinophils were cultured without cytokines, with IL-
5, or with IL-5 and LY294002 (10 mM). Equal amounts of  protein were analyzed for levels of  p27KIP1
(top) or ERK1 and -2 (bottom) by Western blotting. The percentages of  apoptotic cells are shown
below. (F) Ba/F3 cells were either cytokine-starved or cultured with IL-3 or IL-3 together with
LY294002 (10 mM) overnight, equal amounts of  protein were immunoprecipitated (IP) with cyclin E
antibody and associated kinase activity was analyzed (top). Equal protein loading was verified by analyz-
ing CDK2 expression (bottom) of whole cell lysate (WCL). 
chapter3_2803.qxd  2-5-01  18:10  Page 64
IL-3 downregulates p27KIP1 mRNA levels in a PI3K-dependent manner
The regulation of  p27KIP1 protein expression by phosphorylation, resulting in its degra-
dation by the ubiquitin system, has been extensively studied42,43. As upregulation of
p27KIP levels upon IL-3 withdrawal was completely abrogated by inhibiting transcrip-
tion, we investigated whether IL-3 is also capable of  regulating p27KIP1 mRNA levels. We
observed a very rapid upregulation of  p27KIP1 mRNA upon IL-3 withdrawal, whereas
addition of  IL-3 rapidly downregulated p27KIP1 mRNA (Fig. 3A). To establish a poten-
tial role for PI3K in downregulating p27KIP1 mRNA, cytokine-starved Ba/F3 cells were
either left untreated or preincubated with LY294002 before IL-3 stimulation. In agree-
ment with the findings for p27KIP1 protein expression, p27KIP1 mRNA expression was
also dependent on PI3K activity, since preincubation with LY294002 was found to sig-
nificantly abrogate downregulation of  p27KIP1 mRNA expression by IL-3 (Fig. 3B). 
In addition to analyzing p27KIP1 mRNA, we also examined p27KIP1 promoter regulation
by IL-3, utilizing a p27KIP1 promoter luciferase construct32. In agreement with the upreg-
ulation of  p27KIP1 mRNA in cells cultured without IL-3, p27KIP1 promoter activity was
upregulated in cytokine-starved cells compared to that in cells cultured with IL-3 (Fig.
3C). Addition of  LY294002 inhibited IL-3-mediated downregulation of  p27KIP1
luciferase activity (data not shown). Luciferase activity of  control plasmids was unaltered
upon IL-3 addition, whereas cyclin D1 promoter activity was upregulated. These data
indicate that IL-3 represses p27KIP1 transcription in a PI3K-dependent fashion.
FKHR-L1 is inhibited by PI3K-PKB and elevates p27KIP1 promoter 
activity.
The data obtained so far raise the possibility that PI3K activity results in inactivation of
a transcription factor responsible for p27KIP1 transcription. To identify a possible molec-
ular mechanism by which PI3K could regulate p27KIP1 transcription, we focused on the
forkhead-related transcription factor FKHR-L1, which has recently been identified as a
target of  PI3K signaling14. The activity of  FKHR-L1 is inhibited upon phosphorylation
by PKB, resulting in nuclear exclusion14. First we analyzed whether IL-3 could regulate
the activity of  this transcription factor in a PI3K-dependent manner. Indeed, IL-3 stim-
ulation resulted in a rapid transient phosphorylation of  endogenous FKHR-L1 (Fig. 4A, 
left), whereas preincubation of  cells with LY294002 completely abrogated this phospho-
rylation (Fig. 4A, right). 
Since PKB has been shown to critically regulate FKHR-L1 we wished to determine
whether in Ba/F3 cells FKHR-L1 is phosphorylated in a PKB-dependent fashion. To
address this, we constructed a 4-OHT-inducible active-PKB Ba/F3 cell line
(myrPKB:ER*)44. Concomitant with PKB activation (Fig. 4B), FKHR-L1 phosphoryla-
tion was greatly increased upon 4-OHT addition (Fig. 4C). PKB activation was also suf-
ficient to rescue cells from cytokine withdrawal induced apoptosis (data not shown). This
demonstrates that ligand-independent activation of  PKB alone is sufficient for FKHR-
L1 phosphorylation in Ba/F3 cells.
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Transcription factor binding site analysis of  the p27KIP1 promoter sequence revealed
consensus forkhead transcription factor binding sites, suggesting that FKHR-L1 may reg-
ulate p27KIP1 expression. To investigate whether p27KIP1 promoter activity could also be
enhanced by FKHR-L1, we expressed either wild-type FKHR-L1 or an "active" FKHR-
L1 mutant in which all three PKB phosphorylation sites were mutated to alanine [FKHR-
L1(A3)]14. Ectopic expression of  FKHR-L1 increased p27KIP1 promoter activity, which
was further enhanced when FKHR-L1(A3) was expressed (Fig. 4D). To determine
whether PKB could regulate FKHR-L1-induced promoter activity, we cotransfected a
constitutively active PKB mutant (gagPKB) with FKHR-L1 expression vectors29.
Cotransfection of  gagPKB completely inhibited p27KIP1 promoter activity induced by
wild-type FKHR-L1, whereas the increase in promoter activity induced by FKHR-L1(A3)
was unaffected (Fig. 4D). 
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Figure 3. Cytokine-mediated regulation of  p27KIP1 transcription requires PI3K. 
(A) Ba/F3 cells were either IL-3-starved or IL-3-starved overnight and subsequently stimulated with IL-
3 for the indicated times. Twenty micrograms of  total RNA was used for Northern blotting and
hybridized with a p27KIP1 probe (top). Equal RNA loading was verified by GAPDH reprobing (bottom).
(B) Ba/F3 cells were IL-3-starved overnight and restimulated with IL-3 for the indicated times with or
without preincubation with LY294002 (10 mM) and analyzed as for panel (A) (C) Ba/F3 cells were elec-
troporated with 10 mg of  either pGL2 (CON), pGL2-TK (TK), pGL2-p27KIP1 (KIP1) or cyclin D1 (D1)
luciferase constructs together with 500 ng of  renilla, cultured with or without IL-3 for 24 h and
luciferase activity was analyzed as described in Materials and Methods.
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Figure 4. Analysis of  FKHR-L1 phosphorylation and activity in Ba/F3 cells. 
(A) Ba/F3 cells were cytokine-starved and stimulated with IL-3 for the indicated times (left) or pre-treat-
ed with LY294002 (10 mM) for 20 min prior to IL-3 stimulation (right). FKHR-L1 phosphorylation was
analyzed using an FKHR-L1(Thr32) specific antibody (top); equal protein loading was verified by
RACK1 reprobing (bottom). (B) Ba/F3 cells stably expressing myrPKB:ER* were cytokine-starved
overnight and stimulated with 4-OHT (100 nM) for the indicated times. Phosphorylated myrPKB-ER
was analyzed using a PKB(Ser473)-specific antibody (top); equal PKB levels were verified by reprobing
the blot with a PKB antibody (bottom). (C) Ba/F3 cells stably expressing myrPKB:ER* were cytokine-
starved overnight, stimulated with 4-OHT (100 nM) for the indicated times and FKHR-L1 phosphory-
lation was analyzed using an FKHR-L1(Thr32) specific antibody (top). (D) Ba/F3 cells were electropo-
rated with 12 mg of  p27KIP1 luciferase construct together with either 4 mg of  pSG5-gagPKB, FKHR-
L1(wt), or FKHR-L1(A3) or combinations thereof  as indicated. The DNA concentration was adjusted
to 20 mg with pSG5. Cells were cultured with IL-3 and luciferase activity was analyzed 24 h later as
described in Materials and Methods. 
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Transcriptional activity of FKHR-L1 directly induces p27KIP1 expression.
Previous studies investigating the function of  forkhead-related transcription factors have
all utilized transient overexpression of  these proteins14,45. To allow us to specifically ana-
lyze the consequence of  FKHR-L1 activation in more detail, we generated several mon-
oclonal Ba/F3 cell lines expressing a 4-OHT-inducible FKHR-L1(A3) construct, FKHR-
L1(A3):ER*. Expression levels of  FKHRL1(A3):ER* in all cell lines were approximately
one-third to one-fifth of  that of  endogenous FKHR-L1 (Fig. 5A). Similar to what was
found in the cotransfection experiments (Fig. 4D), p27KIP1 promoter activity was upreg-
ulated upon 4-OHT addition (Fig. 5B). Furthermore, addition of  4-OHT resulted in a
striking upregulation of  p27KIP1 mRNA within 30 to 60 min (Fig. 5C), providing com-
pelling evidence for direct FKHR-L1 transciptional regulation of  p27KIP1 expression in
vivo. In accordance with induction of  p27KIP1 mRNA, p27KIP1 protein levels were also
highly elevated in cells treated with 4-OHT (Fig. 5D). To confirm that upregulation of
p27KIP1 levels was indeed a result of  FKHR-L1 mediated transcription, actinomycin D
was added prior to 4-OHT addition. As shown in Fig. 5E this completely abrogated
upregulation of  p27KIP1 protein, as well as mRNA (data not shown). Finally, we analyzed
levels of  p27KIP1 with various concentrations of  4-OHT; the levels were elevated in a
dose-dependent fashion (Fig. 5F). 
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Figure 5. FKHR-L1 directly regulates p27KIP1 transcription.
(A) Expression of  FKHR-L1 in Ba/F3 cells or Ba/F3 cells stably expressing FKHR-L1(A3):ER* was
verified by immunoblotting with FKHR-L1 antibody. (B) Ba/F3 cells stably expressing FKHR-
L1(A3):ER* were electroporated with 12 mg of  p27KIP1 luciferase construct together with 8 mg of  pSG5.
Cells were cultured with IL-3 (CON) or with IL-3 and 4-OHT (100 nM), and luciferase activity was ana-
lyzed 24 h later as described in Materials and Methods. (C) Ba/F3 cells stably expressing FKHR-
L1(A3):ER* were treated with 4-OHT (100 nM) for the indicated times; 20 mg of  total RNA was used
for Northern blotting and hybridized with a p27KIP1 probe (top). Equal RNA loading was verified by
GAPDH reprobing (bottom). (D) Ba/F3 cells and Ba/F3 cells stably expressing FKHR-L1(A3):ER*
were cytokine-starved overnight and were cultured with IL-3 or with IL-3 and 4-OHT (100 nM). Equal
amounts of  protein were loaded, and the levels of  p27KIP1 (upper panel) or RACK1 (lower panel) were
determined by immunoblotting as described in Materials and Methods. (E) Ba/F3 cells stably express-
ing FKHR-L1(A3):ER* were treated with 4-OHT (100 nM) in the absence or presence of  actinomycin
D (5 mg/ml) for the the indicated times and analyzed as for panel (D). (F) Ba/F3 cells stably expressing
FKHR-L1(A3):ER* were cultured in the absence or presence of  IL-3 or IL-3 together with various con-
centrations 4-OHT overnight and were analyzed as for panel (D).
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FKHR-L1 function has also been linked with the induction of  apoptosis in fibrob-
lasts, cerebellar neurons and T cells14. We analyzed the induction of  apoptosis upon tran-
sient overexpression of  either FKHR-L1 or the active mutant FKHR-L1(A3) in Ba/F3
cells. Apoptosis was significantly increased in cells electroporated with FKHR-L1, and
was further enhanced when the active mutant FKHR-L1(A3) was overexpressed (Fig.
6C). Next, we analyzed the effect of  the addition of  increasing 4-OHT concentrations to
the FKHR-L1(A3):ER* stable cell lines. 4-OHT addition resulted in the induction of
apoptosis in a dose-dependent fashion (Fig. 6D). 
Finally, we reasoned that if  the elevation of  p27KIP1 plays a critical role in FKHR-L1
mediated induction of  apoptosis, coexpression of  cyclin-CDK complexes should be
capable of  titrating away the induced p27KIP1 and thereby rescuing cells from apopto-
sis17,45. Indeed, expression of  cyclin D together with a kinase-dead form of  CDK4 in 4-
OHT treated cells was sufficient to significantly rescue FKHR-L1(A3) induced apoptosis
in two independent clones (Fig. 6E). These data confirm that increases in p27KIP1 levels
play a significant role in FKHR-L1 induced apoptosis. 
Regulation of p27KIP1 expression is important for maintenance of cell
survival
The data described above suggest that repression of  p27KIP1 levels through PKB-medi-
ated FKHR-L1 phosphorylation may be necessary for cytokine-mediated survival and
proliferation. To address whether mere ectopic expression of  p27KIP1 is sufficient to
induce apoptosis, we introduced an expression plasmid for p27KIP1 in Ba/F3 cells,
together with spectrin-GFP as a marker for transfected cells. Twenty-four h after elec-
troporation, cells were fixed and stained with PI and the DNA content of  the spectrin-
GFP-expressing cells was analyzed. Cells transfected with both spectrin-GFP and p27KIP1
exhibited a significantly higher percentage of  apoptotic cells and cells in G0/G1 than con-
trol cells (Fig. 6A). To exclude the possibility that supra-physiological levels of  p27KIP1
expression alone cause cells to undergo apoptosis, p27KIP1 levels in transfected cells were
analyzed. This was performed by coexpressing LNGFR34, sorting LNGFR expressing
cells by magnetic cell sorting (MACS), and analyzing p27KIP1 expression levels in cor-
rected protein samples. Levels of  p27KIP1 inducing apoptosis in transfected cells did not
exceed the levels in IL-3-starved cells (Fig. 6B). Thus uncontrolled expression of  physio-
logical levels of  p27KIP1 is sufficient to induce apoptosis in cytokine-dependent cells. 
P27KIP1 deficiency increases hematopoietic cell survival after cytokine
withdrawal.
Finally, to examine the importance of  p27KIP1 in the regulation of  apoptosis in vivo, we
utilized hematopoietic stem cells obtained from either wild-type mice, or mice lacking one
or both p27KIP1 alleles46. Bone marrow derived Sca1+ stem cells were cytokine-starved
and analyzed 24 h later, using annexin-V staining to label apoptotic cells. Strikingly, stem
cells obtained from mice lacking one p27KIP1 allele exhibited a moderate protection 
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Figure 6. IL-3 mediated survival requires inactivation of  FKHR-L1 and 
downregulation of  p27KIP1 levels. 
(A) Ba/F3 cells were electroporated with 2 mg of  spectrin-GFP vector together with either 18 mg of
empty vector (pSG5; left) or 18 mg of  p27KIP1 vector (right). Dead cells were removed by separation
through a Ficoll gradient. Twenty-four h after electroporation cells were fixed and stained with PI and
the DNA contents of  5,000 GFP-positive cells were analyzed by FACS. The data are representative of
several independent experiments. (B) Ba/F3 cells were electroporated with 2 mg of  LNGFR DNA, 2 mg
LNGR together with 2 or 4 mg of  p27KIP1 DNA and the total amount of DNA was adjusted to 20 mg
with pSG5. Dead cells were removed by separating cells through a Ficoll gradient and LNGFR-express-
ing cells were analyzed 24 h after transfection as described in Materials and Methods. (C) Ba/F3 cells
were electroporated with spectrin-GFP (2 mg) together with either 18 mg pSG5 (CON) vector, FKHR-
L1 vector or FKHR-L1(A3) vector and analyzed as for panel (A). The data represent three independent
experiments (± standard errors of  the means). (D) Ba/F3 cells stably expressing FKHR-L1(A3):ER*
were cytokine-starved and cultured with IL-3 or IL-3 together with various concentrations of  4-OHT,
and the percentages of  apoptotic cells were determined after 48 h by FACS analysis. (E) FKHR-
L1(A3):ER*-expressing cells lines were electroporated with either 18 mg of  pSG5 and 2 mg of  spectrin-
GFP (black bars), or 5 mg of  kinase-dead CDK4, 5 mg of  cyclin D1, 2 mg of  spectrin-GFP and 8 mg of
pSG5 (grey bars). Dead cells were removed by separation through a Ficoll gradient. Cells were treated
with 4-OHT and analyzed 24 h later as for panel (A). The data depicted are representative of  several
independent experiments.
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against cytokine withdrawal-induced apoptosis compared to those from wild-type mice
(Fig. 7). This was significantly enhanced in stem cells from mice lacking both alleles.
These data demonstrate the importance of  regulating p27KIP1 levels in the modulation of
hematopoietic cell apoptosis in vivo.
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Figure 7 Increased survival of  p27KIP1 (-/-) hematopoietic cells after cytokine 
withdrawal. 
Hematopoietic stem cells were isolated from either wild-type mice (+/+) or mice lacking one (-/+) or
both (-/-) alleles of  the p27KIP1 gene and cultured as described in Materials and Methods. Cells were
cytokine-starved for 24 h and the percentages of  apoptotic cells were analyzed by annexin-V staining.
The percentage increase in apoptosis after cytokine withdrawal is shown as D(apoptosis). Data are rep-
resentative of  three independent experiments.
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Discussion
The control of  proliferation and apoptosis by cytokines is critical in the regulation of  a
variety of  hematopoietic lineages2,47. Our data demonstrate PI3K signaling to be indis-
pensable in mediating cellular proliferation and survival. The importance of  PI3K activ-
ity in mediating survival was supported by overexpression the 3-phosphatidylinositol lipid
phosphatase PTEN7, which is a uniquely specific tool for decreasing 3-phosphoinositide
levels in cells. Upon overexpression of membrane-localized PTEN, we observed an
induction of  apoptosis in IL-3-cultured Ba/F3 cells (Fig. 1C). The fact that membrane-
targeted PTEN, unlike wild-type PTEN, is potently active (Fig. 1C), suggests that this is
a critical aspect of  PTEN regulation in vivo. Mutations in the chromosomal region of
PTEN resulting in a loss of  function of  PTEN have been described in a variety of  neo-
plasias, including lymphoid malignancies48. These mutations result in the accumulation of
PtdIns(3,4,5)P3 in the absence of  cellular stimulation. While inhibition of  PTEN activity
may have deleterious effects on cell proliferation, resulting in a neoplastic phenotype, our
data demonstrate that uncontrolled PTEN activity can result in the induction of  an apop-
totic program. 
In search of  a potential mechanism by which PI3K could regulate cytokine-mediated
cell survival and proliferation, we focused on the CKI p27KIP1. P27KIP1 is an inhibitor of
cell cycle progression, exerting its effect through interaction with cyclin-CDK complexes
and arresting cells in G0/G117. Furthermore, p27KIP1 has been implicated in the regula-
tion of  apoptosis in immature B cells22,23. Cross-linking of  surface Ig (IgM) on the
WEHI-231 B-cell lymphoma, for example, results in growth arrest and eventually induc-
tion of  an apoptotic program which can be rescued by CD40 ligand engagement. These
IgM-induced changes are correlated with an increase in p27KIP1 protein which is inhibit-
ed by CD40, although the molecular mechanisms of  these observations are unclear22,23.
A potential role for PI3K in down regulating p27KIP1 levels was suggested by the obser-
vation that overexpression of  PTEN in glioblastoma cells resulted in enhanced p27KIP1
levels49. We have explored the IL-3-mediated regulation of  p27KIP1 levels and a possible
role for PI3K therein. Survival factor withdrawal resulted in an increase of  p27KIP1 pro-
tein levels in a PI3K-dependent manner (Fig. 2A). In cultures of  primary fetal liver cells
cytokine withdrawal also resulted in an increase of  apoptosis paralleled by upregulation
of  p27KIP1, suggesting that this may be a common feature of  primary lymphocyte line-
ages (Fig. 2D). Levels of  p27KIP1 in primary human eosinophils undergoing apoptosis
were also analyzed (Fig. 2E). In eosinophils, both cytokine starvation and inhibition of
PI3K resulted in significantly higher levels of  p27KIP1, correlating with induction of
apoptosis (Fig. 1D). Importantly, induction of  p27KIP1 in these nondividing cells suggests
an additional cell cycle independent role for this CKI. 
While regulation of  p27KIP1 levels has been previously considered to occur predomi-
nantly posttranslationally19,50, we found a rapid and dramatic effect of  IL-3 on p27KIP1
mRNA (Fig. 3A). In addition, IL-3 was also capable of  downregulating p27KIP1 promot-
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er activity in a PI3K-dependent manner (Fig. 3C), prompting us to investigate the role of
PI3K-regulated transcription factors in this process. Transcription factors of  the
AFX/FKHR forkhead family are phosphorylated by the PI3K target PKB, resulting in
inhibition of  their activity14,15,51,52. One member, FKHR-L1, has been linked to induction
of  apoptosis, possibly by the upregulation of  Fas ligand on cells14. FKHR-L1 is endoge-
nously expressed in Ba/F3 cells and phosphorylated in a PI3K-PKB-dependent manner
(Fig. 4A and C). Furthermore, overexpression of  an active FKHR-L1 mutant resulted in
induction of  apoptosis (Fig. 6C). Since Fas ligand was unable to induce apoptosis in
Ba/F3 cells (data not shown), a role for FKHR-L1 in induction of  apoptosis must be
mediated by an alternative mechanism. The presence of  several forkhead transcription
factor binding sites in the p27KIP1 promoter suggested a possible link between FKHR-L1
and transcription of  p27KIP1. Indeed, overexpression of  FKHR-L1 elevated p27KIP1 pro-
moter activity, which could be inhibited by cotransfection of  active PKB (Fig. 4D). To
specifically analyze the effect of  FKHR-L1 on p27KIP1 transcription we utilized Ba/F3
cells stably expressing a 4-OHT-inducible active FKHR-L1 construct. Upon FKHR-L1
activation, p27KIP1 mRNA was greatly elevated within 30 to 60 min, concomitant with a
spectacular elevation of  p27KIP1 protein levels (Fig. 5C to E). These data clearly demon-
strate that activation of  FKHR-L1 alone is sufficient to induce rapid upregulation of
p27KIP1 mRNA in vivo. To determine if  p27KIP1 is indeed an important target of  FKHR-
L1-induced apoptosis, we overexpressed cyclin D-CDK4 complexes to titrate away func-
tional p27KIP1. Indeed, overexpression of  cyclin D-CDK4 complexes was sufficient to
significantly reduce FKHR-L1 induced apoptosis, thus suggesting that p27KIP1 is an
important FKHR-L1 target for the induction of  apoptosis. The fact that apoptosis was
not completely rescued by overexpression of  cyclin D-CDK4, it suggests that there are
possibly additional targets accounting for FKHR-L1-induced apoptosis. During the
preparation of  this paper it was reported that FKHR-L1-related transcription factor AFX
was able to induce growth suppression through regulation of  p27KIP1 expression45.
However, these overexpression studies were performed with cells normally not express-
ing AFX. We have now been able to demonstrate that regulation of  p27KIP1 transcription
can be controlled through cytokines and further that this seems to play a role in the reg-
ulation of  survival. 
Here we also provide proof  for the importance of  p27KIP1 in the induction of  apop-
tosis by utilizing mice lacking one or both alleles of  the p27KIP1 gene46. There was a sig-
nificant decrease in apoptosis upon cytokine withdrawal in mice lacking one p27KIP1 gene
allele (change in apoptosis [Dapoptosis]=10.6%) compared to that in wild-type mice
(Dapoptosis=24.6%), this decrease was even more striking in mice lacking both alleles
(Dapoptosis=6.1%). While the role of  p27KIP1 in regulating growth arrest is fairly well
defined, relatively little is known regarding the mechanisms by which this protein may reg-
ulate apoptosis. A potential mechanism is suggested by a recent report by Boussiotis et
al., who demonstrated that p27KIP1 is capable of  directly influencing transcription inde-
pendently of  its ability to block cell cycle progression53. Increased p27KIP1 levels were
found to inhibit IL-2 transcription in T cells through the binding, nuclear export, and
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subsequent degradation of  the Jun transcription factor coactivator JAB1 (Jun activation
domain-binding protein-1)54. Potentially, inhibition of  anti-apoptotic gene expression
through p27KIP1-mediated degradation of  JAB1 could play a role in the induction of
apoptosis. In various malignancies it has been shown that reduced levels of  p27KIP1 cor-
relate with poor prognosis55-57. The levels of  p27KIP1 do not, however, correlate with the
proliferative status of  the tumor cells, suggesting that the benefits of  p27KIP1 reflect an
additional function such as increased apoptosis. Indeed, decreased p27KIP1 expression in
gastric carcinomas correlates with decreased apoptosis and increased aggressiveness of
the tumor58.
The regulation of  both proliferation and survival by p27KIP1 has parallels with that by
the tumor suppressor protein p53. P53 has a major G1 checkpoint function and can medi-
ate a transient growth arrest in certain situations that favor cell survival, while inducing
apoptosis in others59. Interestingly, one study has demonstrated that overexpression of
Bcl-2 can significantly counteract the apoptotic effects of  p27KIP1, preventing caspase
activation60. This suggests that p27KIP1 may either inhibit specific anti-apoptotic Bcl-2
family members or activate pro-apoptotic family members such as Bim that have recent-
ly been shown to play a critical role apoptosis induced by cytokine withdrawal61. 
Our findings demonstrate a novel mechanism by which cytokines mediate rescue
from apoptosis. This involves the downregulation p27KIP1 levels through the PI3K-PKB-
regulated inactivation of  transcription factors of  the AFX/FKHR forkhead family.
Exposure of  hematopoietic cells to cytokines acts to stimulate both survival and prolif-
eration. The regulation of  p27KIP1 expression by PI3K allows the modulation of  both
these processes by altering the levels of  a single protein. Our data not only provide insight
into the mechanisms of  cytokine-mediated signal transduction regulating cell prolifera-
tion and survival, but also identify critical components regulating p27KIP1 transcription.
The mechanism of  PI3K-mediated forkhead transcription factor regulation is conserved
between the nematode worm Caenorhabditis elegans62 and mammalian cells. Our data
implicate the regulation of  p27KIP1 by this evolutionarily conserved signaling pathway as
a general mechanism for controlling cell fate decisions regulating survival and prolifera-
tion or differentiation.
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CHAPTER 4
Expression of  the pro-apoptotic Bcl-2 family member Bim
is regulated by the Forkhead transcription factor FKHR-L1
Pascale F. Dijkers, Rene H. Medema, Jan-Willem J. Lammers, Leo Koenderman and
Paul J. Coffer.
Adapted from Dijkers et al., 2000 Curr. Biol. 10: 1201-1204
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Introduction
The regulation of  cell death is regulated mainly through an evolutionary conserved form
of  cell suicide termed apoptosis1. Deregulation of  this process has been associated with
cancer, autoimmune diseases and degenerative disorders. Many cells, particularly those of
the hematopoietic system, have a default program of  cell death and survival is dependent
on the constant supply of  survival signals. The Bcl-2 family, which has both pro- and anti-
apoptotic members, plays a critical role in determining cell survival fate2. One family
member, the Bcl-2 interacting mediator of  cell death (Bim), contains only a protein-inter-
action motif  known as the BH3 domain, allowing it to bind to pro-survival Bcl-2 mem-
bers, neutralizing their function3. Disruption of  the bim gene results in resistance to
apoptosis following cytokine withdrawal in leukocytes, indicating that regulation of  the
pro-apoptotic activity Bim is critical for maintenance of  the default apoptotic program4.
Here we show that cytokine withdrawal results in upregulation of  Bim expression con-
comitant with induction of  the apoptotic program in lymphocytes. Activation of  the
forkhead transcription factor FKHR-L1, previously implicated in regulation of  apoptosis
in T lymphocytes5, is sufficient to induce Bim expression. We propose a mechanism by
which cytokines promote lymphocyte survival by inhibition of  FKHR-L1, preventing
Bim expression. 
Results and Discussion
While Bim is expressed in many hematopoietic lineages, it is not known how its expres-
sion is affected after cytokine withdrawal1. Here, we determined whether changes in the
levels of  Bim expression could be responsible for regulation of  cell survival. The mouse
pro-B cell line, Ba/F3, has a default apoptotic pathway, which is repressed upon the addi-
tion of  IL-3. We examined Bim protein levels in these cells following cytokine withdraw-
al. Interestingly, Bim expression increased steadily after IL-3 deprivation, correlating with
induction of  the apoptotic program (Fig. 1A; left panel). To determine whether this
observation may represent a more general phenomenon, primary mouse fetal liver cells
cultured in the presence or absence of  survival factors6 were analyzed for Bim expres-
sion. Indeed, fetal liver cells undergoing apoptosis following cytokine withdrawal exhib-
ited elevated Bim protein levels (Fig 1A; right panel). To determine whether upregulation
of  Bim expression by IL-3 withdrawal was a result of  enhanced transcription, bim
mRNA was also analyzed. Bim has three isoforms (BimS, BimL and BimEL) that are gen-
erated by alternative splicing3. Northern blot analysis has shown several Bim transcripts,
although the specific relationship between these transcripts and the three Bim isoforms
is unclear3. We detected several transcripts as described previously, and importantly,
expression of  these mRNAs was significantly elevated upon IL-3 withdrawal (Fig. 1B).
To determine whether increased expression of Bim is sufficient to induce apoptosis,
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we transiently expressed BimS or BimL, together with spectrin-linked GFP in Ba/F3
cells. This approach enables analysis of  apoptosis in the transfected (GFP-positive) ver-
sus untransfected (GFP-negative). In cells that expressed only spectrin-GFP, cell survival
was unaffected relative to control cells (Fig. 1C ; left panel). In cells expressing either
BimL or BimS the level of  apoptosis in GFP-positive cells was dramatically increased
(Fig. 1C; middle and right panels). 
Previous work has implicated phosphatidylinositol 3-kinase (PI3K) activity as being
critical for cytokine-mediated rescue from apoptosis in lymphocytes7. To determine
whether changes in Bim expression may be dependent on PI3K activity, Ba/F3 cells were
either cytokine-starved, cultured with IL-3 or IL-3 in combination with the specific PI3K
inhibitor LY294002. Bim protein levels were elevated in cells undergoing apoptosis
induced either by IL-3 withdrawal or by inhibition of  PI3K (Fig. 1D). As there was no
change in Bax levels it appears that a general increase in pro-apoptotic Bcl-2 family mem-
bers is not in itself  a feature of  cell death.
Protein Kinase B (PKB/Akt), a target of  PI3K-activation, has recently been reported
to inhibit transcriptional activity of  a subfamily of  forkhead transcription factors, which
include FKHR-L1, AFX and FKHR8. FKHR-L1 activity, for example, is inhibited by
PKB phosphorylation on three sites, resulting in an inability to translocate to the nucle-
us5. Mutation of  these phosphorylation sites results in the generation of  a constitutively
active transcription factor and such a mutant, FKHR-L1(A3), has recently been shown to
induce apoptosis in T cells through induction of  Fas-L5. Ba/F3 cells, however, do not
appear to be susceptible to Fas-L induced apoptosis (P.J.C. and P.F.D., unpublished obser-
vations). IL-3 withdrawal resulted in dephosphorylation of  FKHR-L1 (Fig. 2A), which
leads to nuclear translocation and activation of  this transcription factor5. To determine
whether activity of  FKHR-L1 is linked to upregulation of Bim protein levels we gener-
ated a novel inducible FKHRL1(A3) expression construct. FKHR-L1(A3) was fused to
the hormone-binding domain of  the estrogen receptor9, resulting in a 4-hydroxy tamox-
ifen (4-OHT) inducible protein, FKHR-L1(A3):ER*. We generated several stable clonal
Ba/F3 cell lines in which expression levels of  FKHR-L1(A3):ER* were approximately 3-
5 times lower than of  endogenous FKHR-L1 (data not shown). Addition of  4-OHT in
the presence of  IL-3 resulted in a dramatic induction of  apoptosis, coinciding with an ele-
vation of Bim protein levels (Fig. 2B, C). Levels of  Bcl-2 and Bax were unaffected,
demonstrating that the FKHR-L1 effects appear to be specific for Bim. Elevation of Bcl-
2 levels, however, has previously been shown to counteract the pro-apoptotic activity of
Bim3. To determine whether the increase in Bim levels may be a critical mechanism by
which FKHR-L1 is able to induce apoptosis, Ba/F3 FKHR-L1(A3):ER* cells were elec-
troporated with or without Bcl-2, together with spectrin-GFP as a marker for transfect-
ed cells. GFP-positive cells transiently expressing Bcl-2 were considerably more resistant
to FKHRL1-induced apoptosis than GFP-negative control cells (Fig. 2C; lower panel).
Finally, to examine whether the enhanced expression of Bim protein by FKHR-L1 activ-
ity was a result of  transcriptional regulation, bim mRNA was analyzed. Similarly to IL-3
withdrawal (Fig. 1C), 4-OHT mediated FKHR-L1 activation significantly elevated Bim 
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Figure 1 Bim levels are regulated by cytokines and determine cell survival fate.
(A) Left,  Ba/F3 cells were IL-3-starved and lysed after the indicated times. Equal amounts of  protein
were loaded and Bim levels were determined by probing with anti-Bim. The blot was reprobed with anti-
RACK1 to confirm equal protein loading. Right, Mouse fetal liver cultures were treated with or without
cytokines for 24 hours, and the percentage of  apoptotic cells were measured as well as levels of  Bim and
RACK1. (B) IL-3 withdrawal induces Bim mRNA expression. Ba/F3 cells were IL-3-starved for the
indicated time points. PolyA+ RNA was isolated and Bim mRNA levels were analyzed using full length
BimL cDNA as a probe. Equal RNA loading was confirmed by reprobing the blot with glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). (C) Bim expression is sufficient to induce cell death. Ba/F3 cells
were electroporated with 18 mg empty vector, BimS or BimL, together with 2 mg spectrin-GFP. After 24
hours cells were fixed, stained with propidium iodide and the DNA content of  5000 GFP-positive or
20,000 GFP-negative cells was analysed by FACS. The data depicted is representative of  several inde-
pendent experiments. (D) PI3K activity is critical for cytokine-mediated repression of  Bim. Ba/F3 cells
were either cytokine-starved, cultured overnight with IL-3 without or with LY294002 (10 mM) and lev-
els of  Bim, Bcl-2 and Bax were determined. Blots were reprobed with RACK1 to confirm equal protein
loading. The percentage of  apoptotic cells was also determined by FACS analysis.
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transcripts (Fig. 2D; left panel). To demonstrate that upregulation of  Bim levels through
FKHR-L1 occurs directly and does not require de novo protein synthesis, Ba/F3 FKHR-
L1(A3):ER* cells were treated with 4-OHT for indicated timepoints in combination with
the protein synthesis inhibitor cycloheximide. An elevation of  Bim mRNA was also
observed in cycloheximide treated cells (Fig. 2D, right panel), demonstrating that Bim
transcription is indeed directly regulated by FKHR-L1.
Relatively little is known regarding transcriptional regulation of  pro-apoptotic pro-
teins in cells undergoing apoptosis. Our data identify cytokine-mediated inhibition of
Bim expression as a novel mechanism of  apoptotic regulation. In Caenorhabditis elegans,
transcriptional repression of  Egl-1, a pro-apoptotic protein related to Bim, is critical for
regulating developmental cell death10. Recently, expression of  the pro-apoptotic protein
Hrk in hematopoietic progenitor cells was also found to be rapidly upregulated upon
growth factor withdrawal11. Bim, like other BH3-domain proteins, exerts its pro-apop-
totic activity through heterodimerization with anti-apoptotic Bcl-2 members3. Previously,
regulation of  pro-apoptotic activity of Bim has been reported to occur through its re-
localization12. In this model, Bim is sequestered to the microtubular motor complex by
binding to dynein light chain (LC8). Pro-apoptotic stimuli release LC8 together with Bim
into the cytoplasm, allowing interaction of  Bim with anti-apoptotic Bcl-2 members12.
While this may indeed modulate the activity of  Bim isoforms, we clearly demonstrate that
the regulation of  Bim expression by cytokines is very likely a contributory factor, defin-
ing the balance between cell survival and apoptosis. Moreover, the identification of Bim
as a novel target of  FKHR-L1 highlights the functional importance of  this recently iden-
tified subfamily of  forkhead transcription factors.
Bim levels are critical in regulating apoptosis since Bim (-/-) lymphocytes have an
increased resistance to cell death induced by cytokine-withdrawal, surviving 10-30 times
better than wild-type cells4. These results suggest that at least in lymphocytes Bim is the
dominant transducer of  death signals. By controlling the level of  Bim through cytokine-
mediated regulation of  forkhead transcription factors, cell survival fate decisions can be
rapidly made in response to changes in the local lymphocyte environment. This is analo-
gous to the regulation of  DAF-16, a C. elegans Forkhead transcription factor, which con-
trols longevity in response to changes in environmental nutrient content13. Our data sug-
gest that this evolutionary conserved signaling pathway has been exploited in mammals
to regulate the lifespan of  cytokine-dependent cells.
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Figure 2. Bim levels are transcriptionally regulated by IL-3 through the forkhead
transcription factor FKHR-L1.
(A) FKHR-L1 phosphorylation in Ba/F3 cells. IL-3 Ba/F3 cells were IL-3-starved and lysed at the indi-
cated times. Levels of  phosphorylated FKHR-L1 were analyzed by hybridizing with antibodies that
detect the Thr32-phosphorylated (P-Thr-32) or Ser253-phosphorylated (P-Ser253) forms of  FKHR-L1,
and equal protein loading was verified by reprobing with FKHR-L1 antibody. (B) Activation of  FKHR-
L1 induces Bim expression. Ba/F3 cells stably expressing FKHR-L1(A3)-ER were treated with 4-OHT
(100 nM) for 24 hours as indicated and levels of  Bim, Bcl-2 and Bax were determined. Blots were
reprobed with RACK1 to confirm equal protein loading. (C) Ba/F3 cells expressing FKHR-L1(A3):ER*
were electroporated with 2 mg spectrin-GFP together with either 18 mg empty vector (control) or Bcl-2,
and the percentage of  apoptotic cells upon treatment with 4-OHT (100 nM) for 24 hours was measured
as in 1C. (D) Bim mRNA levels are upregulated by FKHR-L1 activity. Left, Ba/F3 cells stably express-
ing FKHR-L1(A3):ER* were treated with 4-OHT (100 nM) for indicated time points. PolyA+ RNA was
isolated and Bim mRNA levels were analysed using full length BimL cDNA as a probe. Equal RNA
loading was confirmed by reprobing the blot with GAPDH. Right, same as left panel except that cells
were pretreated with cycloheximide (CHX, 10 mg/ml) before addition of  4-OHT.
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Materials and Methods
Plasmids
BimS and BimL constructs were generated by PCR from Ba/F3 cDNA isolated from IL-
3 deprived cells, cloned into pSG5-MYC and verified by sequencing. pCDNA3- FKHR-
L1(A3):ER* was generated by cloning FKHR-L1(A3) without the stop codon into
pCDNA3 containing the hormone-binding domain of  the estrogen receptor (pCDNA3-
ER). Spectrin-linked GFP was a kind gift from Dr. A. Beavis and T. Sheck (Princeton,
U.S.A.) and has been described previously14. pSG5-Bcl-2 was a kind gift from Dr. R.P. de
Groot.
Western blotting
For determining protein levels, cells were lysed in a buffer containing (0.1% NP-40, 20
mM HEPES pH 7.5, 5 mM EDTA, 150 mM NaCl supplemented with 10 mg/ml apro-
tinin, 1 mM leupeptin, 1 mM PMSF, 1 mM Na3VO4, 40 mM b-glycerophosphate and 50
mM NaF). Protein content was determined and equal amounts of  protein were analysed
by SDS-PAGE and blots were probed with the appropriate antibodies. Bim polyclonal
antibody was purchased from Affinity Bioreagents (Golden, CO, U.S.A.), Bcl-2 antibody
from Santa Cruz (Santa Cruz, CA, U.S.A.); Bax mAb from BD PharMingen (San Diego,
CA, U.S.A.); RACK1 mAb from Transduction Laboratories (Kentucky, U.S.A.); FKHR-
L1, phospho-Thr32 FKHR-L1 and phospho-Ser253 FKHR-L1 were from UBI (Lake
Placid, NY, U.S.A.). 
Cell culture, transient electroporation and FACS analysis
Ba/F3 cells were cultured in RPMI 1640 supplemented with 8% Hyclone serum (Gibco)
and recombinant mouse IL-3 (IL-3) produced in COS cells. Fetal liver-derived myeloid
cultures were prepared from day 17 mouse embryos by culture of  suspension cells in
RPMI supplemented with IL-3, IL-6 and SCF as previously described6. 
For transient transfection, Ba/F3 cells were electroporated (0.28 kV; capacitance 960
mFD) and 2 hours after electroporation dead cells were removed by separating through a
Ficoll gradient (2500 rpm for 20 minutes). After 24 hours cells were harvested, washed
twice in PBS and fixed for at least 2 hours in 300 ml PBS and 700 ml ethanol. Cells were
spun down gently and permeabilized in 200 ml 0.1% Triton X-100, 0.045 M Na2HPO4
and 0.0025 M sodium citrate at 37°C for 20 minutes. Next, 750 ml apoptosis buffer (0.1%
Triton X-100, 10 mM PIPES, 2 mM MgCl2, 40 mg/ml RNase, 20 mg/ml propidium
iodide) was added and incubated for 30 minutes in the dark. The percentage of  apoptot-
ic cells was analysed by FACS as the percentage of  cells with a DNA content of <2N,
counting 5,000 cells. Thresholds were set to gate out cellular debris. Cell cycle profiles
were determined using a FACS calibur (Becton and Dickson, Mountainview, CA, U.S.A.)
and analysed using Cell Quest and MofFit software.
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Northern blotting
Total RNA was isolated from Ba/F3 and 500 mg was used for the isolation of  polyA+ RNA
using polyA Tract mRNA isolation kit from Promega (Madison, WI, U.S.A.). Equal RNA load-
ing was verified by reprobing the blots with a 1.4 kb cDNA fragment of  the human glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene.
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CHAPTER 5
FKHR-L1 is a critical effector of  cell death induced by interleukin-3
withdrawal: PKB-mediated inhibition of  FKHR-L1 activity enhances
cell survival by maintenance of mitochondrial integrity
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Abstract
Survival signals elicited by cytokines include activation of  phosphatidyl inositol 3-kinase
(PI3K), which in turn promotes activation of  Protein Kinase B (PKB). Recently, PKB has
been demonstrated to phosphorylate and inactivate Forkhead transcription factor FKHR-
L1, which is a potent inducer of  apoptosis. To explore the mechanisms underlying induc-
tion of  apoptosis following cytokine withdrawal or FKHR-L1 activation, we have utilized
a cell line in which FKHR-L1 activation can be specifically induced. Both cytokine with-
drawal and FKHRL1 activation induce apoptosis as measured by Annexin-V binding and
DNA laddering. The onset of  apoptosis is preceded by an upregulation in p27KIP1 and a
concomitant decrease in cells entering the cell cycle. Induction of  apoptosis by both
cytokine withdrawal and FKHR-L1 activation correlates with disruption of mitochon-
drial membrane integrity and cleavage of  effector caspases. This was preceeded by upreg-
ulation of  the pro-apoptotic Bcl-2 family member Bim, suggesting a critical role for Bim
in this process. Apoptosis does not correlate with cleavage of  caspase-8, demonstrating
that it is a death receptor independent process. Activation of  PKB alone was sufficient
to promote cell survival through maintenance of mitochondrial integrity and the result-
ant inhibition of  effector caspases. Importantly, these data demonstrate that activation of
FKHR-L1 alone is sufficient to induce the complete program of  apoptotic events nor-
mally associated with survival factor withdrawal, suggesting it is a critical player in this
process.
Introduction
In the absence of  cytokines, hematopoietic cells stop proliferating and undergo pro-
grammed cell death, also known as apoptosis. This dependence on cytokines is necessary
to maintain homeostasis in the immune system, and dysregulation of  this process has
been associated with autoimmune diseases, as well as malignancies (reviewed in 1). The
activation of  cysteine proteases, caspases, leading to the cleavage of  various substrates,
including PARP (poly (ADP-ribose) polymerase) and the degradation of  chromosomal
DNA characterize a crucial step in the induction of  apoptosis2. Caspases exist as inactive
pro-enzymes in the cell, which themselves are activated through proteolytic cleavage upon
induction of  the apoptotic program (reviewed in 3). 
A well-characterized mechanism of  initiating apoptosis is through ligand-mediated acti-
vation of  cell surface death receptors, such as the TNF receptors and CD95 (APO-1/
Fas) (reviewed in 4). Caspase-8 is indispensable for transducing apoptotic signals initiated
by death receptors, demonstrated by the observation that CD95 signaling is abrogated in
caspase-8 (-/-) mice5. Caspase activation can also be triggered via a death receptor-inde-
pendent mechanism, involving regulation of mitochondrial membrane permeability.
Central to this "intrinsic" means of mitochondrial-initiated caspase activation is the
release of  cytochrome c from the intermembrane space of mitochondria into the cytosol.
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Cytochrome c, together with Apaf-1 (apoptosis activating factor 1) promote activation of
caspase-96,7, which activates downstream caspases, such as caspase-3 and 73. Although
loss of mitochondrial integrity can also be induced by death receptors, it is not essential
for their induction of  apoptosis8. 
Indispensable for the regulation of mitochondrial integrity are proteins of  the Bcl-2
family. These consist of  anti-apoptotic members, such as Bcl-2, Mcl-1 and Bcl-XL and
pro-apoptotic members, such as Bad, Bim and Bid (reviewed in 9). One mechanism by
which cytokines are believed to promote survival is by inhibiting transcription10,11 or
activity12,13 of  pro-apoptotic members, as well as transcriptionally upregulating anti-apop-
totic members14,15. 
The serine and threonine protein kinase, Protein Kinase B (PKB), also known as c-
Akt, is involved in cytokine-mediated cell survival12,16,17. Anti-apoptotic signals from
PKB include upregulation of Mcl-118 and inhibitory phosphorylation of  Bad12, although
the relevance of  Bad phosphorylation for the survival of  hematopoietic cells remains
unclear19. A recently identified mechanism by which PKB can promote rescue from
apoptosis is through inhibitory phosphorylation of  the Forkhead transcription factor
FKHR-L1 (FOXO3a)10,20. Activity of  this transcription factor has been linked to induc-
tion of  apoptosis in hematopoietic cells10,20. Although PKB is a well-established player in
rescue from apoptosis, it is not clear whether PKB exerts its anti-apoptotic effect
upstream21 or downstream22 of mitochondria. Furthermore, little is known concerning
the mechanisms by which FKHR-L1 can lead to activation of  caspases, resulting in induc-
tion of  apoptosis.
Here, we investigate the mechanisms of  cytokine withdrawal and Forkhead-induced
apoptosis and the role of  PKB in rescue from apoptosis in cytokine-deprived cells. Our
data demonstrate that FKHR-L1, as well as cytokine withdrawal, induces apoptosis
through a death receptor-independent pathway. This involves upregulation of  the pro-
apoptotic Bcl-2 family member Bim, loss of mitochondrial integrity and caspase activa-
tion.  Thus PKB can protect cells from cytokine withdrawal-induced apoptosis by inhibit-
ing FKHR-L1, resulting in maintenance of mitochondrial integrity. These data shed new
light on the mechanisms by which cytokines, through regulation of  PKB activity, can
modulate the survival of  hematopoietic lineages.
Experimental Procedures
Cell culture
Ba/F3 cells were cultured in RPMI 1640 supplemented with 8% Hyclone serum (Gibco)
and recombinant mouse IL-3 produced in COS cells23. Monoclonal Ba/F3 cells stably
expressing FKHR-L1(A3):ER* and the polyclonal myrPKB:ER* Ba/F3 cell line have
been described previously10,24 and were cultured together with 500 mg/ml G418. For
cytokine withdrawal experiments, cells were washed twice with PBS and resuspended in
RPMI 1640 supplemented with 8% Hyclone serum and, in case of  the polyclonal
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myrPKB:ER* Ba/F3 cell line, cultured for two hours prior to adding 4-hydroxy tamox-
ifen (4-OHT).
Antibodies and reagents
Polyclonal antibodies against cleaved caspase-3 (#9661), cleaved caspase-7 (#9491S) and
PARP (#9542) and phospho-Ser473 PKB (#9271S) were from New England Biolabs
(Beverly, MA, U.S.A). Polyclonal caspase-8 antibody (559932) was from BD Pharmingen
(San Diego, CA, USA). Bim polyclonal antibody was purchased from Affinity Bioreagents
(Golden, CO, U.S.A.). p27KIP1 and RACK1 mAb were purchased from Transduction
Laboratories (Lexington, Kentucky, U.S.A.). Propidium iodide was from Sigma- Aldrich
Chemie (Zwijndrecht, The Netherlands).  Annexin V-FITC kit from Alexis (Kordia bv,
The Netherlands). Rhodamine-123 was purchased from Molecular Probes (Leiden, The
Netherlands).  All other chemicals were reagent grade.
DNA laddering
107 cells were treated as indicated, lysed on ice for 10 minutes in buffer A (10 mM Tris-
Cl pH 7.4, 10 mM EDTA, 0.2% TX-100, supplemented with 1 mM PMSF, 0.1 mM apro-
tinin and 1 mM leupeptin) and centrifuged at 14000 rpm 4°C for 10 minutes. The super-
natant was added to an equal volume phenol:chloroform, rocked gently for 10 minutes,
centrifuged and the upper phase was added to 1/10th volume sodium acetate (3 M, pH
5.4) and 2.5 volumes ethanol and incubated at -20°C for 15 minutes and subsequently
spun down. The pellet was air-dried, resuspended in TE containing 2 mg/ml RNase A,
incubated at 37°C for 30 minutes and run on a 2% agarose gel.
Western blotting 
For the detection of  all proteins, cells were lysed in ELB buffer (50 mM HEPES, pH 7.4,
150 mM NaCl, 5 mM EDTA together with inhibitors)25. Protein concentration was meas-
ured and equal amounts of  protein were analyzed by SDS-PAGE.  Blots were incubated
overnight at 4°C with the appropriate antibodies (1:1000) and after hybridization with
secondary antibodies developed utilizing Enhanced Chemiluminescence (ECL,
Amersham).
FACS analysis of apoptosis
Preparation of  cells for the analysis of  cell cycle profiles has been described previously10.
For the analysis of  apoptosis by Annexin-V staining, cells were washed with ice-cold PBS,
resuspended in binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).
Cells were then incubated with fluorescein isothiocyanate (FITC)-conjugated Annexin-V
(Bender Medsystems, Vienna, Austria) for 10 min at room temperature, washed and
resuspended in binding buffer containing 1 mg of  propidium iodide (PI)/ml and fluores-
cence was analyzed by fluorescence-activated cell sorter (FACS). 
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Analysis of mitochondrial depolarization
For the analysis of  changes in mitochondrial potential, Dym 26, cells were incubated in
RPMI together with 10 mg/ml Rhodamine-123 (Rh-123; Molecular Probes, Eugene, OR,
U.S.A.) at 37°C for 30 minutes, washed twice with PBS and analyzed by FACS10. The per-
centage of  cells falling within the range of  Rh-123 fluoresence, indicative of  depolarized
cells, is shown.
Results 
Induction of apoptosis correlates with upregulation of p27KIP1 and Bim. 
Cytokines of  the interleukin (IL)-3, IL-5 and GM-CSF (granulocyte macrophage colony
stimulating factor) family have a well-established function in transducing a proliferative
and anti-apoptotic response in hematopoietic target cells and their precursors27-29. To
examine the mechanisms underlying cytokine withdrawal induced apoptosis we utilized
the mouse pre-B cell line, Ba/F3, which requires IL-3 both for proliferation as well as to
overcome the default apoptotic program. Previously, we and others have shown that one
mechanism by which cytokine-mediated rescue from apoptosis may be achieved is
through inhibitory phosphorylation of  the Forkhead transcription factor FKHR-L1 by
PKB20,24,30,31. To specifically analyze the effect of  FKHR-L1, we generated cell lines sta-
bly overexpressing an inducible form of  active FKHR-L1, in which all 3 phosphorylation
sites were mutated to alanine, FKHR-L1(A3):ER*. Addition of  4-hydroxy tamoxifen (4-
OHT) to these cells results in the rapid induction of  FKHR-L1 transcriptional activity,
promoting induction of  bona fide Forkhead targets10.
Cells were either cytokine starved or treated with 4-OHT for 24 hours and apoptosis
was measured by analyzing binding of Annexin-V-FITC. While cells that are Annexin-V
positive represent early apoptotic cells; cells that are stained for both Annexin-V and PI
represent cells that have initiated the apoptotic program for a longer period of  time. Both
cytokine withdrawal, as well as FKHR-L1 activity, induced apoptosis to a similar degree
(Fig. 1A). 
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Next, we analyzed the kinetics by which apoptosis was induced utilizing DNA laddering,
a measure for the final events characterizing apoptosis. Both cytokine withdrawal, as well
as FKHR-L1 activity, induced apoptosis within a similar time frame (Fig. 1B). Recently,
we have demonstrated that both p27KIP1 and Bim (Bcl-2 interacting mediator of  cell
death) transcriptional targets of  FKHR-L110,24. We examined whether the kinetics of
upregulation of  p27KIP1 and Bim protein correlated with induction of  apoptosis. Both
cytokine withdrawal and FKHR-L1 activation resulted in an upregulation of  p27KIP1, and
Bim (Fig. 1B, C).  These events occur relatively early and precede the cleavage of DNA
observed in Fig. 1B.
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Figure 1. Induction of  apoptosis by cytokine withdrawal or FKHR-L1 activity.
(A) Left: Ba/F3 cells were cultured in the presence or absence of  cytokines and FKHR-L1(A3):ER*
cells were cultured with IL-3 without or with 4-OHT (100 nM) for 24 hours and analyzed for Annexin-
V binding and PI-staining as described in Experimental Procedures. Right: Ba/F3 cells were IL-3 starved
(left) or FKHR-L1(A3):ER*  expressing cells were treated with 4-OHT (100 nM, right) for the times
indicated. DNA laddering was analyzed as described in Experimental Procedures. (B) Ba/F3 cells were
cytokine-starved for the indicated times, lysed and equal amounts of  protein were analyzed for levels of
p27KIP1 (upper panel) or Bim (middle panel). Samples were analyzed with a RACK1 antibody to verify
equal protein loading (lower panel). (C) Ba/F3 cells stably expressing FKHR-L1(A3):ER* were treated
with 4-OHT for indicated times, lysed and analyzed as above.
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Cytokine withdrawal and FKHR-L1 activity induce cell cycle arrest fol-
lowed by apoptosis.
p27KIP1 is involved in cell cycle arrest in G1 through inhibition of  cyclin-CDK complex-
es32,33, but has also been described to function in the induction of  apoptosis through a
yet unidentified mechanism10,34. Bim is a potent inducer of  apoptosis through binding to
and thus inhibiting anti-apoptotic Bcl-2 members35. To see whether upregulation of
p27KIP1 and Bim reflected an altered distribution of  cells in the cell cycle, we analyzed the
cell cycle profile of  cells at various times. Upon cytokine withdrawal, cells stop initiating
cell division and accumulate in G1, within the first 8 hours of  starvation (Fig. 2A). After
16 hours of  cytokine deprivation cells start to undergo apoptosis, as measured by a DNA
content less than 2N chromosomes, the sub-G1 peak. (Fig. 2A). By 48 hours, a majority
of  cells has initiated a program of  apoptotic cell death. Similar findings were observed in
4-OHT-treated FKHR-L1(A3):ER* cells (Fig. 2B), suggesting that indeed the presence of
a G1 arrest before undergoing apoptosis is related to the initial upregulation of  p27KIP1
and Bim (Fig . 1B and 1C). 
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Figure 2. Cell cycle analysis of  cytokine-starved cells and cells in which FKHR-
L1 activity is induced.
(A) Ba/F3 cells were cytokine-starved for indicated times, fixed, stained with propidium iodide and ana-
lyzed by FACS. (B) Ba/F3 cells stably expressing FKHR-L1(A3):ER* were treated with 4-OHT (100
nM) for the times indicated and processed as in (A). Data depicted are representative of  at least three
independent experiments.
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Caspase activation and PARP cleavage follow cytokine withdrawal and
FKHR-L1 activation.
Very little is known of  the mechanisms by which cytokine withdrawal promotes caspase
activation and cleavage of  apoptotic substrates36,37. Whether this occurs through a death
receptor-dependent or -independent pathway and whether the function of  FKHR-L1 is
implicated therein remains to be established. We have recently reported that Bim is an
important mediator of  FKHR-L1-induced apoptosis10. Furthermore, Forkhead-mediat-
ed upregulation of  Fas ligand has been proposed in T cells20. This suggests that both
death receptor-dependent, as well as death receptor-independent mechanisms may be
involved in Forkhead-mediated induction of  apoptosis. We sought to investigate this in
more detail, examining both cytokine withdrawal and FKHR-L1 activity. Utilizing anti-
bodies specific for cleaved caspase-3 and caspase-7, their activation was analyzed follow-
ing cytokine withdrawal. Caspase-3 (Fig. 3A, upper panel) and caspase-7 (Fig. 3A, middle
panel) were both cleaved after cytokine withdrawal. This occurred approximately 16
hours after removal of  cytokine. Analysis of  4-OHT-treated FKHR-L1(A3):ER* cells
showed similar kinetics of  caspase-3 and caspase-7 cleavage (Fig. 3B, upper and middle
panel). A well-characterized caspase substrate that is cleaved when cells undergo apopto-
sis is PARP (poly (ADP-ribose) polymerase)38, an enzyme involved in DNA repair
(reviewed in 39). To examine whether PARP is cleaved in either cytokine withdrawal or
Forkhead-induced apoptosis, lysates of  cytokine-starved cells or 4-OHT-treated FKHR-
L1(A3):ER* cells were again analyzed. Both IL-3 withdrawal (Fig. 3C, left), as well as
Forkhead activity (Fig. 3C, right) resulted in PARP cleavage with kinetics similar to cas-
pase activation (Fig. 3A,B). These data suggest that similar mechanisms are involved in
both cytokine withdrawal and FKHR-L1-induced apoptosis. Furthermore, the activation
of  caspases proceeds the upregulation of  both p27KIP1 and Bim (Fig. 1B,C).
Cytokine withdrawal and FKHR-L1 activity promote mitochondrial 
depolarization.
Mitochondria play a critical role in the initiation of  apoptosis, which is accompanied by a
loss of mitochondrial transmembrane potential (Ym) and leakage of  cytochrome c40.
This, together with Apaf-1 is required for the onset of  the activation of  the "caspase-cas-
cade"6,7 and is indispensable for death receptor-independent induction of  apoptosis. To
analyze mitochondrial integrity in apoptotic Ba/F3 cells we utilized rhodamine-123 (Rh-
123), a dye that binds to mitochondria in a membrane potential-dependent way26,41. In
cytokine-starved Ba/F3 cells (Fig. 4A), as well as in 4-OHT-treated FKHR-L1(A3):ER*
cells (Fig. 4B), loss of  Ym was observed after 16 hours, and increased dramatically over
time. The kinetics are similar to those of  caspase activation (Fig. 3A and 3B). This sug-
gests that both cytokine withdrawal, as well as FKHR-L1 activation result in loss of mito-
chondrial transmembrane potential, subsequently resulting in cytochrome c release and
activation of  caspases. 
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PKB-mediated rescue from apoptosis correlates with maintenance of
mitochondrial integrity.
PKB is involved in inhibition of  apoptosis by cytokines12,16,17, however, a role for this
kinase in the regulation of mitochondrial integrity remains unclear. PKB has been pro-
posed to rescue cells from apoptosis by maintenance of mitochondrial transmembrane
potential and preventing cytochrome c release21. However, others have observed rescue
from apoptosis downstream from cytochrome c release22. To investigate the role of  PKB
in maintenance of mitochondrial integrity in more detail, we made use of  a polyclonal
Ba/F3 cell line stably expressing a 4-OHT-inducible, active form of  PKB,
myrPKB:ER*10. Treatment of  these cells with 4-OHT resulted in a dramatic phosphory-
lation of myrPKB:ER* (Fig. 5A, upper panel), allowing us to analyze the effect of  PKB
activation following cytokine withdrawal. Indeed, activation of  PKB in the absence of
cytokines was sufficient to rescue cytokine-starved myrPKB:ER* cells from apoptosis
(Fig. 5B), as measured by Annexin-V-FITC staining. To further elucidate a role for PKB
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Figure 3. Analysis of  caspase activation and PARP cleavage in cytokine-starved
cells and 4-OHT-treated FKHR-L1(A3):ER* cells.
(A) Cells were IL-3-starved for the times indicated and caspase-3 and 7 activation was analyzed using
cleavage-specific antibodies. Equal protein loading was verified by analyzing samples for RACK1 expres-
sion. (B) 4-OHT-treated FKHR-L1(A3):ER* cells were analyzed as in (A). (C) PARP cleavage was exam-
ined in cytokine-starved cells (left) or 4-OHT-treated FKHR-L1(A3):ER* cells (right). 
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upstream or downstream of mitochondria, we analyzed whether PKB was capable of
abrogating cytokine withdrawal induced loss of mitochondrial transmembrane potential.
Ba/F3 cells and myrPKB:ER* cells were cultured with or without IL-3 in the presence or
absence of  4-OHT. In Ba/F3 cells, loss of mitochondrial transmembrane potential in the
absence of  cytokines could not be rescued by 4-OHT (Fig. 5C, upper panel), excluding
aspecific effects of  4-OHT. In myrPKB:ER* cells however, addition of  4-OHT substan-
tially decreased the loss of  Ym upon cytokine withdrawal (Fig. 5C, lower panel). This sug-
gests that PKB exerts its anti-apoptotic activity by maintaining mitochondrial integrity.
Caspase activity was subsequently analyzed. Activity of  both caspase-3 and caspase-7 was
substantially reduced in 4-OHT-treated compared to untreated myrPKB:ER* cells. Our
findings of  a partial rescue from apoptosis (Fig. 5B) and caspase activity (Fig. 5D) may be
explained by the fact that the myrPKB:ER* cell line is a polyclonal cell line, potentially
expressing heterogeneous levels of myrPKB:ER*, the lower levels being insufficient to
rescue cells from cytokine withdrawal-induced apoptosis.  Taken together, these findings
demonstrate that PKB-mediated rescue from apoptosis correlates with maintenance of
mitochondrial potential, resulting in a reduction of  caspase activity.
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Figure 4. Induction of mitochondrial transmembrane depolarization by cytokine
starvation or FKHR-L1 activity.
(A) Ba/F3 cells were IL-3 starved for the times indicated and mitochondrial transmembrane depolar-
ization was measured using rhodamine-123 staining as described in Experimental Procedures. (B) 4-
OHT-treated FKHR-L1(A3):ER* cells were analyzed as in (A). Data are representative of  several inde-
pendent experiments.
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Cytokine withdrawal and FKHR-L1 activity induce apoptosis independ-
ent of death receptor activation.
FKHR-L1 has been proposed to induce Fas ligand (FasL) in T cells20, which could con-
tribute to FKHR-L1-mediated induction of  apoptosis. Fas/FasL signaling induces cleav-
age and activation of  caspase-8 cleavage which is an indispensable and specific down-
stream event of  death receptor induced apoptosis5,42.  Analysis of  caspase-8 cleavage is
thus a means to discriminate between death receptor-dependent or death receptor-inde-
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Figure 5. Activation of  PKB rescues cells from apoptosis and maintains mito-
chondrial transmembrane potential. 
(A) Ba/F3 cells stably expressing myrPKB:ER* were left untreated or treated with 4-OHT (100 nM) for
36 hours and PKB phosphorylation was measured using a PKB phospho ser-473-specific antibody. (B)
myrPKB:ER* cells were cytokine-starved in the absence (left) or presence (right) of  4-OHT (100 nM)
for 36 hours and the percentage of Annexin-V-FITC positive cells was determined as describe in the
Experimental Procedures. (C) Ba/F3 cells or Ba/F3 cells stably expressing myrPKB:ER* were cytokine-
starved in the absence or presence of  4-OHT (100 nM) or cultured with IL-3 for 36 hours and mito-
chondrial integrity was examined using rhodamine-123 as described in Experimental Procedures. (D)
Caspase-3 (left) and caspase-7 (right) activation was measured in myrPKB:ER* cells that were cytokine-
starved for 36 hours in the absence or presence of  4-OHT (100 nM) using activation-specific antibod-
ies and reprobed with RACK1 antibody to verify equal protein loading. 
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pendent induction of  apoptosis. As Ba/F3 cells express Fas, albeit at very low levels43,44,
Forkhead-mediated induction of  Fas ligand could potentially trigger apoptosis by induc-
ing caspase-8 activation. We analyzed a potential role for Fas/FasL signaling in the induc-
tion of  apoptosis by cytokine withdrawal or Forkhead activation by measuring caspase-8
cleavage. While Ba/F3 cells expressed caspase-8, neither cytokine withdrawal (Fig. 6A)
nor Forkhead activity (Fig. 6B) resulted in caspase-8 cleavage. As a positive control Jurkat
T-cells were treated with a cross-linking anti-Fas antibody which clearly induced cleavage
and activation of  caspase-8 (Fig. 6C).  This argues against a role for Fas/Fas ligand sig-
naling in FKHR-L1-mediated apoptosis. 
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Figure 6. Caspase-8 is not activated in response to cytokine starvation or FKHR-
L1 activation. (A) Caspase-8 cleavage was analyzed in Ba/F3 cells that were cytokine-starved for the
times indicated. (B) Analysis of  capase-8 cleavage in 4-OHT (100 nM) treated FKHR-L1(A3):ER* cells.
(C) Jurkat cells were treated with or without aFAS18 (1 mg/ml). After 24 hours samples were harvested
and protein concentration measured. Equal amounts of  protein were analyzed by SDS-PAGE and anti-
caspase-8 western blotting.
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Discussion
In this report we analyzed the mechanisms of  cytokine withdrawal and FKHR-L1-
induced apoptosis, as well as PKB-mediated rescue from apoptosis. Utilizing cells
expressing FKHR-L1(A3):ER* allowed us to uniquely analyze the effects of  FKHR-L1
activation. Interestingly, no differences between cytokine withdrawal and FKHR-L1-
mediated apoptosis were observed. Importantly, our results suggest that FKHR-L1 alone
could account for induction of  the apoptotic program triggered by cytokine withdrawal.
In both cases, cells were first arrested in G1 and then underwent apoptosis (Fig. 2). This
was accompanied by a sequential upregulation of  p27KIP1, which is involved in arresting
cells in G1 and the induction of  apoptosis10,32,33, and Bim, which can induce apoptosis by
binding to anti-apoptotic members of  the Bcl-2 family35 (Fig. 1B and 1C). Bim appears
to be essential for the induction of  apoptosis in lymphocytes, since cytokine-deprived
lymphocytes from Bim (-/-) mice fail to undergo apoptosis45. Furthermore, lymphocytes
derived from p27KIP1 (-/-) mice undergo apoptosis at a significantly decreased rate com-
pared to those from wildtype mice10. This suggests that the upregulation of  both p27KIP1
and Bim may play critical roles in the induction of  the apoptotic program initiated by
cytokine withdrawal.
We also analyzed whether Fas/Fas ligand signaling may be involved in induction of
apoptosis upon cytokine withdrawal as previously proposed20. Neither cytokine with-
drawal nor FKHR-L1 activity resulted in cleavage of  caspase-8, an event specific for
death receptor signaling5,42. This suggests that apoptosis either by cytokine withdrawal or
FKHR-L1 activity is initiated through a death receptor-independent mechanism. In sup-
port of  this, overexpression of  anti-apoptotic Bcl-2 members, which rescue death recep-
tor-independent apoptosis, but not death receptor-dependent apoptosis in lympho-
cytes46,47 are able to rescue both cytokine withdrawal, as well as FKHR-L1-induced apop-
tosis14,24. 
PKB has been demonstrated to negatively regulate members of  a subfamily of
Forkhead transcription factors: AFX, FKHR and FKHR-L1 (reviewed in 48). Recently,
members of  the SGK (serum- and glucocorticoid-induced kinases) family, phosphorylat-
ing consensus sequences similar to PKB were found to be required for full phosphoryla-
tion of  FKHR-L1 in vivo and IL-3-mediated survival49,50. This suggests that both kinas-
es may be required for phosphorylation-mediated inactivation of  FKHR-L1. This may
explain why PKB was unable to completely inhibit cytokine withdrawal-induced apopto-
sis (Fig. 5). However, PKB was capable of  significantly abrogating cytokine withdrawal
induced loss of mitochondrial potential (Fig. 5C). Thus we can conclude that PKB exerts
its anti-apoptotic effect at a pre-mitochondrial level, preventing intracellular release of
cytochrome c. A potential role for PKB in rescue from apoptosis and prevention of
cytochrome c leakage has also been proposed in apoptosis induced in Rat1 fibroblasts by
UV-irradiation21, as well as in epithelial cells by detachment from extracellular matrix51.
However, PKB has also been previously shown to inhibit ceramide-induced apoptosis in
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hybrid neuron motor 1 cells downstream of  cytochrome c release22. These findings may
be explained by differences in apoptotic stimuli in different cell types suggesting that
PKB has the potential to act at multiple levels. Furthermore, difference in species could
be an explanation for the differential contribution of  PKB to rescue from apoptosis. PKB
promotes rescue from apoptosis by inhibitory phosphorylation of  caspase-9 in human
cells52, but not in mouse or rat cells since the PKB phosphorylation site in caspase-9 is
not present53. PKB has also been linked to the upregulation of  anti-apoptotic Bcl-2 mem-
ber Mcl-118, which is essential in cytokine-mediated rescue from apoptosis14. This regu-
lation of  an anti-apoptotic Bcl-2 member, involved in the maintenance of mitochondrial
integrity also supports a role for PKB upstream of  cytochrome c leakage in cytokine-
mediated rescue from apoptosis.
The p21ras-activated protein kinase MEK has also been proposed to rescue cells from
apoptosis54-56, potentially through activation of  downstream targets that phosphorylate
Bad55. Furthermore, MEK initiated signals can result in the phosphorylation of  anti-
apoptotic members of  the Bcl-2 family56, thereby enhancing their stability57. However,
utilizing the myrPKB:ER* cell line we have demonstrated that PKB alone is sufficient to
protect cells from programmed cell death (Fig. 5B,C). Our data do not however rule out
the possibility that MEK plays a role in these events.
Increased PKB activity can result in cellular transformation58-60. Although the exact
mechanisms by which PKB is capable of  promoting oncogenesis remains to be estab-
lished, inhibitory phosphorylation of  FKHR-L1 could very well contribute to this
process, leading to a decrease both Bim and p27KIP1 levels. This is supported by the
observation that a decrease in p27KIP1 levels is associated with a poor prognosis in can-
cer61-63.
Taken together, our data suggests that cytokine-induced signaling can inhibit cells
from apoptosis through activation of  PKB (or SGK), which inhibits FKHR-L1 and Bad
through phosphorylation, and transcriptionally upregulates Mcl-1. In the absence of
cytokines, PKB is inactive, resulting in dephosphorylation and activation of  Bad and tran-
scription of  FKHR-L1 targets p27KIP1 and Bim. This results in induction of  the apop-
totic program through loss of mitochondrial integrity, leakage of  cytochrome c, subse-
quent activation of  caspases and cleavage of  substrates. These events are summarized in
a model (Fig. 7).  
Our findings provide a greater insight into the mechanisms regulating induction of
apoptosis in lymphocytes, and probably other hematopoietic cells, upon cytokine with-
drawal. PKB alone is sufficient to inhibit apoptosis through the maintenance of mito-
chondrial transmembrane potential. This is likely to be due to the inhibition of  FKHR-
L1, thus preventing transcription of  the pro-apoptotic Bcl-2 family member Bim. A
greater understanding of  the mechanisms by which cytokines regulate cellular survival
will help towards the design of  novel pharmacological agents for therapeutic intervention
in a variety of  proliferative and degenerative disorders of  the immune system. 
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Figure 7. A model for cytokine withdrawal-induced apoptosis. 
In the absence of  cytokines, PKB and SGK are inactive, resulting in dephosphorylation and subsequent
activation of  pro-apoptotic Bcl-2 member Bad and the FKHR-L1 transcription factor. Transcriptional
activity of  FKHR-L1 elevates levels of Bim and p27KIP1. p27KIP1 inhibits cell cycle progression and
helps to promote apoptosis in an as yet unidentified manner. Bim, possibly together with Bad, promotes
loss of mitochondrial integrity and leakage of  cytochrome c. This triggers activation of  caspases and
subsequent cleavage of  downstream targets, resulting in apoptosis. 
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CHAPTER 6
Identification of  novel targets of  the Forkhead transcription
factor FKHR-L1 by gene array analysis
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Abstract
The Forkhead/ winged helix family of  transcription factors shares a structurally related
domain, the Forkhead domain, but are highly divergent in their tissue distribution and
their contribution to cellular functions. One subclass of  this family, consisting of AFX,
FKHR and FKHR-L1, have recently been described as targets of  Protein Kinase B. Their
transcriptional activity, resulting in cell cycle arrest, as well as induction of  the apoptotic
program, is inhibited by PKB. To obtain further insight into the mechanism of  action of
this subclass of  transcription factors, we performed a gene array screen using cells stably
expressing an 4-hydroxy tamoxifen (4-OHT) inducible construct of  FKHR-L1. A mouse
gene array was probed with cDNA generated from cells treated with or without 4-OHT
for three hours. Two members of  the AP-1 family of  transcription factors, c-Jun and Fra-
2, were found to be rapidly and specifically upregulated upon activation of  FKHR-L1.
Both proteins were also upregulated upon cytokine withdrawal. These findings may help
to shed light on the mechanisms by which the AFX, FKHR and FKHR-L1 subclass of
transcription factors can regulate proliferation and survival in a variety of  cell types.
Introduction
The family of  Forkhead/ winged helix transcription factors consists of  over 100 mem-
bers, that vary in their tissue distribution, regulation, and also in their DNA binding
sequence specificity and thus also in their transcriptional targets. They all share a con-
served 100 amino acid DNA-binding domain, called the Forkhead domain1. These tran-
scription factors are involved in a myriad of  cellular functions, including embryogenesis,
cellular differentiation, mediating cell death, immune homeostasis, maintenance of  ovar-
ian follicles2-6. Recently, a subclass of  Forkhead transcription factors was identified, com-
prising AFX, FKHR and FKHR-L1, of which chromosomal rearrangement has been
linked to oncogenesis7-10. These transcription factors are highly homologous in their
DNA binding domain which binds to a similar core sequence (TTGTTTAC), but their
binding specificity of  the surrounding sequences is distinct for each protein11. The tissue
distribution patterns of  AFX, FKHR and FKHR-L1 mRNAs overlaps in the embryo,
being high in muscle, adipose tissue and liver. These patterns of  expression are similar in
the adult, although FKHR-L1 is then ubiquitously expressed11,12. These proteins have
been identified as targets of  PI3K-PKB signaling6,13-15. Phosphorylation by PKB results
in nuclear exclusion and thus inhibits their activity6,13-15. As AFX, FKHR and FKHR-L1
have been linked to both cell cycle arrest and induction of  apoptosis6,14,16,17, chromoso-
mal rearrangement might promote oncogenesis by interfering with their physiological
activity. Transcriptional activity of AFX, FKHR and FKHR-L1 can upregulate the cell
cycle inhibitor p27KIP1(16-18). In addition, transcriptional activity of  FKHR-L1 has been
shown to upregulate pro-apoptotic protein Bim (Bcl-2 interacting mediator of  cell death),
which binds to and inactivates anti-apoptotic Bcl-2 members19. Furthermore, FKHR-L1
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has also been proposed to regulate the expression of  Fas ligand6, which can initiate apop-
tosis through binding to Fas (CD95, Apo-1) reviewed by Nagata20. Recently, signaling by
cytokines was also demonstrated to promote survival by inhibiting the activity of
Forkhead transcription factor FKHR-L1 through PKB19,21. Upon cytokine-withdrawal
FKHR-L1 is dephosphorylated19, which is accompanied by a cell cycle arrest and induc-
tion of  the apoptotic program, suggesting that these events might be mediated by FKHR-
L1. In addition, the activity of  this subclass of  Forkhead transcription factors might also
be involved in the differentiation of  cells, as FKHR has recently been described in posi-
tive selection of T cells5.
To identify novel transcriptional targets for AFX, FKHR and FKHR-L1 we made use
of  cells stably overexpressing an inducible FKHR-L1 mutant, FKHR-L1(A3):ER*, in
which all three phosphorylation sites have been mutated. This construct is expressed con-
stitutively in the cell, but is only active when 4-hydroxy tamoxifen (4-OHT) is added.
Addition of  4-OHT results in rapid induction of  FKHR-L1(A3):ER* activity, and has
been proven to be an excellent tool to specifically analyze FKHR-L1 activity17,19. To
define novel FKHR-L1 target genes we took a gene array approach. ATLAS array filters
were screened with probes generated from RNA isolated from FKHR-L1(A3):ER* cells
that were treated with or without 4-OHT. Using this strategy, we have identified two
potential FKHR-L1 targets, the immediate-early genes c-Jun and Fra-2 (fos-related anti-
gen 2). FKHR-L1 activity, as well as cytokine-withdrawal resulted in an elevation of  c-Jun
and Fra-2 protein levels. These data have consequences for the regulation of  survival,
proliferation and differentiation by Forkhead-related transcription factors in a variety of
cell systems.
Experimental procedures
Cell culture
Ba/F3 cells were cultured in RPMI 1640 supplemented with 8% Hyclone serum (Gibco)
and recombinant mouse IL-3 produced in COS cells22. Ba/F3 cells stably expressing
FKHR-L1(A3):ER* have been described previously17 and were cultured in the presence
of  500 mg/ml G418. For cytokine-withdrawal experiments, cells were washed twice with
PBS and resuspendend in RPMI 1640 supplemented with 8% Hyclone.
ATLAS array screen
To perform the ATLAS array screen the Mouse Broad-Coverage ATLAS array #7741-1
was purchased (Clontech, Palo Alto, CA, U.S.A.), which was provided with reagents for
all RNA treatments described below. For the isolation of  RNA, FKHR-L1(A3):ER* cells
(108) were cultured in the presence of  IL-3 with or without 4-OHT (100 nM) for three
hours and RNA was isolated as described previously23. Next, 500 mg RNA of  each sam-
ple was subjected to a DNAse treatment to avoid contamination with genomic DNA.
RNA was subsequently analyzed on gel to verify that the RNA was not degraded.
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Efficiency of  the DNAse treatment was verified by testing whether a PCR (35 cycles) on
2 mg RNA with b-actin primers did not give any visible product. Next, polyA+ RNA was
isolated with magnetic beads coated with poly dT using 250 mg of  total RNA and a probe
of  cDNA was generated using specific primers for the genes on the array to specifically
generate cDNA of  those genes. The reverse transcription of  the RNA to generate cDNA
was carried out at 54ºC by incubating in the presence of  radioactive g32P-dATP. The
duplo array filters were incubated overnight with the probe generated from either
untreated or 4-OHT treated cells at 72ºC, washed the next day filter and exposed to X-
ray film.
Antibodies and reagents
Constructs for mouse c-Jun24 and the c-Jun promoter25 have been described previously.
Fra-2 was obtained by PCR amplification from 4-OHT-treated FKHR-L1(A3):ER* cells,
cloned into pSG5-myc and verified by sequencing. Polyclonal antibodies against c-Jun (H-
79), Jun B (N17), Jun D (329)-G, Fra-2 (Q20), Fra-1 (Q20) were obtained from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, U.S.A.); p27 and RACK1 mAb were purchased
from Transduction Laboratories (Lexington, Kentucky, U.S.A.). 
Western blotting 
For the detection of  all proteins, cells were lysed in ELB buffer (50 mM HEPES, pH 7.4,
150 mM NaCl, 5 mM EDTA together with inhibitors)26, protein concentration was meas-
ured and equal amounts of  protein were loaded. Blots were incubated overnight at 4°C
with appropriate antibodies (1:1000) and after hybridization with secondary antibodies
developed utilizing Enhanced Chemiluminescence (ECL, Amersham).
Northern blotting
FKHR-L1(A3):ER* cells were cultured in the presence of  IL-3 with or without 4-OHT
for appropriate times prior to RNA isolation. Total RNA was isolated as described pre-
viously23 and twenty micrograms were used for Northern blotting and hybridized with a
Fra-2 probe consisting of  full-length Fra-2 cDNA. Equal RNA loading was verified by
reprobing the blots with a 1.4 kb cDNA fragment of  the human glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) gene.
Luciferase assays
Ba/F3 cells were electroporated (0.28 kV; capacitance 960 mF) with c-Jun-CAT promot-
er construct together with an internal transfection control (pRL-TK; Promega).
Transfections were divided over two wells and 4-OHT was added to one well 2 hours
after transfection. 24 hours after transfection, cells were harvested for both CAT assays
as described previously27 to assess c-Jun promoter activity and luciferase activity to cor-
rect for transfection efficiency. 
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Results and discussion
The Forkhead transcription factor FKHR-L1 has previously been shown to be a potent
inducer of  apoptosis in both T cells, as well in an IL-3-dependent pro B cell line,
Ba/F36,17. In T cells, FKHR-L1 has been proposed to promote apoptosis through upreg-
ulation of  Fas ligand6; in Ba/F3 cells, both p27KIP1, as well as Bim (Bcl-2 interacting
mediator of  cell death) have been demonstrated to be upregulated and involved in
FKHR-L1-mediated cell cycle arrest, as well as induction of  apoptosis17,19. As Forkhead
transcription factors are also involved in triggering differentiation5,28,29, the subclass of
Forkhead transcription factors AFX, FKHR and FKHR-L1 might also play a role in the
differentiation of  hematopoietic cells. Indeed, FKHR has recently been described to be
involved in the negative selection of  thymocytes5. To identify novel FKHR-L1 transcrip-
tional targets we used Ba/F3 cells stably expressing FKHR-L1(A3):ER*. This cell line
allows us to specifically analyze effects of  FKHR-L1 transcriptional activity which is
induced upon treatment with 4-OHT. ATLAS array filters (Mouse Broad Coverage
#7741) were hybridized with probes generated from either untreated or 4-OHT-treated
FKHR-L1(A3):ER* cells (Fig. 1A). p27KIP1 was upregulated in 4-OHT-treated cells com-
pared to untreated cells (data not shown), demonstrating that this approach is suitable to
identify FKHR-L1 target genes. Of  the genes whose expression was regulated on the fil-
ter hybridized with the probe from FKHR-L1(A3):ER* cells we focused on two poten-
tial FKHR-L1 targets. These proteins are c-Jun and Fra-2 (fos-related antigen 2), which
are both members of  the transcription factor AP-1 family (activator protein 1, reviewed
in 30,31) (Fig. 1A). AP-1 refers to the assembly of  Jun:Jun or Jun:Fos/Fra proteins that
bind together to specific regulatory sequences in the promoter of  target genes. Jun mem-
bers include c-Jun, JunB and JunD, whereas Fos members include c-Fos, FosB, Fra-1 and
Fra-2. While JunB, JunD and Fos were also present on the ATLAS gene array filter, they
were not upregulated following FKHR-L1 activity (data not shown). This suggests that
FKHR-L1 activity promotes upregulation of  specific AP-1 members.
Although c-Jun32,33, as well as Fra-233 have both been proposed to be involved in pro-
liferation, c-Jun32,34,35, as well as Fra-234 have also been described to be involved in induc-
tion of  apoptosis as well as differentiation36-39, thus prompting us to further investigate
these proteins. To examine whether the upregulation of  c-Jun and Fra-2 was also reflect-
ed in an increase in protein levels, FKHR-L1(A3):ER* cells were cultured in the absence
or presence of  4-OHT. A dramatic induction of  c-Jun, as well as Fra-2 was observed after
overnight treatment with 4-OHT (Fig. 1B). The extent of  this induction was similar to
that of  p27KIP1, a recently described FKHR-L1 target16,17.
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Next, we analyzed the kinetics of  FKHR-L1-mediated upregulation of  c-Jun and Fra-
2 by analyzing FKHR-L1(A3):ER* cells that were treated with 4-OHT for the times indi-
cated (Fig. 2). c-Jun induction was clearly visible as early as 4 hours after induction of
FKHR-L1 activity, and increased over time with kinetics similar to those of  FKHR-L1
target p27KIP1. Fra-2 protein levels were increased as early as 2 hours after induction of
FKHR-L1 activity, but were not further elevated over time (Fig. 2 and data not shown).
No elevation in protein levels was observed in JunB, JunD or Fra-1 (data not shown), sug-
gesting that induction of  FKHR-L1 activity promotes upregulation of  specific AP-1
members. 
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Figure 1 c-Jun, Fra-2 and p27KIP1 are upregulated in 4-OHT-treated FKHR-
L1(A3):ER* cells.
(A) Schematic representation of  the Forkhead array screen (B) FKHR-L1(A3):ER* cells were cultured
with IL-3 with or without 4-OHT (100 nM) overnight, lysed and analyzed for levels of  c-Jun, Fra-2 or
p27KIP1. Blots were reprobed with a RACK1 antibody to verify equal protein loading.
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IL-3 has previously been demonstrated to result in phosphorylation and subsequent
inactivation of  FKHR-L117. Conversely, withdrawal of  IL-3 results in the dephosporyla-
tion of  FKHR-L1, which is accompanied by upregulation of  FKHR-L1 targets p27KIP1
and Bim17,19. To examine whether IL-3 withdrawal also resulted in an induction of  c-Jun
and Fra-2, Ba/F3 cells were IL-3-starved for the times indicated and assessed for levels
of  c-Jun and Fra-2. c-Jun was quite rapidly upregulated following IL-3 withdrawal (Fig.
3A), with levels being highly elevated as early as one hour, which was much faster than
the upregulation observed in FKHR-L1(A3):ER* cells (compare with Fig. 1B upper
panel). However, levels of  c-Jun decreased as early as 4 hours after cytokine withdrawal,
with levels returning to basal levels after 16 hours. Similar observations were made for
Fra-2 (Fig. 3B). Also in the case of  Fra-2, cytokine withdrawal resulted in a much more
rapid elevation of  Fra-2 than observed in FKHR-L1(A3):ER* cells (Fig. 1B). 
The differences in kinetics of  upregulation between cytokine withdrawal and 4-OHT-
treated FKHR-L1(A3):ER* cells could be explained in that experiments in 4-OHT-treat-
ed cells were carried out in the presence of  IL-3. IL-3 might act to induce the activity of
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Figure 2 Time course analysis of  levels of  c-Jun, Fra-2, JunB and p27KIP1.
FKHR-L1(A3):ER* cells were either left untreated or treated with 4-OHT (100 nM) for indicated times,
lysed and analyzed for protein levels of  c-Jun, Fra-2, JunB, JunD and p27KIP1. Equal protein loading was
verified by reprobing the blot with a RACK1 antibody. Data are representative of  at least two different
clonal FKHR-L1(A3):ER* cell lines.
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a transcriptional repressor of  c-Jun and Fra-2, which is rapidly degraded in the absence
of  IL-3. The kinetics of  elevation of  c-Jun and Fra-2 protein levels in FKHR-
L1(A3):ER* cells might subsequently be delayed as the activity of  this repressor needs to
be overcome first. 
Although activity of  FKHR-L1 is probably sustained over time following cytokine
withdrawal17, this is not reflected by an increase in upregulation of  c-Jun and Fra-2. An
explanation for the sustained c-Jun and Fra-2 levels in 4-OHT-treated cells might be that
IL-3 in some way increases their stability. Indeed, MAPK-mediated phosphorylation
results in a reduction of  ubiquitination and potential degradation of  c-Jun40. MAPK-
mediated stabilization has also been suggested for Fra-241. 
Thus far we only examined the effect of  FKHR-L1 transcriptional activity on the ele-
vation of  protein levels of  c-Jun and Fra-2. To analyze whether indeed upregulation of
these protein levels is also reflected by an increase of mRNA levels or promoter activity,
FKHR-L1(A3):ER* cells were cultured with or without 4-OHT for the indicated times.
Fra-2 mRNA (Fig. 4A) was dramatically elevated upon 4-OHT-treatment, suggesting that
indeed transcriptional activity of  FKHR-L1 is involved in the elevation Fra-2 protein lev-
els observed. Unfortunately, as pretreatment of  cells with protein synthesis inhibitor
cycloheximide results in a superinduction of  c-Jun42, as well as Fra-2 (data not shown),
we were not able to use this approach to demonstrate that FKHR-L1 directly upregulates
c-Jun and Fra-2. However, Forkhead consensus DNA binding sites were found in both
the c-Jun43 and Fra-244 promoter, suggesting that FKHR-L1 may indeed directly induce
c-Jun or Fra-2 transcription.
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Figure 3 IL-3 withdrawal promotes a transient upregulation of  c-Jun, as well as
Fra-2.
(A) Ba/F3 cells were IL-3-starved for the indicated times, lysed and assessed for levels of  c-Jun (top) or
RACK1 (bottom) to verify equal protein loading. (B) As in (A) but probing with Fra-2 instead of  c-Jun. 
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Next, we examined whether FKHR-L1 activity could also promote transcriptional
activation of  the c-Jun promoter. Two clonal Ba/F3 cell lines stably expressing FKHR-
L1(A3):ER* cells were analyzed, to exclude artefacts due to clonal selection. In both of
the clones examined, 4-OHT treatment of  FKHR-L1(A3):ER* cells strikingly elevated c-
Jun promoter activity (Fig. 4B, left). This demonstrates FKHR-L1 regulation of  both pro-
moter activity, as well as induction of mRNA levels. Furthermore, analysis of  c-Jun pro-
moter activity in Ba/F3 cells cultured in the absence or presence of  IL-3 also revealed
that IL-3 withdrawal resulted in an elevation of  c-Jun promoter activity (Fig. 4B, right).
Taken together, this suggests that FKHR-L1 activity can result in elevation of  c-Jun and
Fra-2 protein levels by enhancing their transcription. 
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Figure 4 FKHR-L1 induces an increase of  Fra-2 mRNA levels, as well as an 
induction of  c-Jun promoter activity.
(A) IL-3-cultured FKHR-L1(A3):ER* cells were either left untreated or treated with 4-OHT (100 nM)
for indicated times, 20 mg of  total RNA was used for Northern blotting and hybridized with a Fra-2
probe (top). Equal RNA loading was verified by GAPDH reprobing (bottom). (B) Two different clonal
Ba/F3 cell lines stably expressing FKHR-L1(A3):ER* (left) or Ba/F3 cells (right) were electroporated
with 20 mg of  c-Jun-CAT plasmid together with 500 ng of  pRL-TK plasmid as an internal transfection
control. FKHR-L1(A3):ER* cells were cultured for 24 hours with IL-3 in the absence or presence of  4-
OHT (100 nM) and Ba/F3 cells in the absence of  presence of  IL-3 before analyzing CAT and luciferase
activity as described in Materials and Methods. The data are representative of  several independent exper-
iments.
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If  a Forkhead transcriptional target were to be important for regulation of  apoptosis
or cell cycle arrest, then overexpression of  this protein should be sufficient to promote
apoptosis or cell cycle arrest. However, overexpression of  neither c-Jun nor Fra-2 result-
ed in Ba/F3 cells resulted in an alteration of  cell cycle distribution or decreased survival
(data not shown). However, in neuronal cells, c-Jun and Fra-2 have both been demon-
strated to promote induction of  apoptosis. NGF withdrawal-induced apoptosis is
accompanied by elevation of  c-Jun mRNA and microinjection of  antibodies against c-
Jun, as well as Fra-2 protected NGF-deprived neurons from apoptosis34. Furthermore,
overexpression of  dominant negative c-Jun was found to protect sympathetic neurons
from apoptosis following NGF-withdrawal45 and increased c-Jun activity was sufficient to
trigger apoptotic cell death in NIH 3T3 fibroblasts35. This suggests that activity and func-
tion of  AP-1 members may differ depending on the cell type and conditions. Thus, in
neuronal cells, Forkhead-related transcription factors may play a an important role in the
induction of  apoptosis through transcriptional induction of AP-1 family members.
Importantly, the PI3K-PKB pathway has been shown to be critical in NGF-mediated
survival46.
Fra-2 and c-Jun have also been proposed to function in the differentiation of  cells.
Ectopic expression of  c-Jun is sufficient to induce differentiation of  P19 embryonal car-
cinoma cells43, as well as murine myelomonocytic WEHI-3B D+ cells47. In addition,
expression of  antisense c-Jun blocked differentiation in a murine erythroleukemia cell
line48. Fra-2 and JunD heterodimers have also been proposed to be involved in osteoblast
differentiation49 as well as with the transition of  proliferating granulosa cells to terminal-
ly differentiated, non-dividing luteal cells39. These observations suggest that transcrip-
tional upregulation of  c-Jun and Fra-2 by FKHR-L1 or related Forkhead family members
might be linked to differentiation of  cells. It will be interesting to examine this in one of
the cell types in which AP-1-mediated differentiation has been proposed.
It should be noted that Fra-2 has a high affinity for JunD and increases the activity of
JunD, upon heterodimerization50. Thus, upregulation of  Fra-2 may promote het-
erodimerization of  Fra-2 to other AP-1 members. c-Jun itself  is also involved in the acti-
vation of  transcription factors other than members of  the AP-1 family, such as PU.151. 
These data demonstrate that FKHR-L1(A3):ER* cells are a powerful tool to obtain
further insight into potential targets of  Forkhead transcription factors AFX, FKHR and
FKHR-L1 and their mechanism of  action. While c-Jun and Fra-2 do not appear to have
an apparent role in the induction of  the apoptotic program in Ba/F3 cells, there may be
a role in neuronal cells. A further challenge will be to identify what the consequences of
Forkhead-mediated upregulation of  c-Jun and Fra-2 is on the transcriptional activity of
AP-1 family members and investigate how this is related to their transcriptional regula-
tion of  genes in a variety of  physiological processes. 
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General discussion
Maintaining a correct number of  cells in the hematopoietic system, as well as having suf-
ficient differentiated cells to carry out specialized tasks and to be able to respond in
changes in the extracellular environment requires a highly organized network to coordi-
nate these events. Terminally differentiated cells generally do not divide, but arise from
precursors (stem cells), which can either proliferate, giving rise to more precursors, or dif-
ferentiate, which in general is accompanied with a loss of  their proliferative capacity;
reviewed in 1,2. Somewhere in the life of  a stem cell the decision is made to proliferate or
to undergo differentiation. This decision can be governed by a specific combination of
extracellular factors, cytokines, which activate a network of  intracellular signaling path-
ways. Mutations in components of  this signaling network can disturb the balance between
proliferation and differentiation, as well as abrogate the dependence of  the cell for sur-
vival factors. This can result in leukemia, characterized by a block in differentiation of
hematopoietic precursors, accompanied with inappropriate proliferation and expansion.
Thus, an important feature of  leukemic cells is that they exhibit a block in differentiation
and have gained the capacity for unlimited proliferation, without being restrained by the
normal mechanisms that promote apoptosis upon inappropriate division. Generally, in
addition to exhibiting unrestrained proliferation, tumor cells also need to have adapted to
overcome apoptosis. The differentiation block in leukemias is often a result of  chromo-
somal translocations of  genes encoding transcription factors (reviewed in 3,4). The result-
ing protein products of  these translocations can interfere with the normal growth factor
activated signaling network and transcription factors that act in concert to promote dif-
ferentiation. 
Terminal differentiation is in general accompanied with an arrest in the cell cycle and
evidence is accumulating that this arrest is mediated by CKIs acting together to induce a
G1 arrest and exit from the cell cycle (known as G0, reviewed in 5). In tumor cells, expres-
sion of  CKIs is often lost or substantially decreased (reviewed in 6,7). Elevation of  the
CKI p27KIP1 is an adverse  prognostic indicator in cancer in that low levels are correlat-
ed with a poor prognosis8-10. Although it is not clear whether this simply reflects the fact
that relatively undifferentiated cells have a higher tumorigenic capacity and lower levels of
CKIs, it is worth noticing that induction of  differentiation in some leukemias in combi-
nation with chemotherapy increases the chance of  ablating the leukemia11. In addition,
lower levels of  p27KIP1 might also reflect a defect in the pathways regulating p27KIP1
expression, which might also include other proteins, whose dysregulation is more direct-
ly related to oncogenesis.
To obtain more insight into the mechanisms by which cytokine-activated signaling
pathways could promote proliferation and survival and potentially obtain insight into
strategies of  clinical interference in leukemias or inflammatory diseases, we studied IL-3,
IL-5 and GM-CSF-induced signaling.  Receptors for IL-3 and GM-CSF are present on a
wide variety of  hematopoietic cells, whereas expression of  the IL-5 receptor is restricted
to eosinophils and basophils in man, and in mice also on B cells12,13. As eosinophils are
Chapter 7
118
Chapter 7_2703.qxd  2-5-01  18:03  Page 118
believed to be involved in the pathogenesis of  allergic diseases14,15, potential eradication
by interference with signaling pathways involved in IL-5-mediated survival might allevi-
ate the disease symptoms. A useful therapeutic agent might result from the recent devel-
opment of  peptides that bind to and antagonize the IL-5 receptor16. However, the
requirement for this strategy is that cells are still responsive to IL-5, and have not devel-
oped mechanisms that result in cytokine-independent growth or survival.
Upon analyzing which signaling pathways are essential for IL-3, IL-5 and GM-CSF-
mediated proliferation utilizing specific pharmacological inhibitors, only inhibition of
PI3K abrogated both cytokine-mediated survival and proliferation (Chapter 3, Fig. 1). We
have demonstrated that PI3K target PKB can account for the anti-apoptotic effect of
PI3K (Chapter 3, Chapter 5, Fig. 5). Previously identified targets of  PKB, caspase-9 and
Bad, whose activity is inhibited following PKB phosphorylation, have been described in
PKB-mediated survival17,18. However, phosphorylation of  these targets is not required
for survival in all cellular systems19,20. Therefore we set out to investigate other targets of
PKB. This resulted in the observation that PKB-mediated phosphorylation of  Forkhead
transcription factor FKHR-L1 appears to be required for IL-3, IL-5 and GM-CSF-medi-
ated rescue from apoptosis (Chapter 3 Fig. 4). Phosphorylation of  FKHR-L1 by PKB
promotes association of  FKHR-L1 with 14-3-3 proteins, resulting in cytoplasmic reten-
tion, thus inhibiting its transcriptional activity21. Upon investigation as to how FKHR-L1
activity promotes cell cycle arrest and induction of  apoptosis in cells, two FKHR-L1 tar-
gets were identified, p27KIP1 and pro-apoptotic Bcl-2 family member Bim (Chapter 3,
Chapter 4). These findings are summarized in Fig. 1.
General discussion
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p27KIP1, a critical mediator of proliferation and apoptosis ?
p27KIP1 was initially identified as an inhibitor of  CDK/ cyclin complexes that are pres-
ent in G1 and constitute an important mediator of  the "restriction point" (Chapter 1, Fig.
3) which can be overcome by growth factors22,23. At the end of  G1, levels of  p27KIP1
decrease, which is predominantly mediated by phosphorylation by cyclin E/CDK2,
resulting in degradation by the ubiquitin system24-26. Transcriptional regulation of
p27KIP1 has, in contrast to our observations in Chapter 3, never been considered an
important mechanism of  regulation of  p27KIP1 levels. These differences might be
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Figure 1 Model.
Cytokine-mediated rescue from apoptosis can be mediated by activation of  PKB, which phosphorylates
pro-apoptotic Bcl-2 family member Bad and Forkhead transcription factor FKHR-L1, thus inhibiting
their activity. In the absence of  cytokines, FKHR-L1 is active, promoting transcription of  p27KIP1 and
pro-apoptotic Bcl-2 family member Bim. P27KIP1 can promote either cell cycle arrest by inhibiting G1
CDK-cyclin complexes or inhibit apoptosis through an unidentified mechanism. Bim can promote
apoptosis by inhibiting the activity of  anti-apoptotic Bcl-2 family members. FKHR-L1 activity results in
subsequent activation of  caspases, executing the apoptotic program through proteolytic cleavage of  sub-
strates, such as PARP. 
Chapter 7_2703.qxd  2-5-01  18:03  Page 120
explained in that many previous studies have been carried out in fibroblasts, in which
mRNA levels of  p27KIP1 do not or only mildly increase in response to growth factor dep-
rivation23,27. With respect to this it is also interesting to note that overexpression of
p27KIP1 in fibroblasts results only in a G1 arrest, whereas in hematopoietic cells overex-
pression can in addition promote induction of  apoptosis28,29. A potential explanation of
induction of  the apoptotic program by p27KIP1 in hematopoietic cells has been provided
by Boussiotis and coworkers, who observed that p27KIP1 associates with c-Jun co-activa-
tor JAB1, resulting in defective AP-1-mediated transcription in T cells30. Increases in
p27KIP1 levels may then result in a decrease in transcription of  anti-apoptotic genes,
resulting in apoptosis (Fig. 2A). To examine whether this might be an explanation for the
induction of  apoptosis that we observed upon overexpression of  p27KIP1, we analyzed
the effect of  overexpression of  p27KIP1 on the luciferase activity of  an AP1-responsive
luciferase construct. Indeed, luciferase activity of  cells overexpressing p27KIP1 was sub-
stantially decreased compared to control cells (Fig. 2B), whereas overexpression of
p27KIP1 did not alter luciferase activity of  an unrelated cyclin D1 luciferase construct. 
While this could indicate that displacement of  JAB1 from AP-1 complexes is  a poten-
tial mechanism by which p27KIP1 could promote apoptosis in hematopoietic cells, this still
awaits further analysis. As an alternative explanation for induction of  apoptosis, we can-
not exclude that overexpression of  p27KIP1 in cells which have already passed the restric-
tion point might result in induction of  the apoptotic program as a result of  simultane-
ously receiving both proliferative and anti-proliferative signals, as usually levels of  p27KIP1
decrease towards the end of  G122,23. Further evidence for a function of  p27KIP1 other
than inducing  G1 arrest is provided in that p27KIP1 expression is regulated in terminally
differentiated eosinophils (Chapter 3 Fig. 2). Although expression of  CKIs in terminally
differentiated cells has been suggested to be required for the maintenance of  their non-
proliferative status2, p27KIP1 is upregulated upon IL-5 withdrawal, suggesting that in
some cell types p27KIP1 might indeed be involved in induction of  the apoptotic program. 
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Function of pro-apoptotic Bcl-2 family members in development and
potential mechanism of regulation.
A second FKHR-L1 target that we identified was the BH3-only protein Bim (Chapter 4).
In addition to Bim there are other BH3-only proteins that interact with anti-apoptotic
Bcl-2 family members through their BH3-region and thus inhibit their activity, resulting
in induction of  the apoptotic program31. Interestingly, expression and regulation of  Bim
was only observed in hematopoietic cells28, but not in fibroblasts (G. Kops et al., personal
communication). Moreover, activity of  FKHR-L1 results in a G1 arrest in fibroblasts, and
induction of  apoptosis in hematopoietic cells27,28, suggesting that Bim is indeed a critical
mediator of  the apoptotic program in hematopoietic cells.
Regulation of  activity of  BH3-only proteins in mammals can occur posttranslational-
ly, such as for Bad18,32. In addition, evidence is accumulating for transcriptional regulation
of  some of  these proteins. DNA damage-induced activation of  transcription factor p53
promotes transcription of BH3-only protein Noxa, concomitant with elevation of  CKI
p21CIP1(33; reviewed in 34). This is similar to our own observations of  FKHR-L1-medi-
ated  upregulation of  a CKI and a BH3-only protein. NGF withdrawal-induced apopto-
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Figure 2 Expression of  p27KIP1 decreases collagenase promoter activity.
(A) Model for p27KIP1 in induction of  apoptosis. When levels of  p27KIP1 are low, JAB1 translocates to
the nucleus and serves as a cofactor for AP-1 complexes. High levels of  p27KIP1 promote translocation
of  JAB1 to the cytoplasm, resulting in a destabilization of  AP-1 complexes and reduction of  AP-1-medi-
ated transcription. (B) Ba/F3 cells were electroporated with either 2 mg of  collagenase-luciferase con-
struct (black bars), or cyclin D1 luciferase constructs (white bars) together with 500 ng of  renilla as an
internal transfection control, together with 8 mg of  c-Jun, JAB1 or p27KIP1 as indicated. Cells were cul-
tured in the absence or presence IL-3 for 24 hours and luciferase activity was analyzed as described in
Chapter 3. 
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sis of  neuronal cells, but also survival factor withdrawal of  several hematopoietic cell lines
and  bone marrow-derived CD34(+) cells, induces elevation of  the BH3-only protein
Harakiri (Hrk, also known as DP5)35,36. However, the transcription factor(s) responsible
for this upregulation still remains to be elucidated. We have set out to investigate whether
FKHR-L1 might be involved in regulation of Hrk, but failed to detect Hrk expression in
Ba/F3 cells (data not shown). It is still of  course interesting to examine this in the con-
text of  other hematopoietic cells. 
Could there be a function for BH3-only proteins in apoptosis during development, for
example to eliminate unwanted cells during T and B cell selection, where autoreactive
cells undergo apoptosis ?  The observation that B and T cell development is perturbed in
Bim (-/-) mice and is accompanied with autoimmune diseases suggests that this might
indeed be the case37. Here, research on model organisms such as C. elegans can shed light
on BH3 only proteins in development, as many components of  the apoptotic machinery
are conserved through evolution38. Moreover, the recently elucidated sequence of  the
human genome will be of  help in identifying additional components in human39. In C.
elegans, the BH3-only protein EGL-1 has been demonstrated to be essential for the
majority apoptotic cell deaths during development, since loss of  function of  the egl-1
gene abrogated apoptosis this process40. Additional research suggested that regulation of
EGL-1 might be cell-type dependent41. In some cells, transcription of  egl-1 can be
repressed by the zinc-finger protein CES-1, which in turn is repressed by CES-2, a mem-
ber of  the basic-leucine zipper family of  transcription factors42 (reviewed in 38, see Fig.
3). 
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Figure 3 Evolutionary conservation of  players of  the apoptotic program.
In C. elegans, as well as in mammals, members of  the Bcl-2 family play an important role in mediating
apoptosis. Upstream regulators of  the BH3-only protein EGL-1 in C. elegans have orthologs in mam-
mals, although their function in regulating the expression of  BH3-only proteins in mammals still needs
to be established.
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Upstream regulators of  egl-1 transcription have orthologs in mammals. Recently, a mam-
malian homolog of  CES-1, Slug, was identified, which exhibits anti-apoptotic effects42.
This suggests that transcriptional repression of  pro-apoptotic Bcl-2 members could also
be an important means of  regulation in mammalian cells. Indeed, IL-3 signaling was
recently found to repress protein levels of  Bim, which might be due to transcriptional
repression43,44. Interestingly, chromosomal translocation of  a potential mammalian
ortholog of  CES-2, hepatic leukemia factor (HLF), resulting in the fusion gene E2A-
HLF, has been associated with perturbed development of  lymphoid cells and leukemia45-
47. Furthermore, whereas Slug expression appears to be restricted to lymphoid progeni-
tors, expression of E2A-HLF results in sustained expression of  Slug, which might be
linked to the leukemogenic effects of E2A-HLF42. However, the normal activity of HLF
or other potential mammalian orthologs of  CES-2, as well as regulation of BH3-only
proteins by Slug still remains to be demonstrated. 
FKHR-L1 and its potential involvement in disease.
In our studies, FKHR-L1 activity promoted G1 arrest and apoptosis concomitant with an
elevation of  p27KIP1 and Bim28,43. The PI3K- PDK-1-PKB- FKHR-L1 pathway is evo-
lutionarily conserved and has orthologs in C. elegans. However, a role for the Forkhead
ortholog Daf-16 in apoptosis has not yet been demonstrated, although its activity is asso-
ciated with an increase in life span48-50. 
There are many examples of  tumors, and also autoimmune diseases that result from
increased activity of  PI3K and its downstream effectors51-54. In addition to promoting
cell division and survival through inhibiting members of  the Forkhead family AFX,
FKHR and FKHR-L1, rearrangements of  FKHR and AFX, have also been demonstrat-
ed in certain cancers (reviewed in 55). However, a potential role for FKHR-L1 in the clear-
ing of  inflammatory cells remains to be established. Inflammation in allergic diseases due
to enhanced activity, but also enhanced numbers of  inflammatory cells, such as neu-
trophils or eosinophils. Enhanced numbers of  these cells might be a result of  overpro-
duction or increased mobilization, but also of  defective regulation of  apoptosis. To dis-
criminate between those possibilities, we analyzed eosinophils of  a hypereosinophilic
patient having a marked elevation of  eosinophil numbers in the peripheral blood (white
blood cell count 23x109 cells/l, 95% eosinophils). Cytokine-deprived cells from this
patient failed to undergo apoptosis (Fig. 4A, kindly provided by M. Rosas), suggesting
that the default apoptotic pathway is affected. Interestingly, whereas in the absence of
cytokines activity of  FKHR-L1 is induced through dephosphorylation, phosphorylation
of  FKHR-L1 in eosinophils was sustained even in the absence of  cytokines and not
altered upon addition of  IL-5 (Fig. 4B), in contrast with eosinophils derived from a
healthy donor (Fig. 4C). The observation that phosphorylation of  ERK decreased in
cytokine-starved eosinophils from the patient (Fig. 4A, right) suggests that sustained sur-
vival is not simply a result from autocrine survival factor secretion. These data provide
evidence that aberrant regulation of  FKHR-L1 may not only be related to oncogenesis,
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but also to the pathogenesis of  inflammatory diseases. We have shown that apoptosis
induced by FKHR-L1 is a result from a decrease of mitochondrial transmembrane poten-
tial, resulting in release of  cytochrome c and activation of  caspases (Chapter 5). Although
mitochondria are present in low numbers in eosinophils, it has recently been shown that
also in these cells mitochondria play a central role in the induction of  apoptosis56. Indeed,
we have recently demonstrated that removal of  IL-5 from eosinophils results in decrease
of mitochondrial transmembrane potential (data not shown).
Although negative regulation of  PI3K and its effectors is mediated by lipid phos-
phatases57,58, inhibitory regulation of  PKB targets by phosphatases is largely elusive.
Recently, the PKB target Bad has been demonstrated to be dephosphorylated by the ser-
ine-threonine phosphatases PP1A  and PP2A, raising the possibility that these phos-
phatases could also dephosphorylate FKHR-L159,60. As dysregulation of  the activity of
these phosphatases has been associated with malignancies (reviewed in 61), it would be of
interest to investigate whether this is associated with constitutive phosphorylation of
FKHR-L1.  
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Figure 4 Constitutive phosphorylation of  FKHR-L1 correlates with enhanced sur-
vival of  eosinophils.
(A) Eosinophils from a hypereosinophilic patient (black bars) or a healthy donor (grey bars) were cul-
tured in the absence of  presence of  IL-5 (10-10 nM) for 48 hours and the percentage of  apoptotic cells
was analyzed as in Chapter 3. (B) Left: cells from a hypereosinophilic patient were stimulated with IL-5
(10-10 nM) and the phosphorylation of  FKHR-L1 was determined using FKHR-L2-Thr-32 phosphos-
pecific antibody as described in Chapter 3. Right: Cells from the same patient were stimulated with IL-
5 (10-10 nM) for 10 minutes and ERK2 phosphorylation was analyzed using an ERK2 phospho-specif-
ic antibody. (C) Eosinophils from a healthy donor were treated with IL-5 (10-10 nM) for indicated times
either without or with pretreatment of  LY294002 (10 mM) analyzed as in (B). 
Chapter 7_2703.qxd  2-5-01  18:03  Page 125
Induction of  apoptosis in response to DNA damage has been attributed to p53
through upregulation of  pro-apoptotic Bcl-2 members Bax and Noxa33,62. However,
mechanisms of  transcriptional upregulation of  pro-apoptotic proteins in development or
in the absence of  growth factors is still largely elusive. In addition to FKHR-L1-induced
apoptosis in hematopoietic cells, another putative transcription factor, Requiem, might
also be involved. Requiem was identified in a screen to identify genes mediating pro-
grammed cell death triggered by IL-3-deprivation and encodes a zinc-finger protein, but
its mechanism of  action still remains to be elucidated63.  The transcriptional upregulation
of  pro-apoptotic proteins after cytokine withdrawal might prove to be a common mech-
anism regulating survival of  hematopoietic cells.
Strategies for the development of therapeutic agents. 
Cancer cells exhibit unrestricted proliferation independent of  environmental regulatory
mechanisms having adapted to the apoptotic restraints that are normally be imposed on
them. These cells are often more sensitive to irradiation and chemotherapeutic agents
than their normal counterparts. Given the side effects of  these treatments, it would be
desirable to develop a therapy that is more specific and restricted to malignant cells. For
many leukemias, this would require a better characterization of  the different  develop-
mental stages in order to specifically target the therapy. Although this still requires addi-
tional research, knowledge of  apoptosis is currently being used for clinical interference.
For example, adaptive mechanisms in cancer cells often involve the Bcl-2 family, where
the activity of  anti-apoptotic members is enhanced over pro-apoptotic members
(reviewed in 31,64).  Interestingly, treatment of melanoma cells that have elevated levels of
Bcl-2 with Bcl-2 antisense oligonucleotides enhanced their susceptibility to chemothera-
peutic agents65. Studies of  the inhibitory effects of  BH3-only proteins have resulted in
the observation that only a small peptide derived from the BH3 domain, which specifi-
cally interacts with and inhibits the activity of  anti-apoptotic Bcl-2 family members, is suf-
ficient to trigger apoptosis of  cells66,67. Recently, research towards developing therapeu-
tic agents to inhibit anti-apoptotic Bcl-2 family members has taken an additional step with
the characterization of  cell-permeable small molecule inhibitors that compete with the
binding of  the BH3 domain of  BH3-only proteins to anti-apoptotic Bcl-2 family mem-
bers68-70. Addition of  these small molecules to cells promotes apoptosis similar to the
mechanism of  action of  BH3-only proteins. Although development of  such molecules is
promising and has advantage over peptides in that they are more stable, it still requires
the development of  strategies to be able to specifically target these inhibitors to malig-
nant cells. Taken together, the knowledge generated by fundamental research into the reg-
ulation of  apoptosis allows the development of more specific means for clinical interfer-
ence in disease. Further research could contribute to increase the specificity of  the ther-
apeutic agent, and limit its effects to malignant cells.
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Nederlandse samenvatting
In het immuunsysteem zorgen witte bloedcellen voor de afweer tegen schadelijke orga-
nismen van buitenaf. In laboratorium longziekten te Utrecht wordt onderzoek verricht
naar een bepaald type witte bloedcellen, eosinofielen, omdat die een rol spelen bij het
ontstaan van allergische astma. Eosinofielen zijn normaliter betrokken bij de afweer tegen
bepaalde parasieten, maar die komen in de westerse wereld nog maar weinig voor, dus de
fysiologische functie van eosinofielen kan in de westerse wereld wellicht gemist worden.
Kortom, je zou dus de aktiviteit van eosinofielen kunnen remmen, zonder dat een astma
patient er last van heeft, en alleen een verlichting van zijn ziekte ervaart. 
Witte bloedcellen zijn voor hun groei, overleving en specialisatie afhankelijk van
groeifactoren. Groeifactoren binden aan de buitenkant van de cel aan een "groeifactor
receptor". Er zijn verschillende typen groeifactoren die ieder binden aan hun eigen recep-
tor. Doordat ieder celtype weer andere groeifactor receptoren bezit kunnen verschillende
celtypes door specifieke groeifactoren gereguleerd worden. Binding tussen groeifactor en
groeifactor receptor resulteert in een cascade van signalen binnenin de cel. Het geheel van
deze signaleringscascades, signaaltransductie genaamd, resulteert in stimulatie van witte
bloedcellen. Hierdoor kunnen witte bloedcellen aktief  zijn in de afweer van schadelijke
organismen en gaan delen. Behalve dat groeifactoren ervoor zorgen dat er voldoende
cellen zijn doordat de celdeling gestimuleerd wordt, zorgen ze er ook voor dat cellen niet
dood gaan. Het idee achter het bestuderen van signaaltransductie in (bijvoorbeeld) eosi-
nofielen is dat als men begrijpt hoe groeifactoren deze cellen stimuleren, vervolgens
gekeken kan worden op welke manier deze signalering geremd kan worden. Uiteindelijk
zou hierdoor een middel gevonden kunnen worden om (bijvoorbeeld) allergische astma
te remmen. 
In dit proefschrift wordt beschreven hoe signaaltransductie in een witte bloedcel
(zoals een eosinofiel) kan leiden tot celdeling en survival. Er is gekeken naar een bepaalde
"groeifactor receptor", de "interleukine-5 receptor", die alleen maar op eosinofielen
voorkomt, hetgeen bestudering van de signalering van deze receptor geschikt maakt om
uiteindelijk mogelijk specifiek de activiteit van eosinofielen te kunnen remmen. 
Behalve dat in dit proefschrift gekeken is hoe groeifactoren kunnen zorgen voor
celdeling en survival is ook onderzocht wat er gebeurt met witte bloedcellen in
afwezigheid van groeifactoren. Zonder groeifactoren stoppen de meeste witte bloedcellen
met delen en ondergaan uiteindelijk "apoptose", ook wel “geprogrammeerde celdood”
genoemd. De afhankelijkheid van groeifactoren om te delen en te blijven leven zorgt
ervoor dat een cel niet op eigen houtje besluit iets te doen en in zekere zin "in dienst 
blijft van het organisme". Kortom, enerzijds de vermeerdering van witte bloedcellen in de
aanwezigheid van groeifactoren en anderzijds het ondergaan van apoptose in afwezigheid
van groeifactoren reguleert het totaal aantal witte bloedcellen in een organisme. Soms kan
er echter iets mis zijn met de afhankelijkheid van een cel voor groeifactoren en kan een
cel blijven leven of  zelfs delen, ook als er geen groeifactoren zijn. Een manier waarop een
cel onafhankelijk van groeifactoren kan delen en leven is door mutaties in componenten
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van signaaltransductie cascades. Deze mutaties kunnen ertoe leiden dat de cascade ook
zonder groeifactoren geaktiveerd is. Als je weet waardoor een cel apoptose ondergaat in
afwezigheid van groeifactoren zou het ook wellicht mogelijk zijn om deze kennis te
gebruiken om farmacologische drugs te ontwikkelen. Deze farmacologische drugs
zouden apoptose kunnen induceren in cellen die blijven leven zonder groeifactoren en zo
die ongewenste cellen (met een te grote eigen wil) uit de weg ruimen.
Een cel bezit pro-apoptotische eiwitten die apoptose kunnen induceren en anti-apop-
totische eiwitten die apoptose tegengaan. Groeifactor geinduceerde signaal transductie
resulteert in verhoging van de aktiviteit van anti-apoptotische eiwitten en remming van de
aktiviteit van de pro-apoptotische eiwitten. Vaak kan de aktiviteit van een bepaald type
eiwit verhoogd worden simpelweg door ervoor te zorgen dat er meer van dat eiwit (een
hogere expressie) in de cel is. Eiwitten die zorgen voor een hogere expressie van een
bepaald eiwit in een cel worden "transcriptie factoren" genoemd. Vaak wordt de aktiviteit
van transcriptie factoren die zorgen voor meer anti-apoptotische eiwitten in een cel ver-
hoogd door groeifactor signalering. 
Of  een cel overleeft of  apoptose ondergaat is vaak de resultante van een balans tussen
pro- en anti-apoptotische eiwitten. Een hele belangrijke balans wordt gevormd door
eiwitten van de Bcl-2 (B cell lymphoma) familie. Deze bestaat uit eiwitten die apoptose
tegengaan (anti-apoptotische Bcl-2 leden), maar ook eiwitten die apoptose kunnen indu-
ceren (pro-apoptotische Bcl-2 leden). De anti-apoptotische Bcl-2 familie leden remmen
de aktiviteit van de pro-apoptotische Bcl-2 familie leden en vice versa, waardoor de netto
aktiviteit van de Bcl-2 familie belangrijk is voor de cel óf  om te overleven óf  om apop-
tose te ondergaan. Signalering van groeifactoren leidt tot verhoging van expressie van
anti-apoptotische Bcl-2 en inaktivatie van pro-apoptotische Bcl-2 leden, waardoor sur-
vival bewerkstelligd wordt. In de afwezigheid van groeifactoren is de expressie van de
anti-apoptotische Bcl-2 familieleden lager, en krijgt de aktiviteit van de pro-apoptotische
Bcl-2 familieleden de overhand, waardoor een cel uiteindelijk apoptose ondergaat.
In dit proefschrift is onderzocht welke groeifactor-geinduceerde signaleringsroutes
ervoor zorgen dat witte bloedcellen delen en overleven, maar ook waardoor een cel stopt
met delen en apoptose ondergaat in afwezigheid van groeifactoren. Een manier waarop
groeifactoren kunnen resulteren in celdeling is mogelijkerwijs door verlaging van de
expressie van het eiwit p27KIP1. In afwezigheid van groeifactoren is er meer p27KIP1 aan-
wezig in de cel (hoofdstuk 3). p27KIP1 heeft een belangrijke rol in het stoppen van de
celdeling in afwezigheid van groeifactoren. Kortom, verhoging van de expressie van
p27KIP1 is een manier om celdeling in de afwezigheid van groeifactoren te remmen.
Verantwoordelijk voor de verhoging van de expressie van p27KIP1 in afwezigheid van
groeifactoren bleek de transcriptie factor FKHR-L1. In tegenstelling tot veel andere 
transcriptie factoren is deze transcriptie factor aktief  in afwezigheid van groeifactoren en
inaktief  in aanwezigheid van groeifactoren. Kortom, door middel van deze transcriptie
factor zou bewerkstelligd kunnen worden dat in afwezigheid van groeifactoren de cel niet
meer deelt en uiteindelijk apoptose ondergaat. Waarschijnlijk ligt het inderdaad aan de
aktivatie van FKHR-L1 dat witte bloedcellen in afwezigheid van groeifactoren stoppen
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met delen en  apoptose ondergaan (hoofdstuk 5). Aangezien de Bcl-2 familie een belan-
grijke rol speelt in de balans tussen overleven en apoptose hebben is onderzocht of  het
mogelijk zou kunnen zijn dat FKHR-L1 aktiviteit leidt tot verhoging van expressie van
pro-apoptotische Bcl-2 familieleden. Dit heeft geresulteerd in de bevinding dat FKHR-
L1 verantwoordelijk is voor de transcriptionele regulatie van een pro-apoptotische Bcl-2
familielid, Bim (hoofdstuk 4). Dat regulatie van Bim expressie belangrijk is voor de regu-
latie van de hoeveelheid witte bloedcellen blijkt uit studies in Bim-deficiente muizen.
Deze muizen hebben veel te veel witte bloedcellen die geen apoptose ondergaan in
afwezigheid van groeifactoren. 
Samenvattend hebben de resultaten beschreven in dit proefschrift geleid tot een beter
inzicht in groeifactor signalering. De toekomst zal leren in hoeverre kennis van de signaal
transductie routes die hier bestudeerd zijn toepasbaar zou kunnen zijn in de ontwikkeling
van farmacologische drugs ter bestrijding van bijvoorbeeld allergische astma.
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Dankwoord
Bij het tot stand komen van dit proefschrift hebben veel mensen ertoe bijgedragen dat ik
de afgelopen 4 jaar (meestal) met veel plezier hieraan gewerkt heb (en het ook af  heb
gekregen).
Paul, bij het verstrijken van mijn AIO-tijd dacht ik "Nu al?" (zonder tijdsdrukgevoel
overigens). Ik heb enorm veel van je geleerd, zowel qua onderzoek alsmede ook qua
omgaan met onderzoek. Bedankt voor je enthousiasme, je muzieksmaak, taalverhaspelin-
gen en je (Engelse) moeheid. Er was altijd wel wat (surrealistische) stress; gelukkig hebben
we het "Dinosaur-egg"-experiment niet hoeven doen. Leo en Jan-Willem, bedankt voor
de vrijheid die ik kreeg om dit onderzoek te doen, jullie belangstelling en het af  en toe
plaatsen van een klinisch relevante noot waardoor het wellicht niet in al te academisch
gezwam verzandde. Leo, ook bedankt voor je optimisme en je gave om geld los te
peuteren. 
Verder de andere mensen van Laboratorium Longziekten voor een bijzonder
plezierige werksfeer. Sandra, begonnen op dezelfde dag (ik zie ons nog naar elkaar loeren
op dag 1 als prille AIOs), bedankt voor een gezellige tijd, het oor voor mijn geklets en het
zelfs onthouden daarvan (om P.J. nooit meer te vergeten?) en dat je mijn paranimf  wilde
zijn. Cornelieke voor het behouden van een goede sfeer op het lab en je droge humor;
verder ook de andere "mensen van boven": Evert (voor het verlichten van mijn compu-
ter analfabetisme), Marcela, Lisa, Belinda en Miranda. Oude garde: Thamar, Rolf  (voor
het korter maken van mijn tenen); Niels, Madelon, Annelien: bedankt ook voor de tijd
buiten het lab: proost! 
Jan, Deon, Corneli, bedankt voor het instellen van de FACS dat jullie zo goed kunnen
dat ik er nog steeds niks van begrijp en andere "mensen van (inmiddels) beneden": (won-
derbaarlijk altijd vrolijke) Laurien, Dianne, Lei, Andy, Jacqueline, Paula, Nadia en Jaap. 
Inmiddels uit de gang: René Medema voor de adviezen rondom de celcyclus, de tal-
loze FACS-proeven en wederzijdse jataktiviteiten; Geert en Boudewijn voor de Forkhead
tips. Zowel op de gang als daarbuiten: Veronique, de meest attente persoon die ik ken,
voor de tijd op de bank met wederzijds stoom afblazen en regeltips (nog steeds niet mijn
sterkste kant). Verder (the editorial board of) The Journal of  Losers: ik hoop dat ik bij jul-
lie nog eens wat geaccepteerd krijg. Half  binnen, half  buiten het AZU: René Scriwanek
(slachtoffer van de alsmaar minder wordende tolerantie tegen rokers): bedankt voor de
tijd rondom automatenkoffie en hier of  daar een (last minute) fotografie- of  computer-
tip. 
Mensen die ertoe bij hebben gedragen dat het werk in het lab relativeerbaar was: Index
waarbij het bijeenkomen om een boek te bespreken voor mij in de loop der jaren van
steeds minder belang werd maar het bijkletsen des te meer; bedankt voor het mij erop
wijzen dat “een muis maken” eigenlijk heel raar is. Nicole, Veronique, Sandra en Martine
voor de weekends weg waarna uiteindelijk niemand meer single is (ik ga er maar vanuit
dat dat gerelateerd aan elkaar is). Nicole, na een avondje bijkletsen op de Markstraat is het
altijd mooi weer, hetgeen in Nederland een unicum is. Paul, jammergenoeg ver weg nu ik
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dit schrijf, hopelijk kom je binnenkort langs als het mijn beurt is om de benen te nemen.
Kris, thanks for a great time, for the stories around bad people being eaten by dragons,
as well as Whiskey in pigeon gambling or toenail painting. Whiskey, bedankt voor het
hooghouden van de nationale eer en de begeleidende dans, Oranje boven!.
Thanks to Uwe for showing me that there's more besides food, hope to find some
nearby "vreetzak-ness" soon though.
Als laatste wil ik mijn naaste familie bedanken: Francijntje, voor de zuster ruzies
vroeger en de gezelligheid nu, bedankt dat je mijn paranimf  wilde zijn; papa en mama,
voor het enerzijds mij zelf  aan laten modderen, maar er anderzijds altijd zijn.
Pascale
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Curriculum Vitae
De schrijfster van dit proefschrift werd op 19 juni 1972 geboren te Veghel. Na het
behalen van het diploma op R.K. Gymnasium "Beekvliet" te Sint Michielsgestel werd in
1991 begonnen met de studie Medische Biologie de Universiteit van Utrecht. In agustus
1996 werd het Doctoraal diploma behaald met als hoofdvakken Celbiologie (Dr. P.J.
Peters, vakgroep Celbiologie, Universiteit Utrecht en Dr. V.W. Hsu, Department of
Rheumatology and Immunology, Brigham and Women's Hospital, Boston, USA) en
Fysiologische Chemie (Dr. B.M.T. Burgering, Prof. dr. J.L. Bos, Universiteit Utrecht). Het
in dit proefschrift beschreven onderzoek werd uitgevoerd in de periode maart 1997 tot 
februari 2001 onder begeleiding van Dr. P.J. Coffer, Prof. dr. L. Koenderman en Prof. dr.
J-W. J. Lammers in het laboratorium Longziekten te Utrecht.
Vanaf  augustus 2001 zal zij werkzaam zijn als post doctoraal onderzoeker, in het lab van
Prof. P.H. O'Farrell op het UCSF in San Francisco, USA.
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